<!DOCTYPE html><html lang="en" class="scroll-smooth"><head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>060 Pharmacology Neet 2024 - Brain And Scalpel</title>
    <link rel="preload" href="assets/background.jpg" as="image">
    <script src="https://cdn.tailwindcss.com"></script>
    <!-- HLS.js for M3U8 support -->
    <script src="https://cdn.jsdelivr.net/npm/hls.js@latest"></script>
    <style>
        
/* Liquid Glass Morphism Universal Theme - Enhanced & Mobile-First */
:root {
  --glass-bg: rgba(0, 0, 0, 0.6);
  --glass-bg-light: rgba(255, 255, 255, 0.1);
  --glass-bg-medium: rgba(255, 255, 255, 0.15);
  --glass-bg-heavy: rgba(255, 255, 255, 0.2);
  --glass-border: rgba(255, 255, 255, 0.2);
  --glass-border-light: rgba(255, 255, 255, 0.1);
  --text-primary: rgba(255, 255, 255, 0.95);
  --text-secondary: rgba(255, 255, 255, 0.7);
  --text-tertiary: rgba(255, 255, 255, 0.5);
  --accent-blue: #60a5fa;
  --accent-purple: #a855f7;
  --accent-green: #34d399;
  --accent-orange: #fb923c;
  --accent-red: #f87171;
  --accent-yellow: #fbbf24;
}

* {
  margin: 0;
  padding: 0;
  box-sizing: border-box;
}

html {
  scroll-behavior: smooth;
}

body {
  margin: 0;
  min-height: 100vh;
  font-family: system-ui, -apple-system, BlinkMacSystemFont, 'Segoe UI', sans-serif;
  position: relative;
  overflow-x: hidden;
  color: var(--text-primary);
  background-color: #000;
}

/* iOS Background Fix */
body::before {
  content: '';
  position: fixed;
  top: 0;
  left: 0;
  height: 100vh;
  width: 100vw;
  z-index: -2;
  background: url("assets/background.jpg") center center / cover no-repeat;
}

body::after {
  content: "";
  position: fixed;
  inset: 0;
  background: rgba(0, 0, 0, 0.4);
  backdrop-filter: blur(10px);
  -webkit-backdrop-filter: blur(10px);
  z-index: -1;
}

/* Glass morphism components */
.glass {
  background: var(--glass-bg);
  backdrop-filter: blur(20px);
  -webkit-backdrop-filter: blur(20px);
  border: 1px solid var(--glass-border);
  border-radius: 16px;
}

.glass-light {
  background: var(--glass-bg-light);
  backdrop-filter: blur(15px);
  -webkit-backdrop-filter: blur(15px);
  border: 1px solid var(--glass-border-light);
  border-radius: 12px;
}

.glass-medium {
  background: var(--glass-bg-medium);
  backdrop-filter: blur(20px);
  -webkit-backdrop-filter: blur(20px);
  border: 1px solid var(--glass-border);
  border-radius: 16px;
}

.glass-heavy {
  background: var(--glass-bg-heavy);
  backdrop-filter: blur(25px);
  -webkit-backdrop-filter: blur(25px);
  border: 1px solid var(--glass-border);
  border-radius: 20px;
}

.glass-card {
  background: rgba(255, 255, 255, 0.08);
  backdrop-filter: blur(20px);
  -webkit-backdrop-filter: blur(20px);
  border: 1px solid rgba(255, 255, 255, 0.15);
  border-radius: 20px;
  transition: all 0.3s cubic-bezier(0.4, 0, 0.2, 1);
  box-shadow: 0 8px 32px rgba(0, 0, 0, 0.3);
}

.glass-card:hover {
  transform: translateY(-8px);
  background: rgba(255, 255, 255, 0.12);
  border-color: rgba(255, 255, 255, 0.25);
  box-shadow: 0 20px 60px rgba(0, 0, 0, 0.4);
}

.glass-button {
  background: linear-gradient(135deg, rgba(96, 165, 250, 0.8), rgba(168, 85, 247, 0.8));
  backdrop-filter: blur(15px);
  -webkit-backdrop-filter: blur(15px);
  border: 1px solid rgba(255, 255, 255, 0.2);
  border-radius: 12px;
  color: white;
  font-weight: 600;
  transition: all 0.3s cubic-bezier(0.4, 0, 0.2, 1);
  box-shadow: 0 4px 20px rgba(96, 165, 250, 0.3);
  cursor: pointer;
  border: none;
}

.glass-button:hover {
  transform: translateY(-2px);
  box-shadow: 0 8px 30px rgba(96, 165, 250, 0.4);
  background: linear-gradient(135deg, rgba(96, 165, 250, 0.9), rgba(168, 85, 247, 0.9));
}

.glass-button:disabled {
  opacity: 0.5;
  cursor: not-allowed;
  transform: none;
}

.glass-input {
  background: rgba(255, 255, 255, 0.08);
  backdrop-filter: blur(15px);
  -webkit-backdrop-filter: blur(15px);
  border: 1px solid rgba(255, 255, 255, 0.2);
  border-radius: 12px;
  color: var(--text-primary);
  transition: all 0.3s ease;
}

.glass-input:focus {
  outline: none;
  border-color: var(--accent-blue);
  background: rgba(255, 255, 255, 0.12);
  box-shadow: 0 0 20px rgba(96, 165, 250, 0.3);
}

.glass-input::placeholder {
  color: var(--text-tertiary);
}

/* Performance analysis styles */
.performance-card {
  background: rgba(255, 255, 255, 0.08);
  backdrop-filter: blur(20px);
  -webkit-backdrop-filter: blur(20px);
  border: 1px solid rgba(255, 255, 255, 0.15);
  border-radius: 20px;
  box-shadow: 0 8px 32px rgba(0, 0, 0, 0.3);
}

.score-circle {
  position: relative;
  width: 150px;
  height: 150px;
  margin: 0 auto;
}

.score-circle svg {
  transform: rotate(-90deg);
}

.score-circle .circle-bg {
  fill: none;
  stroke: rgba(255, 255, 255, 0.1);
  stroke-width: 8;
}

.score-circle .circle-progress {
  fill: none;
  stroke-width: 8;
  stroke-linecap: round;
  transition: stroke-dasharray 2s cubic-bezier(0.4, 0, 0.2, 1);
}

.score-text {
  position: absolute;
  top: 50%;
  left: 50%;
  transform: translate(-50%, -50%);
  text-align: center;
}

/* Review question styles */
.review-question {
  background: rgba(255, 255, 255, 0.05);
  border: 1px solid rgba(255, 255, 255, 0.1);
  border-radius: 16px;
  padding: 20px;
  margin-bottom: 20px;
}

.review-question.correct {
  border-left: 4px solid #22c55e;
}

.review-question.incorrect {
  border-left: 4px solid #ef4444;
}

.review-question.not-attempted {
  border-left: 4px solid #6b7280;
}

/* Gradient backgrounds for accents */
.gradient-blue {
  background: linear-gradient(135deg, var(--accent-blue), #3b82f6);
}

.gradient-purple {
  background: linear-gradient(135deg, var(--accent-purple), #8b5cf6);
}

.gradient-green {
  background: linear-gradient(135deg, var(--accent-green), #10b981);
}

.gradient-orange {
  background: linear-gradient(135deg, var(--accent-orange), #f97316);
}

.gradient-red {
  background: linear-gradient(135deg, var(--accent-red), #ef4444);
}

.gradient-yellow {
  background: linear-gradient(135deg, var(--accent-yellow), #f59e0b);
}

/* Navigation button styles */
.nav-btn-not-attempted {
  background: rgba(255, 255, 255, 0.1);
  border: 1px solid rgba(255, 255, 255, 0.2);
  color: rgba(255, 255, 255, 0.7);
}

.nav-btn-current {
  background: linear-gradient(135deg, var(--accent-blue), #3b82f6);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
  box-shadow: 0 0 20px rgba(96, 165, 250, 0.4);
}

.nav-btn-correct {
  background: linear-gradient(135deg, var(--accent-green), #10b981);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

.nav-btn-incorrect {
  background: linear-gradient(135deg, var(--accent-red), #ef4444);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

.nav-btn-bookmarked {
  background: linear-gradient(135deg, var(--accent-yellow), #f59e0b);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

.nav-btn-marked-review {
  background: linear-gradient(135deg, var(--accent-purple), #8b5cf6);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

.nav-btn-answered {
  background: linear-gradient(135deg, #6b7280, #4b5563);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

/* Option button styles - REVISED FOR INLINE FEEDBACK */
.option-button {
  background: rgba(255, 255, 255, 0.05);
  border: 1px solid rgba(255, 255, 255, 0.15);
  transition: all 0.3s cubic-bezier(0.4, 0, 0.2, 1);
  position: relative;
  overflow: hidden;
  width: 100%;
  text-align: left;
  padding: 1rem;
  border-radius: 12px;
  color: var(--text-primary);
  cursor: pointer;
  display: flex;
  align-items: center;
  gap: 1rem;
  font-size: 1rem;
}

.option-button:hover {
  background: rgba(255, 255, 255, 0.1);
  border-color: rgba(96, 165, 250, 0.5);
  transform: translateX(8px);
}

.option-button.selected {
  background: linear-gradient(135deg, rgba(96, 165, 250, 0.3), rgba(59, 130, 246, 0.3));
  border-color: var(--accent-blue);
  transform: translateX(8px);
}

#optionsContainer.answered .option-button:hover {
    transform: translateX(0); /* Disable hover effect after answering */
}

#optionsContainer.answered .option-button {
    cursor: not-allowed;
    pointer-events: none;
}

#optionsContainer.answered .option-button:not(.correct):not(.incorrect) {
    opacity: 0.5;
}

.option-button.correct {
    background: linear-gradient(135deg, #22c55e, #16a34a);
    border-color: #22c55e;
    color: white;
    transform: translateX(0);
}

.option-button.incorrect {
    background: linear-gradient(135deg, #ef4444, #dc2626);
    border-color: #ef4444;
    color: white;
    transform: translateX(0);
}

.option-letter {
  background: rgba(255, 255, 255, 0.1);
  border: 1px solid rgba(255, 255, 255, 0.2);
  transition: all 0.3s ease;
  width: 2.5rem;
  height: 2.5rem;
  border-radius: 50%;
  display: flex;
  align-items: center;
  justify-content: center;
  font-weight: bold;
  color: var(--text-primary);
  flex-shrink: 0;
}

.option-button.selected .option-letter {
  background: var(--accent-blue);
  border-color: var(--accent-blue);
  color: white;
}

.option-button.correct .option-letter, .option-button.incorrect .option-letter {
    background: rgba(255, 255, 255, 0.2);
    border-color: rgba(255, 255, 255, 0.3);
}

.option-text {
  flex: 1;
  font-size: 1rem;
  line-height: 1.5;
}

/* Stats bar responsive grid */
.stats-grid {
  display: grid;
  grid-template-columns: repeat(5, 1fr);
  gap: 1rem;
  align-items: center;
  justify-items: center;
}

@media (max-width: 768px) {
  .stats-grid {
    grid-template-columns: repeat(3, 1fr);
    gap: 0.5rem;
  }
  
  .stats-grid > div:nth-child(4),
  .stats-grid > div:nth-child(5) {
    grid-column: span 1;
  }
}

@media (max-width: 480px) {
  .stats-grid {
    grid-template-columns: repeat(2, 1fr);
  }
  
  .stats-grid > div:last-child {
    grid-column: span 2;
    justify-self: center;
  }
}

/* Animations */
@keyframes float {
  0%, 100% { transform: translateY(0px); }
  50% { transform: translateY(-20px); }
}

@keyframes pulse-glow {
  0%, 100% { box-shadow: 0 0 20px rgba(96, 165, 250, 0.3); }
  50% { box-shadow: 0 0 40px rgba(96, 165, 250, 0.6); }
}

@keyframes checkmark {
  0% { transform: scale(0) rotate(0deg); }
  50% { transform: scale(0.8) rotate(180deg); }
  100% { transform: scale(1) rotate(360deg); }
}

@keyframes cross {
  0% { transform: scale(0) rotate(0deg); }
  50% { transform: scale(0.8) rotate(90deg); }
  100% { transform: scale(1) rotate(180deg); }
}

.animate-float {
  animation: float 6s ease-in-out infinite;
}

.animate-pulse-glow {
  animation: pulse-glow 2s ease-in-out infinite;
}

.animate-checkmark {
  animation: checkmark 0.6s cubic-bezier(0.4, 0, 0.2, 1);
}

.animate-cross {
  animation: cross 0.6s cubic-bezier(0.4, 0, 0.2, 1);
}

/* Custom scrollbar */
::-webkit-scrollbar {
  width: 8px;
}

::-webkit-scrollbar-track {
  background: rgba(255, 255, 255, 0.05);
  border-radius: 4px;
}

::-webkit-scrollbar-thumb {
  background: rgba(255, 255, 255, 0.2);
  border-radius: 4px;
}

::-webkit-scrollbar-thumb:hover {
  background: rgba(255, 255, 255, 0.3);
}

/* --- MOBILE RESPONSIVE STYLES --- */
.quiz-container {
    display: flex;
    flex-direction: column;
    gap: 1.5rem;
}

#mobile-nav-toggle {
    display: none; /* Hidden on desktop */
}

@media (min-width: 1024px) {
    .quiz-container {
        flex-direction: row;
        gap: 2rem;
    }
}

@media (max-width: 1023px) {
    .quiz-sidebar {
        position: fixed;
        top: 0;
        left: 0;
        width: 300px;
        height: 100%;
        z-index: 100;
        transform: translateX(-100%);
        transition: transform 0.3s ease-in-out;
        box-shadow: 10px 0px 30px rgba(0,0,0,0.5);
    }
    .quiz-sidebar.open {
        transform: translateX(0);
    }
    #mobile-nav-toggle {
        display: flex;
        position: fixed;
        bottom: 20px;
        left: 20px;
        z-index: 50;
    }
    .quiz-main-content {
        width: 100%;
    }
}

@media (max-width: 768px) {
    .glass-card, .glass {
        border-radius: 16px;
    }
    h1 { font-size: 2.5rem; }
    #questionText { font-size: 1.125rem; }
    .controls-container {
        flex-direction: column;
        gap: 1rem;
    }
    .controls-container button {
        width: 100%;
    }
}

    </style>
</head>
<body>
    <!-- Mode Selection Modal -->
    <div id="modeModal" class="fixed inset-0 bg-black bg-opacity-70 flex items-center justify-center z-50 backdrop-blur-sm">
        <div class="glass-heavy p-8 max-w-md w-full mx-4 shadow-2xl">
            <h2 class="text-2xl font-bold text-white mb-6 text-center">Choose Study Mode</h2>
            
            <div class="space-y-4">
                <button onclick="selectMode('study')" class="w-full text-left p-4 glass-light hover:bg-white hover:bg-opacity-10 transition-all duration-300 text-white">
                    <div class="flex items-center justify-between">
                        <div>
                            <h3 class="font-semibold">Study Mode</h3>
                            <p class="text-sm text-white text-opacity-70">Interactive learning with immediate feedback</p>
                        </div>
                        <div class="gradient-blue w-10 h-10 rounded-lg flex items-center justify-center">
                            <svg class="w-5 h-5 text-white" fill="currentColor" viewBox="0 0 20 20">
                                <path d="M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z"></path>
                            </svg>
                        </div>
                    </div>
                </button>
                
                <button onclick="selectMode('test')" class="w-full text-left p-4 glass-light hover:bg-white hover:bg-opacity-10 transition-all duration-300 text-white">
                    <div class="flex items-center justify-between">
                        <div>
                            <h3 class="font-semibold">Test Mode</h3>
                            <p class="text-sm text-white text-opacity-70">Practice test with performance analysis at end</p>
                        </div>
                        <div class="gradient-purple w-10 h-10 rounded-lg flex items-center justify-center">
                            <svg class="w-5 h-5 text-white" fill="currentColor" viewBox="0 0 20 20">
                                <path d="M9 2a1 1 0 000 2h2a1 1 0 100-2H9z"></path>
                                <path fill-rule="evenodd" d="M4 5a2 2 0 012-2v1a1 1 0 001 1h6a1 1 0 001-1V3a2 2 0 012 2v6a2 2 0 01-2 2H6a2 2 0 01-2-2V5zm3 4a1 1 0 000 2h.01a1 1 0 100-2H7zm3 0a1 1 0 000 2h3a1 1 0 100-2h-3z" clip-rule="evenodd"></path>
                            </svg>
                        </div>
                    </div>
                </button>
                
                <button onclick="selectMode('timed_study')" class="w-full text-left p-4 glass-light hover:bg-white hover:bg-opacity-10 transition-all duration-300 text-white">
                    <div class="flex items-center justify-between">
                        <div>
                            <h3 class="font-semibold">Timed Study</h3>
                            <p class="text-sm text-white text-opacity-70">Study with time pressure and immediate feedback</p>
                        </div>
                        <div class="gradient-green w-10 h-10 rounded-lg flex items-center justify-center">
                            <svg class="w-5 h-5 text-white" fill="currentColor" viewBox="0 0 20 20">
                                <path fill-rule="evenodd" d="M10 18a8 8 0 100-16 8 8 0 000 16zm1-12a1 1 0 10-2 0v4a1 1 0 00.293.707l2.828 2.829a1 1 0 101.415-1.415L11 9.586V6z" clip-rule="evenodd"></path>
                            </svg>
                        </div>
                    </div>
                </button>
                
                <button onclick="selectMode('timed_exam')" class="w-full text-left p-4 glass-light hover:bg-white hover:bg-opacity-10 transition-all duration-300 text-white">
                    <div class="flex items-center justify-between">
                        <div>
                            <h3 class="font-semibold">Timed Exam</h3>
                            <p class="text-sm text-white text-opacity-70">Real exam simulation with strict timing</p>
                        </div>
                        <div class="gradient-red w-10 h-10 rounded-lg flex items-center justify-center">
                            <svg class="w-5 h-5 text-white" fill="currentColor" viewBox="0 0 20 20">
                                <path fill-rule="evenodd" d="M12.395 2.553a1 1 0 00-1.45-.385c-.345.23-.614.558-.822.88-.214.33-.403.713-.57 1.116-.334.804-.614 1.768-.84 2.734a31.365 31.365 0 00-.613 3.58 2.64 2.64 0 01-.945-1.067c-.328-.68-.398-1.534-.398-2.654A1 1 0 005.05 6.05 6.981 6.981 0 003 11a7 7 0 1011.95-4.95c-.592-.591-.98-.985-1.348-1.467-.363-.476-.724-1.063-1.207-2.03z" clip-rule="evenodd"></path>
                            </svg>
                        </div>
                    </div>
                </button>
            </div>
        </div>
    </div>

    <!-- Performance Analysis Modal -->
    <div id="performanceModal" class="hidden fixed inset-0 bg-black bg-opacity-80 flex items-center justify-center z-50 backdrop-blur-sm">
        <div class="glass-heavy p-8 max-w-4xl w-full mx-4 shadow-2xl max-h-[90vh] overflow-y-auto">
            <div class="flex items-center justify-between mb-8">
                <h2 class="text-3xl font-bold text-white">Performance Analysis</h2>
                <button onclick="closePerformanceModal()" class="glass-light p-2 rounded-lg text-white hover:bg-white hover:bg-opacity-20">
                    <svg class="w-6 h-6" fill="currentColor" viewBox="0 0 20 20">
                        <path fill-rule="evenodd" d="M4.293 4.293a1 1 0 011.414 0L10 8.586l4.293-4.293a1 1 0 111.414 1.414L11.414 10l4.293 4.293a1 1 0 01-1.414 1.414L10 11.414l-4.293 4.293a1 1 0 01-1.414-1.414L8.586 10 4.293 5.707a1 1 0 010-1.414z" clip-rule="evenodd"></path>
                    </svg>
                </button>
            </div>
            
            <!-- Score Overview -->
            <div class="grid grid-cols-1 md:grid-cols-3 gap-6 mb-8">
                <div class="performance-card p-6 text-center">
                    <div class="score-circle mb-4">
                        <svg width="150" height="150" class="mx-auto">
                            <circle class="circle-bg" cx="75" cy="75" r="65"></circle>
                            <circle id="scoreCircle" class="circle-progress" cx="75" cy="75" r="65" stroke="#22c55e" stroke-dasharray="0 408"></circle>
                        </svg>
                        <div class="score-text">
                            <div class="text-3xl font-bold text-white" id="accuracyScore">0%</div>
                            <div class="text-sm text-white text-opacity-70">Accuracy</div>
                        </div>
                    </div>
                </div>
                
                <div class="performance-card p-6">
                    <h3 class="text-lg font-bold text-white mb-4 text-center">Results Summary</h3>
                    <div class="space-y-3">
                        <div class="flex justify-between items-center">
                            <span class="text-white text-opacity-70">Total Questions:</span>
                            <span class="text-white font-semibold" id="totalQuestionsResult">0</span>
                        </div>
                        <div class="flex justify-between items-center">
                            <span class="text-green-400">Correct:</span>
                            <span class="text-green-400 font-semibold" id="correctResult">0</span>
                        </div>
                        <div class="flex justify-between items-center">
                            <span class="text-red-400">Incorrect:</span>
                            <span class="text-red-400 font-semibold" id="incorrectResult">0</span>
                        </div>
                        <div class="flex justify-between items-center">
                            <span class="text-gray-400">Not Attempted:</span>
                            <span class="text-gray-400 font-semibold" id="notAttemptedResult">0</span>
                        </div>
                    </div>
                </div>
                
                <div class="performance-card p-6">
                    <h3 class="text-lg font-bold text-white mb-4 text-center">Time Analysis</h3>
                    <div class="space-y-3">
                        <div class="flex justify-between items-center">
                            <span class="text-white text-opacity-70">Total Time:</span>
                            <span class="text-white font-semibold" id="totalTimeResult">0:00</span>
                        </div>
                        <div class="flex justify-between items-center">
                            <span class="text-white text-opacity-70">Avg per Question:</span>
                            <span class="text-white font-semibold" id="avgTimeResult">0:00</span>
                        </div>
                    </div>
                </div>
            </div>
            
            <!-- Action Buttons -->
            <div class="flex justify-center space-x-4 mb-8">
                <button onclick="reviewQuestions()" class="glass-button px-8 py-3 text-lg">
                    Review All Questions
                </button>
                <button onclick="retakeQuiz()" class="glass-light px-8 py-3 text-lg text-white hover:bg-white hover:bg-opacity-20">
                    Retake Quiz
                </button>
            </div>
            
            <!-- Question Review Section -->
            <div id="questionReviewSection" class="hidden">
                <h3 class="text-2xl font-bold text-white mb-6">Question Review</h3>
                <div id="reviewQuestionsContainer">
                    <!-- Review questions will be populated here -->
                </div>
            </div>
        </div>
    </div>

    <!-- Header -->
    <header class="glass sticky top-0 z-40 mb-6">
        <div class="container mx-auto px-6 py-4">
            <div class="flex items-center justify-between">
                <div class="flex items-center space-x-4">
                    <button onclick="goBack()" class="glass-light px-4 py-2 text-white hover:bg-white hover:bg-opacity-20 transition-all duration-300 flex items-center">
                        <svg class="w-5 h-5 mr-2" fill="currentColor" viewBox="0 0 20 20">
                            <path fill-rule="evenodd" d="M9.707 16.707a1 1 0 01-1.414 0l-6-6a1 1 0 010-1.414l6-6a1 1 0 011.414 1.414L5.414 9H17a1 1 0 110 2H5.414l4.293 4.293a1 1 0 010 1.414z" clip-rule="evenodd"></path>
                        </svg>
                        Back
                    </button>
                    <div id="quizHierarchy" class="text-sm text-white text-opacity-60">
                        Marrow / PYQ / Pharmacology
                    </div>
                </div>
                
                <div class="flex items-center space-x-4">
                    <div class="glass-light px-3 py-1 text-sm text-white">
                        Question <span id="currentQuestion">1</span> of <span id="totalQuestions">24</span>
                    </div>
                    
                    <!-- Timer -->
                    <div id="timerContainer" class="hidden gradient-red px-3 py-1 text-sm text-white font-bold animate-pulse-glow">
                        <span id="timeDisplay">2:00</span>
                    </div>
                </div>
            </div>
        </div>
    </header>

    <!-- Progress Bar -->
    <div class="w-full h-1 bg-black bg-opacity-30 mb-6">
        <div id="progressBar" class="h-1 gradient-blue transition-all duration-500 ease-out" style="width: 0%"></div>
    </div>

    <!-- Stats Bar - Show only in study modes -->
    <div id="statsBar" class="glass-light mb-8">
        <div class="container mx-auto px-6 py-4">
            <div class="stats-grid">
                <div class="text-center">
                    <div class="text-lg font-bold text-green-400" id="correctCount">0</div>
                    <div class="text-xs text-white text-opacity-60">Correct</div>
                </div>
                <div class="text-center">
                    <div class="text-lg font-bold text-red-400" id="incorrectCount">0</div>
                    <div class="text-xs text-white text-opacity-60">Incorrect</div>
                </div>
                <div class="text-center">
                    <div class="text-lg font-bold text-blue-400" id="totalAttempted">0</div>
                    <div class="text-xs text-white text-opacity-60">Attempted</div>
                </div>
                <div class="text-center">
                    <div class="text-lg font-bold text-purple-400" id="accuracy">0%</div>
                    <div class="text-xs text-white text-opacity-60">Accuracy</div>
                </div>
                <div class="text-center">
                    <div class="text-lg font-bold text-orange-400" id="timeSpent">0:00</div>
                    <div class="text-xs text-white text-opacity-60">Time</div>
                </div>
            </div>
        </div>
    </div>

    <div class="quiz-container container mx-auto px-6">
        <!-- Question Navigation Sidebar -->
        <div id="quizSidebar" class="quiz-sidebar glass p-6 h-fit lg:sticky top-24">
            <h3 class="text-lg font-bold text-white mb-4">Question Navigator</h3>
            <div id="questionNav" class="grid grid-cols-5 gap-2 mb-6">
                <!-- Question numbers will be populated here -->
            </div>
            
            <div class="space-y-3 text-xs">
                <h4 class="text-sm font-medium text-white text-opacity-80 mb-3">Legend</h4>
                <div class="flex items-center">
                    <div class="w-6 h-6 nav-btn-not-attempted rounded mr-2"></div>
                    <span class="text-white text-opacity-60">Not Attempted</span>
                </div>
                <div class="flex items-center">
                    <div class="w-6 h-6 nav-btn-current rounded mr-2"></div>
                    <span class="text-white text-opacity-60">Current</span>
                </div>
                <div id="studyModeLegend" class="space-y-2">
                    <div class="flex items-center">
                        <div class="w-6 h-6 nav-btn-correct rounded mr-2"></div>
                        <span class="text-white text-opacity-60">Correct</span>
                    </div>
                    <div class="flex items-center">
                        <div class="w-6 h-6 nav-btn-incorrect rounded mr-2"></div>
                        <span class="text-white text-opacity-60">Incorrect</span>
                    </div>
                </div>
                <div id="testModeLegend" class="hidden space-y-2">
                    <div class="flex items-center">
                        <div class="w-6 h-6 nav-btn-answered rounded mr-2"></div>
                        <span class="text-white text-opacity-60">Answered</span>
                    </div>
                </div>
                <div class="flex items-center">
                    <div class="w-6 h-6 nav-btn-bookmarked rounded mr-2"></div>
                    <span class="text-white text-opacity-60">Bookmarked</span>
                </div>
                <div id="testModeReviewLegend" class="hidden items-center">
                    <div class="w-6 h-6 nav-btn-marked-review rounded mr-2"></div>
                    <span class="text-white text-opacity-60">Marked for Review</span>
                </div>
            </div>
            
            <!-- Submit Quiz Button for test modes -->
            <div id="submitSection" class="hidden mt-6">
                <button onclick="submitQuiz()" class="glass-button w-full py-3 text-lg font-bold">
                    Submit Quiz
                </button>
            </div>
        </div>

        <!-- Main Quiz Interface -->
        <div class="quiz-main-content flex-1 max-w-4xl">
            <div class="glass-card p-4 md:p-8 lg:p-12 mb-8 relative">
                <!-- Question Text -->
                <div id="questionText" class="text-xl lg:text-2xl leading-relaxed text-white mb-8">
                    Loading question...
                </div>

                <!-- Question Media -->
                <div id="questionMedia" class="mb-8"></div>

                <!-- Options -->
                <div id="optionsContainer" class="space-y-3 mb-8">
                    <!-- Options will be inserted here -->
                </div>

                <!-- Solution Display (only for study modes) -->
                <div id="solutionContainer" class="hidden glass-light p-6 border-l-4 border-green-400">
                    <h3 class="text-lg font-bold text-green-400 mb-3 flex items-center">
                        <svg class="w-5 h-5 mr-2" fill="currentColor" viewBox="0 0 20 20">
                            <path fill-rule="evenodd" d="M18 10a8 8 0 11-16 0 8 8 0 0116 0zm-7-4a1 1 0 11-2 0 1 1 0 012 0zM9 9a1 1 0 000 2v3a1 1 0 001 1h1a1 1 0 100-2v-3a1 1 0 00-1-1H9z" clip-rule="evenodd"></path>
                        </svg>
                        Explanation
                    </h3>
                    <div id="solutionText" class="text-white text-opacity-90 leading-relaxed mb-4"></div>
                    <div id="solutionAudio" class="space-y-2 mt-4"></div>
                    <div id="solutionImages" class="space-y-4 mt-4"></div>
                    <div id="solutionVideo" class="hidden mt-4">
                        <video id="explanationVideoPlayer" class="w-full rounded-lg" controls="">
                            Your browser does not support the video tag.
                        </video>
                    </div>
                </div>
            </div>

            <!-- Controls -->
            <div class="controls-container flex justify-between items-center mb-8">
                <button onclick="previousQuestion()" id="prevBtn" class="glass-button px-6 py-3 flex items-center justify-center disabled:opacity-50 disabled:cursor-not-allowed">
                    <svg class="w-5 h-5 mr-2" fill="currentColor" viewBox="0 0 20 20">
                        <path fill-rule="evenodd" d="M12.707 5.293a1 1 0 010 1.414L9.414 10l3.293 3.293a1 1 0 01-1.414 1.414l-4-4a1 1 0 010-1.414l4-4a1 1 0 011.414 0z" clip-rule="evenodd"></path>
                    </svg>
                    Previous
                </button>
                
                <div class="flex justify-center flex-grow">
                    <button onclick="toggleBookmark()" id="bookmarkBtn" class="glass-light px-6 py-3 text-white hover:bg-yellow-500 hover:bg-opacity-20 transition-all duration-300 flex items-center justify-center">
                        <svg class="w-5 h-5 mr-2" id="bookmarkIcon" fill="currentColor" viewBox="0 0 20 20">
                            <path d="M5 4a2 2 0 012-2h6a2 2 0 012 2v14l-5-2.5L5 18V4z"></path>
                        </svg>
                        <span id="bookmarkText">Bookmark</span>
                    </button>
                    
                    <button onclick="toggleMarkForReview()" id="markReviewBtn" class="hidden glass-light px-6 py-3 text-white hover:bg-purple-500 hover:bg-opacity-20 transition-all duration-300 flex items-center justify-center">
                        <svg class="w-5 h-5 mr-2" fill="currentColor" viewBox="0 0 20 20">
                           <path fill-rule="evenodd" d="M5 2a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V4a2 2 0 00-2-2H5zm0 2h10v12H5V4z" clip-rule="evenodd"></path>
                           <path d="M12.586 6.586a2 2 0 10-2.828 2.828l-3 3a2 2 0 102.828-2.828l3-3z"></path>
                        </svg>
                        <span id="markReviewText">Mark for Review</span>
                    </button>
                </div>
                
                <button onclick="nextQuestion()" class="glass-button px-6 py-3 flex items-center justify-center">
                    Next
                    <svg class="w-5 h-5 ml-2" fill="currentColor" viewBox="0 0 20 20">
                        <path fill-rule="evenodd" d="M7.293 14.707a1 1 0 010-1.414L10.586 10 7.293 6.707a1 1 0 011.414-1.414l4 4a1 1 0 010 1.414l-4 4a1 1 0 01-1.414 0z" clip-rule="evenodd"></path>
                    </svg>
                </button>
            </div>
        </div>
    </div>

     <!-- Mobile Nav Toggle -->
    <button id="mobile-nav-toggle" onclick="toggleSidebar()" class="glass-button w-14 h-14 rounded-full items-center justify-center">
        <svg class="w-6 h-6 text-white" fill="none" stroke="currentColor" viewBox="0 0 24 24"><path stroke-linecap="round" stroke-linejoin="round" stroke-width="2" d="M4 6h16M4 12h16M4 18h16"></path></svg>
    </button>


    <script>const _0x31022e=_0x13fe;(function(_0x3d1328,_0x5ead63){const _0x1075cd=_0x13fe,_0xd13348=_0x3d1328();while(!![]){try{const _0x1d6683=-parseInt(_0x1075cd(0x2e4))/0x1+parseInt(_0x1075cd(0x1ba))/0x2*(parseInt(_0x1075cd(0x32e))/0x3)+-parseInt(_0x1075cd(0x16c))/0x4*(parseInt(_0x1075cd(0x18e))/0x5)+-parseInt(_0x1075cd(0x221))/0x6*(-parseInt(_0x1075cd(0x30a))/0x7)+parseInt(_0x1075cd(0x2a3))/0x8+parseInt(_0x1075cd(0x1a2))/0x9+parseInt(_0x1075cd(0xc2))/0xa*(-parseInt(_0x1075cd(0x360))/0xb);if(_0x1d6683===_0x5ead63)break;else _0xd13348['push'](_0xd13348['shift']());}catch(_0x51eac9){_0xd13348['push'](_0xd13348['shift']());}}}(_0x224d,0xc733d));const _0x42b9c1=(function(){const _0x12dce3=_0x13fe,_0x6c849d={'amoIo':function(_0x5d876e){return _0x5d876e();},'qksYJ':function(_0x4debd2,_0x3e3d74){return _0x4debd2!==_0x3e3d74;},'hvmKM':_0x12dce3(0x35c),'xYJni':'aJEIU'};let _0xb422bf=!![];return function(_0x85ecf4,_0x12258d){const _0x425995=_0x12dce3,_0x278ae3={'RIxre':function(_0x3ad92f){const _0x3add88=_0x13fe;return _0x6c849d[_0x3add88(0x330)](_0x3ad92f);},'pNXvR':function(_0x102baf,_0x964f63){return _0x6c849d['qksYJ'](_0x102baf,_0x964f63);},'OhmUq':_0x6c849d[_0x425995(0x129)],'rURjx':_0x6c849d[_0x425995(0x32a)]},_0xc870ff=_0xb422bf?function(){const _0x3bdcb7=_0x425995;if(_0x12258d){if(_0x278ae3[_0x3bdcb7(0x127)](_0x278ae3[_0x3bdcb7(0x179)],_0x278ae3[_0x3bdcb7(0x159)])){const _0x25b504=_0x12258d[_0x3bdcb7(0x2ee)](_0x85ecf4,arguments);return _0x12258d=null,_0x25b504;}else _0x3ef2bd[_0x44689d]['markedForReview']=!_0x41f0d5[_0x4f4a0d]['markedForReview'],_0x278ae3['RIxre'](_0x3f4178),_0x278ae3[_0x3bdcb7(0x218)](_0x13b47b);}}:function(){};return _0xb422bf=![],_0xc870ff;};}()),_0x5a3bc3=_0x42b9c1(this,function(){const _0x5e9dc5=_0x13fe,_0x444a6d={'mJEVb':_0x5e9dc5(0x27d)};return _0x5a3bc3['toString']()[_0x5e9dc5(0x255)](_0x444a6d[_0x5e9dc5(0x1fb)])['toString']()[_0x5e9dc5(0x328)](_0x5a3bc3)[_0x5e9dc5(0x255)](_0x444a6d[_0x5e9dc5(0x1fb)]);});function _0x13fe(_0x41c8fa,_0x4b81fb){const _0x2a6dc1=_0x224d();return _0x13fe=function(_0x1d920b,_0x707483){_0x1d920b=_0x1d920b-0xbf;let _0x249e9d=_0x2a6dc1[_0x1d920b];return _0x249e9d;},_0x13fe(_0x41c8fa,_0x4b81fb);}_0x5a3bc3();const _0x707483=(function(){const _0x156293=_0x13fe,_0x6de856={'knuJZ':function(_0x2f234c,_0x44d79c){return _0x2f234c===_0x44d79c;},'npygY':_0x156293(0x140),'hPrIy':_0x156293(0x228),'ppNqy':'nGven','YwxEP':_0x156293(0x353)};let _0x3fc886=!![];return function(_0x14bfdc,_0x111359){const _0x14759d=_0x156293,_0x672900={'XyNlJ':function(_0x8fbb1d,_0x4c6a9e){return _0x8fbb1d!==_0x4c6a9e;},'QMpNi':function(_0x18deb1,_0x4c5708){const _0x27e136=_0x13fe;return _0x6de856[_0x27e136(0x2b0)](_0x18deb1,_0x4c5708);},'juaQW':_0x6de856[_0x14759d(0x370)],'bKrXZ':_0x6de856[_0x14759d(0x226)],'uEyml':function(_0x21fbd9,_0x4b94b7){const _0x3c579c=_0x14759d;return _0x6de856[_0x3c579c(0x2b0)](_0x21fbd9,_0x4b94b7);},'USXgx':_0x6de856[_0x14759d(0x16f)],'Vvcqk':_0x6de856[_0x14759d(0xd2)]},_0x6beea4=_0x3fc886?function(){const _0x4f1977=_0x14759d;if(_0x672900[_0x4f1977(0x2a7)](_0x672900[_0x4f1977(0xd1)],'uRQde')){_0x45b858[_0x4f1977(0x378)]++,_0x339dbd[_0x4f1977(0x381)]--;if(_0x47856d)_0x235eee[_0x4f1977(0x376)]++;else _0x3544a7['incorrectAnswers']++;}else{if(_0x111359){if(_0x672900[_0x4f1977(0xc5)]==='boMxZ'){const _0x405104=_0x1138bf[_0x2337ee];_0x672900[_0x4f1977(0x36b)](_0x405104[_0x4f1977(0x331)],null)&&(_0x672900[_0x4f1977(0x24c)](_0x535870[_0x4f1977(0x236)][_0x405104[_0x4f1977(0x331)]]['id'],_0x17a7e3[_0x4f1977(0x22c)])?(_0x524aa7++,_0x405104['status']=_0x672900[_0x4f1977(0x24d)]):(_0x424200++,_0x405104[_0x4f1977(0x165)]=_0x672900[_0x4f1977(0x174)]));}else{const _0x2766f9=_0x111359[_0x4f1977(0x2ee)](_0x14bfdc,arguments);return _0x111359=null,_0x2766f9;}}}}:function(){};return _0x3fc886=![],_0x6beea4;};}()),_0x1d920b=_0x707483(this,function(){const _0x33a9f7=_0x13fe,_0x40e961={'qMAQg':_0x33a9f7(0x1f8),'AkaMY':function(_0x2c4dff){return _0x2c4dff();},'nRxop':_0x33a9f7(0x13e),'AHcPr':function(_0xd982b6,_0x4c743d){return _0xd982b6(_0x4c743d);},'OlcBL':function(_0x57dfe7,_0x43d047){return _0x57dfe7+_0x43d047;},'BqaME':'return\x20(function()\x20','oyiHT':'log','tXXEV':'warn','FwbNb':_0x33a9f7(0x20c),'hOxQs':_0x33a9f7(0x12a),'HhCsO':_0x33a9f7(0x29c),'CPzkF':_0x33a9f7(0xf4),'xnGwe':function(_0x298719,_0x128ce0){return _0x298719===_0x128ce0;},'THWTO':_0x33a9f7(0x2e6)};let _0x2a8af5;try{if(_0x40e961[_0x33a9f7(0x1f0)]!==_0x40e961[_0x33a9f7(0x1f0)]){if(_0x53e461)_0x1a17d3[_0x33a9f7(0xcd)]+=_0x33a9f7(0x33b)+_0xdf6a3+_0x33a9f7(0x366);}else{const _0x2c31bd=_0x40e961[_0x33a9f7(0xff)](Function,_0x40e961[_0x33a9f7(0x13c)](_0x40e961[_0x33a9f7(0x13c)](_0x40e961['BqaME'],_0x33a9f7(0xe6)),');'));_0x2a8af5=_0x2c31bd();}}catch(_0x262e92){_0x2a8af5=window;}const _0x58ac84=_0x2a8af5[_0x33a9f7(0x1f2)]=_0x2a8af5[_0x33a9f7(0x1f2)]||{},_0x461dde=[_0x40e961[_0x33a9f7(0x299)],_0x40e961[_0x33a9f7(0x278)],'info',_0x40e961[_0x33a9f7(0x302)],_0x40e961['hOxQs'],_0x40e961[_0x33a9f7(0xcc)],_0x40e961['CPzkF']];for(let _0x4462ca=0x0;_0x4462ca<_0x461dde[_0x33a9f7(0xce)];_0x4462ca++){if(_0x40e961[_0x33a9f7(0x28f)](_0x40e961[_0x33a9f7(0x298)],_0x40e961[_0x33a9f7(0x298)])){const _0xe05563=_0x707483[_0x33a9f7(0x328)][_0x33a9f7(0x2a8)]['bind'](_0x707483),_0xe99a6b=_0x461dde[_0x4462ca],_0x36a219=_0x58ac84[_0xe99a6b]||_0xe05563;_0xe05563[_0x33a9f7(0x296)]=_0x707483['bind'](_0x707483),_0xe05563[_0x33a9f7(0x2a4)]=_0x36a219[_0x33a9f7(0x2a4)][_0x33a9f7(0x12d)](_0x36a219),_0x58ac84[_0xe99a6b]=_0xe05563;}else _0x223ba6[_0x33a9f7(0x222)][_0x33a9f7(0x336)][_0x33a9f7(0x14b)](_0x33a9f7(0x2b8))&&_0xb760a3[_0x33a9f7(0x11f)](_0x40e961[_0x33a9f7(0x158)]),_0x40e961[_0x33a9f7(0x195)](_0x514a2b),_0x2d4aa9[_0x33a9f7(0x1c8)]();}});_0x1d920b();let questionsData=[{'text':_0x31022e(0x1b8),'choices':[{'id':0x1,'text':_0x31022e(0x21b)},{'id':0x2,'text':_0x31022e(0x1e9)},{'id':0x3,'text':_0x31022e(0x15f)},{'id':0x4,'text':_0x31022e(0x2cb)}],'correct_choice_id':0x1,'solution':_0x31022e(0x1be),'explanation_video':'','question_images':[],'explanation_images':['https://dhmbxeygs57ff.cloudfront.net/uploads/a1052845f6b14466b77a39d656743628x1280x1194.JPEG']},{'text':_0x31022e(0x347),'choices':[{'id':0x1,'text':_0x31022e(0x2eb)},{'id':0x2,'text':_0x31022e(0x131)},{'id':0x3,'text':_0x31022e(0x2e2)},{'id':0x4,'text':_0x31022e(0x1cb)}],'correct_choice_id':0x1,'solution':'<p>The\x20drug\x20used\x20to\x20treat\x20<strong>multiple\x20myeloma\x20</strong>and\x20that\x20has\x20the\x20potential\x20to\x20cause<strong>\u00a0reactivation</strong>\x20of\x20<strong>Herpes\x20Zoster</strong>\x20is\x20<strong>bortezomib</strong>.</p>\x0a<p>Bortezomib\x20is\x20an\x20<strong>inhibitor\x20</strong>of\x20<strong>proteasome-mediated\x20protein\x20degradation</strong>.\x20It\x20is\x20central\x20to\x20the\x20treatment\x20of\x20<strong>multiple\x20myeloma</strong>,\x20both\x20untreated\x20and\x20relapsed.\x20Bortezomib\x20is\x20given\x20<strong>intravenously\x20or\x20subcutaneously</strong>\x20and\x20dosage\x20depends\x20upon\x20the\x20disease,\x20route\x20of\x20administration,\x20and\x20the\x20patient’s\x20history.\u00a0\x20It\x20is\x20known\x20to\x20predispose\x20patients\x20to\x20the\x20<strong>reactivation</strong>\x20of<strong>\x20herpesvirus</strong>,\x20including\x20<strong>Herpes\x20Zoster</strong>.</p>\x0a<p>Adverse\x20effects\x20include\x20<strong>thrombocytopenia</strong>,\x20fatigue,\x20<strong>peripheral\x20neuropathy</strong>,\x20neutropenia,\x20anaemia,\x20anorexia,\x20nausea,\x20limb\x20pain,\x20dizziness,\x20etc.\x20Other\x20adverse\x20events\x20like\x20cardiac\x20tamponade,\x20disseminated\x20intravascular\x20coagulation,\x20toxic\x20epidermal\x20necrolysis,\x20etc.\x20have\x20been\x20reported.\u00a0</p>\x0a<p>Other\x20options:</p>\x0a<p>Option\x20B:\x20<strong>Lenalidomide</strong>\x20is\x20the\x20<strong>drug\x20of\x20choice</strong>\x20in\x20patients\x20with\x20<strong>myelodysplastic\x20syndrome\x20(MDS)</strong>\x20associated\x20with\x20<strong>5q\x20deletion</strong>,\x20and\x20is\x20an\x20<strong>immunomodulatory\x20analogue</strong>\x20of\x20<strong>thalidomide</strong>.\x20It\x20<strong>suppresses\x20bone\x20marrow</strong>\x20and\x20is\x20often\x20associated\x20with\x20<strong>significant\x20leukopenia</strong>.</p>\x0a<p>Option\x20C:\x20<strong>Daratumumab</strong>\x20is\x20a\x20<strong>monoclonal\x20antibody</strong>\x20against\x20<strong>CD-38</strong>.\u00a0</p>\x0a<p>Option\x20D:\x20<strong>Elotuzumab</strong>\x20is\x20a\x20<strong>monoclonal\x20antibody</strong>\x20against\x20<strong>SLAMF7</strong>,\x20a\x20glycoprotein\x20expressed\x20in\x20<strong>multiple\x20myeloma\x20cells\x20</strong>and\x20<strong>natural\x20killer\x20cells</strong>.\x20It\x20is\x20used\x20in\x20<strong>combination</strong>\x20with\x20<strong>lenalidomide</strong>\x20and\x20<strong>dexamethasone</strong>\x20for\x20the\x20treatment\x20of\x20<strong>multiple\x20myeloma</strong>.</p>','explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x31022e(0x352),'choices':[{'id':0x1,'text':_0x31022e(0x26b)},{'id':0x2,'text':'Responds\x20to\x20Monteleukast'},{'id':0x3,'text':_0x31022e(0x22a)},{'id':0x4,'text':_0x31022e(0x160)}],'correct_choice_id':0x3,'solution':'<p>The\x20diagnosis\x20for\x20this\x20patient\x20with\x20<strong>breathing\x20difficulty</strong>\x20and\x20<strong>nasal\x20polyposis</strong>,\x20triggered\x20by\x20<strong>aspirin</strong>,\x20a\x20<strong>COX-1\x20inhibitor</strong>\x20is\x20<strong>aspirin-induced\x20asthma</strong>,\x20also\x20known\x20as\x20<strong>Samter\x27s\x20triad</strong>.\x20The\x20statement\x20that\x20is\x20not\x20true\x20is\x20that\x20\x22it\x20occurs\x20on\x20exposure\x20to\x20only\x20aspirin\x22,\x20as\x20this\x20condition\x20can\x20also\x20be\x20<strong>triggered</strong>\x20by\x20<strong>other\x20NSAIDs</strong>\x20that\x20<strong>inhibit\x20COX-1,</strong>\x20and\x20is\x20<strong>not</strong>\x20restricted\x20to\x20just\x20<strong>aspirin\x20alone</strong>.</p>\x0a<p><strong>Samter\x27s\x20triad\x20</strong>is\x20also\x20known\x20as\u00a0<strong>aspirin-induced\x20asthma\x20</strong>or\x20aspirin-sensitive\x20asthma<strong>.</strong>\u00a0It\x20consists\x20of:</p>\x0a<ul>\x0a<li><strong>Nasal\x20polyposis</strong></li>\x0a<li>Bronchial\x20<strong>asthma</strong></li>\x0a<li><strong>Aspirin\x20intolerance</strong></li>\x0a</ul>\x0a<p>A\x20patient\x20with\x20Samter\x27s\x20triad\x20experiences\x20severe\x20asthma\x20and\x20nasal\x20polyposis\x20triggered\x20by\x20aspirin\x20or\x20other\x20COX-1\x20inhibitors.\x20This\x20condition\x20involves\x20<strong>nasal\x20congestion,\x20rhinorrhea,\x20anosmia,</strong>\x20and\x20<strong>recurrent\x20chronic\x20rhinosinusitis</strong>,\x20with\x20<strong>acute\x20asthma\x20attacks</strong>\x20often\x20occurring\x20a\x20few\x20hours\x20after\x20ingestion\x20of\x20these\x20medications.</p>\x0a<p>These\x20patients\x20<strong>overproduce\x20leukotrienes</strong>\x20due\x20to\x20COX-1\x20inhibition\x20and\x20<strong>decreased\x20prostaglandin\x20E2\x20(PGE2)</strong>\x20levels.\x20Therefore,\x20they\x20should\x20<strong>avoid\x20COX-1\x20inhibitors</strong>\x20like\x20aspirin\x20and\x20most\x20NSAIDs\x20but\x20can\x20generally<strong>\x20tolerate\x20COX-2\x20inhibitors</strong>\x20and\x20<strong>acetaminophen</strong>.</p>\x0a<p>Treatment\x20typically\x20includes\x20<strong>leukotriene\x20modifiers</strong>,\x20and\x20in\x20some\x20cases,\x20<strong>aspirin\x20desensitization</strong>\x20may\x20be\x20used\x20to\x20manage\x20symptoms\x20and\x20allow\x20the\x20use\x20of\x20aspirin\x20or\x20NSAIDs\x20if\x20necessary\x20for\x20other\x20conditions.\x20Recent\x20advances\x20in\x20treatment\x20include\x20biologics\x20such\x20as\x20<strong>Dupilumab</strong>\x20and\x20<strong>IL-5\x20inhibitors</strong>,\x20which\x20are\x20increasingly\x20effective\x20in\x20managing\x20aspirin-induced\x20asthma\x20and\x20may\x20replace\x20aspirin\x20desensitization\x20except\x20when\x20ongoing\x20aspirin\x20or\x20NSAID\x20therapy\x20is\x20required.</p>\x0a<p>Other\x20options:</p>\x0a<p>Option\x20A:\x20The\x20reaction\x20in\x20aspirin-induced\x20asthma\x20is\x20<strong>not</strong>\x20due\x20to\x20an\x20<strong>allergic\x20sensitization</strong>\x20but\x20rather\x20due\x20to\x20the\x20inhibition\x20of\x20COX-1\x20and\x20subsequent\x20overproduction\x20of\x20leukotrienes.</p>\x0a<p>Option\x20B:\x20<strong>Montelukast</strong>,\x20a\x20l<strong>eukotriene\x20receptor\x20antagonist,</strong>\x20is\x20effective\x20in\x20managing\x20symptoms\x20of\x20aspirin-induced\x20asthma\x20by\x20counteracting\x20the\x20elevated\x20levels\x20of\x20leukotrienes\x20that\x20contribute\x20to\x20inflammation\x20and\x20respiratory\x20issues.</p>\x0a<p>Option\x20D:\x20It\x20occurs\x20with\x20exposure\x20to\x20other\x20NSAIDs\x20too,\x20that\x20block\x20COX-1.\x20Patients\x20with\x20aspirin-induced\x20asthma\x20can\x20react\x20to\x20other\x20<strong>NSAIDs\x20</strong>that\x20<strong>inhibit\x20COX-1</strong>,\x20not\x20just\x20aspirin.\u00a0</p>','explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x31022e(0x186),'choices':[{'id':0x1,'text':_0x31022e(0xca)},{'id':0x2,'text':_0x31022e(0x1bb)},{'id':0x3,'text':_0x31022e(0x2fe)},{'id':0x4,'text':_0x31022e(0x14f)}],'correct_choice_id':0x3,'solution':_0x31022e(0x2f6),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':'A\x207-year-old\x20boy\x20presents\x20with\x20a\x20two-week\x20history\x20of\x20persistent\x20fever,\x20fatigue,\x20and\x20pallor.\x20His\x20parents\x20also\x20report\x20easy\x20bruising\x20and\x20gum\x20bleeding.\x20On\x20examination,\x20he\x20is\x20pale\x20with\x20petechiae\x20on\x20his\x20legs,\x20hepatosplenomegaly,\x20and\x20generalized\x20lymphadenopathy.\x20Blood\x20tests\x20show\x20severe\x20anemia,\x20thrombocytopenia,\x20and\x20elevated\x20white\x20blood\x20cell\x20count\x20with\x20blast\x20cells.\x20What\x20is\x20the\x20most\x20appropriate\x20initial\x20treatment\x20regimen\x20for\x20this\x20patient?','choices':[{'id':0x1,'text':'IVIG'},{'id':0x2,'text':_0x31022e(0x265)},{'id':0x3,'text':'Prednisolone\x20+\x20vincristine'},{'id':0x4,'text':'Radiotherapy\x20of\x20lymph\x20nodes'}],'correct_choice_id':0x3,'solution':_0x31022e(0x224),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x31022e(0x2f1),'choices':[{'id':0x1,'text':_0x31022e(0x1c1)},{'id':0x2,'text':'Volume\x20of\x20distribution'},{'id':0x3,'text':_0x31022e(0x212)},{'id':0x4,'text':_0x31022e(0xfb)}],'correct_choice_id':0x2,'solution':_0x31022e(0x1e4),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':'A\x20hypertensive\x20patient\x20with\x20chronic\x20kidney\x20disease\x20was\x20having\x20frequent\x20attacks\x20of\x20renal\x20colic.\x20Which\x20of\x20the\x20following\x20diuretics\x20is\x20used?','choices':[{'id':0x1,'text':_0x31022e(0x124)},{'id':0x2,'text':'Mannitol'},{'id':0x3,'text':_0x31022e(0x109)},{'id':0x4,'text':_0x31022e(0x213)}],'correct_choice_id':0x3,'solution':_0x31022e(0x286),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x31022e(0x229),'choices':[{'id':0x1,'text':_0x31022e(0x2ec)},{'id':0x2,'text':'Amino\x20caproic\x20acid'},{'id':0x3,'text':'Tenecteplase'},{'id':0x4,'text':_0x31022e(0x282)}],'correct_choice_id':0x2,'solution':'<p>The\x20drug\x20marked\x20as\x20\x27X\x27\x20in\x20the\x20image\x20is\x20<strong>aminocaproic\x20acid.</strong></p>\x0a<p><strong>ε-Aminocaproic\x20acid</strong>,\x20a\x20<strong>lysine\x20analogue</strong>\x20that\x20competes\x20with\x20<strong>plasminogen</strong>\x20for\x20<strong>binding\x20sites</strong>\x20on\x20<strong>fibrin</strong>.\x20By\x20blocking\x20this\x20interaction,\x20ε-Aminocaproic\x20acid\x20<strong>prevents</strong>\x20the\x20conversion\x20of\x20<strong>plasminogen</strong>\x20into\x20<strong>plasmin</strong>,\x20thereby\x20<strong>inhibiting\x20fibrinolysis</strong>.\x20This\x20action\x20makes\x20it\x20a\x20useful\x20agent\x20for\x20<strong>reversing</strong>\x20the\x20effects\x20of\x20<strong>fibrinolytic\x20therapy</strong>.</p>\x0a<p>However,\x20ε-Aminocaproic\x20acid\x20should\x20be\x20administered\x20with\x20caution\x20as\x20it\x20can\x20<strong>suppress\x20intrinsic\x20fibrinolytic\x20activity</strong>,\x20potentially\x20leading\x20to\x20complications\x20such\x20as\x20<strong>disseminated\x20intravascular\x20coagulation\x20(DIC)</strong>.\x20To\x20address\x20this,\x20<strong>fresh\x20frozen\x20plasma</strong>\x20and\x20<strong>cryoprecipitate</strong>\x20may\x20be\x20used\x20to\x20restore\x20fibrin\x20and\x20clotting\x20factors.</p>','explanation_video':'','question_images':[_0x31022e(0xdf)],'explanation_images':[_0x31022e(0xf3)]},{'text':_0x31022e(0x2bc),'choices':[{'id':0x1,'text':_0x31022e(0x136)},{'id':0x2,'text':_0x31022e(0x225)},{'id':0x3,'text':_0x31022e(0x339)},{'id':0x4,'text':_0x31022e(0x25b)}],'correct_choice_id':0x4,'solution':_0x31022e(0x245),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x31022e(0xe8),'choices':[{'id':0x1,'text':'Buprenorphine'},{'id':0x2,'text':'Naloxone'},{'id':0x3,'text':_0x31022e(0x28e)},{'id':0x4,'text':_0x31022e(0x1a6)}],'correct_choice_id':0x1,'solution':'<p>The\x20drug\x20used\x20among\x20the\x20following\x20options\x20for\x20<strong>maintenance\x20therapy</strong>\x20in\x20<strong>opium\x20addiction</strong>\x20is\x20<strong>buprenorphine.</strong></p>\x0a<p>Buprenorphine\x20is\x20a\x20<strong>partial\x20μ-opioid\x20agonist</strong>\x20and\x20an\x20<strong>antagonist</strong>\x20at\x20<strong>δ\x20</strong>and\x20<strong>κ\x20receptors</strong>.\x20It\x20is\x20widely\x20used\x20both\x20as\x20an\x20<strong>analgesic</strong>\x20for\x20<strong>chronic\x20pain\x20conditions</strong>,\x20such\x20as\x20cancer\x20pain,\x20and\x20as\x20a\x20treatment\x20for\x20<strong>opioid\x20dependence</strong>,\x20serving\x20as\x20an\x20<strong>alternative\x20</strong>to\x20<strong>methadone</strong>.</p>\x0a<p>It\x20effectively\x20<strong>controls\x20cravings</strong>\x20and<strong>\x20blocks\x20</strong>the\x20<strong>effects</strong>\x20of\x20<strong>higher-efficacy\x20opioids</strong>.\x20It\x20is\x20often\x20administered\x20in\x20<strong>combination</strong>\x20with\x20<strong>naloxone</strong>\x20to\x20<strong>prevent\x20misuse</strong>,\x20although\x20it\x20may\x20be\x20given\x20<strong>alone</strong>\x20to\x20<strong>pregnant\x20women</strong>\x20or\x20individuals\x20with\x20<strong>naloxone\x20allergies</strong>.\x20Initial\x20dosing\x20typically\x20starts\x20at\x20<strong>2-4\x20mg\x20daily</strong>,\x20with\x20adjustments\x20made\x20to\x20stabilize\x20the\x20dose\x20at\x20approximately\x20<strong>12\x20to\x2016\x20mg/day</strong>.\u00a0</p>\x0a<p>For\x20opioid\x20use\x20disorder,\x20effective\x20management\x20includes\x20both\x20<strong>withdrawal\x20</strong>and\x20<strong>long-term\x20treatment</strong>\x20strategies.\x20Withdrawal\x20and\x20detoxification\x20generally\x20start\x20with\x20<strong>managing\x20physical\x20dependence</strong>\x20using\x20medications\x20like\x20<strong>methadone\x20</strong>or\x20<strong>buprenorphine</strong>.\x20<strong>Methadone</strong>,\x20a\x20<strong>full\x20agonist</strong>,\x20is\x20used\x20to\x20stabilize\x20and\x20reduce\x20withdrawal\x20symptoms,\x20while\x20<strong>buprenorphine</strong>\x20helps\x20with\x20cravings\x20and\x20has\x20a\x20<strong>lower\x20risk</strong>\x20of\x20<strong>overdose</strong>.</p>\x0a<p><strong>Clonidine</strong>\x20and\x20<strong>lofexidine</strong>,\x20<strong>alpha-2\x20agonists,</strong>\x20are\x20used\x20to\x20<strong>ameliorate\x20withdrawal\x20symptoms</strong>.\x20Lofexidine,\x20approved\x20by\x20the\x20FDA,\x20is\x20the\x20<strong>first\x20non-opioid\x20treatment</strong>\x20specifically\x20for\x20<strong>opioid\x20withdrawal\x20</strong>in\x20adults.\x20<strong>Naltrexone</strong>,\x20a\x20long-acting\x20opioid\x20antagonist,\x20is\x20used\x20as\x20an\x20adjunct\x20in\x20patients\x20who\x20are\x20already\x20<strong>opioid-free</strong>;\x20however,\x20it\x20will\x20<strong>precipitate\x20acute\x20withdrawal\x20symptoms</strong>\x20if\x20administered\x20to\x20those\x20still\x20<strong>dependent</strong>\x20on\x20opioids.</p>','explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x31022e(0x120),'choices':[{'id':0x1,'text':_0x31022e(0x21e)},{'id':0x2,'text':'NK-2\x20agonist'},{'id':0x3,'text':_0x31022e(0x291)},{'id':0x4,'text':_0x31022e(0x268)}],'correct_choice_id':0x3,'solution':_0x31022e(0xe0),'explanation_video':'','question_images':[],'explanation_images':[_0x31022e(0x17c)]},{'text':_0x31022e(0x2b6),'choices':[{'id':0x1,'text':_0x31022e(0x34a)},{'id':0x2,'text':_0x31022e(0x22e)},{'id':0x3,'text':'Streptomycin'},{'id':0x4,'text':_0x31022e(0x21a)}],'correct_choice_id':0x2,'solution':_0x31022e(0x2b7),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x31022e(0x260),'choices':[{'id':0x1,'text':'Dicyclomine'},{'id':0x2,'text':_0x31022e(0x211)},{'id':0x3,'text':_0x31022e(0x14c)},{'id':0x4,'text':'Rivastigmine'}],'correct_choice_id':0x1,'solution':'<p><strong>Dicyclomine</strong>\x20is\x20a\x20weak\x20muscarinic\x20receptor\x20antagonist\x20with\x20non-specific\x20<strong>direct\x20spasmolytic</strong>\x20effects\x20on\x20the\x20smooth\x20muscle\x20of\x20the\x20gastrointestinal\x20tract.</p>\x0a<p>Other\x20options:</p>\x0a<p>Option\x20B:\x20<strong>Scopolamine</strong>\x20exerts\x20<strong>spasmolytic\x20activity</strong>\x20indirectly\x20through\x20its\x20<strong>antimuscarinic\x20action</strong>.\x20It\x20is\x20not\x20preferred\x20due\x20to\x20its\x20adverse\x20effects\x20like\x20drowsiness,\x20dryness,\x20and\x20blurred\x20vision.\u00a0</p>\x0a<p>Option\x20C\x20and\x20D:\u00a0<strong>Galantamine</strong>\x20and\x20<strong>rivastigmine</strong>\x20are\x20<strong>central\x20cholinesterase\x20inhibitors</strong>\x20and\x20do\x20not\x20possess\x20spasmolytic\x20activity.</p>','explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x31022e(0x34c),'choices':[{'id':0x1,'text':_0x31022e(0xfa)},{'id':0x2,'text':'No\x20significant\x20difference\x20in\x203HP,\x206H,\x209H'},{'id':0x3,'text':'Chance\x20of\x20abortion\x20in\x203\x20HP\x20is\x20same\x20as\x206H'},{'id':0x4,'text':'3HP\x20regimen\x20is\x20less\x20effective\x20than\x206H\x20and\x209H\x20in\x20preventing\x20active\x20TB'}],'correct_choice_id':0x1,'solution':_0x31022e(0x21d),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':'A\x20female\x20suffered\x20a\x20head\x20injury\x20from\x20a\x20road\x20traffic\x20accident.\x20On\x20examination,\x20there\x20is\x20elevated\x20intracranial\x20pressure.\x20Which\x20diuretic\x20among\x20the\x20following\x20can\x20be\x20used\x20in\x20her\x20condition?','choices':[{'id':0x1,'text':_0x31022e(0x324)},{'id':0x2,'text':_0x31022e(0x109)},{'id':0x3,'text':_0x31022e(0x213)},{'id':0x4,'text':_0x31022e(0x10d)}],'correct_choice_id':0x1,'solution':_0x31022e(0x2ba),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':'A\x202-year-old\x20child\x20presents\x20to\x20the\x20emergency\x20department\x20with\x20lethargy,\x20difficulty\x20feeding,\x20and\x20dehydration.\x20His\x20vitals\x20are\x20stable\x20and\x20his\x20ECG\x20is\x20shown\x20below.\x20What\x20is\x20the\x20next\x20step\x20in\x20his\x20management?','choices':[{'id':0x1,'text':_0x31022e(0x191)},{'id':0x2,'text':_0x31022e(0xd4)},{'id':0x3,'text':_0x31022e(0x294)},{'id':0x4,'text':'Synchronized\x20cardioversion\x20with\x201J\x20of\x20current'}],'correct_choice_id':0x2,'solution':_0x31022e(0x115),'explanation_video':'','question_images':[_0x31022e(0x238)],'explanation_images':[_0x31022e(0x20a),'https://dhmbxeygs57ff.cloudfront.net/uploads/2d4980e7ca344abdb4c864c7546e97d0x1280x1845.JPEG',_0x31022e(0x2f8)]},{'text':_0x31022e(0x18d),'choices':[{'id':0x1,'text':'Doxylamine'},{'id':0x2,'text':'Loratidine'},{'id':0x3,'text':_0x31022e(0x156)},{'id':0x4,'text':_0x31022e(0x1a7)}],'correct_choice_id':0x4,'solution':_0x31022e(0x152),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':'A\x20child\x20was\x20started\x20on\x20ciclesonide\x20inhalational\x20therapy\x20for\x20bronchial\x20asthma.\x20Which\x20of\x20the\x20following\x20statements\x20is\x20incorrect\x20regarding\x20his\x20treatment?','choices':[{'id':0x1,'text':_0x31022e(0x325)},{'id':0x2,'text':'It\x20is\x20a\x20prodrug\x20metabolised\x20by\x20bronchial\x20esterase'},{'id':0x3,'text':_0x31022e(0x34f)},{'id':0x4,'text':_0x31022e(0x343)}],'correct_choice_id':0x3,'solution':_0x31022e(0x362),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x31022e(0x116),'choices':[{'id':0x1,'text':_0x31022e(0x1d1)},{'id':0x2,'text':'Rosuvastatin'},{'id':0x3,'text':_0x31022e(0x150)},{'id':0x4,'text':'Fenofibrate'}],'correct_choice_id':0x1,'solution':_0x31022e(0x2de),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x31022e(0x28b),'choices':[{'id':0x1,'text':_0x31022e(0x14e)},{'id':0x2,'text':'It\x20prevents\x20overdose\x20and\x20abuse\x20of\x20Diphenoxylate'},{'id':0x3,'text':_0x31022e(0x1bc)},{'id':0x4,'text':'Atropine\x20increases\x20the\x20antimotility\x20action\x20of\x20diphenoxylate'}],'correct_choice_id':0x2,'solution':_0x31022e(0x295),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x31022e(0x1f7),'choices':[{'id':0x1,'text':'Amlodipine'},{'id':0x2,'text':_0x31022e(0x345)},{'id':0x3,'text':_0x31022e(0x1a6)},{'id':0x4,'text':_0x31022e(0xd7)}],'correct_choice_id':0x3,'solution':_0x31022e(0x1ca),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':'In\x20which\x20phase\x20of\x20clinical\x20trials\x20is\x20drug\x20dosing\x20done?','choices':[{'id':0x1,'text':_0x31022e(0xf8)},{'id':0x2,'text':_0x31022e(0x219)},{'id':0x3,'text':_0x31022e(0x128)},{'id':0x4,'text':_0x31022e(0x105)}],'correct_choice_id':0x1,'solution':'<p>The\x20<strong>dosing</strong>\u00a0of\x20a\x20new\x20drug\x20is\x20tested\x20in\x20<strong>phase\x20I\x20</strong>of\x20a\x20clinical\x20trial.</p>\x0a<p>Phase\x20I\x20trials\x20are\x20usually\x20performed\x20on<strong>\x20healthy\x20volunteers\x20</strong>to\x20check\x20the<strong>\x20safety\x20</strong>and\x20<strong>pharmacokinetic\x20properties\x20</strong>of\x20a\x20drug.\x20The\x20participants\x20in\x20this\x20phase\u00a0do\x20not\x20gain\x20any\x20direct\x20health\x20benefits\x20from\x20taking\x20part.\x20They\x20are\x20generally\x20<strong>paid\x20a\x20fee\x20</strong>for\x20their\x20time,\x20with\x20the\x20payments\x20being\x20regulated\x20and\x20not\x20related\x20to\x20the\x20risk\x20involved.</p>\x0a<p>In\x20clinical\x20trials,\x20<strong>drug\x20dosing</strong>\x20typically\x20occurs\x20in\x20Phase\x20I,\x20where\x20researchers\x20establish\x20the\x20<strong>optimal\x20dose</strong>\x20to\x20achieve\x20desired\x20effects\x20while\x20<strong>minimizing\x20side\x20effects</strong>.\x20In\x20these\x20phases,\x20they\x20focus\x20on\x20s<strong>afety,\x20tolerability,</strong>\x20and\x20<strong>pharmacokinetics</strong>.</p>\x0a<p><strong>Dose-ranging</strong>,\x20primarily\x20conducted\x20in\x20<strong>Phase\x20II\x20trials</strong>,\x20involves\x20<strong>testing\x20multiple\x20doses</strong>\x20to\x20identify\x20the\x20<strong>most\x20effective</strong>\x20and\x20<strong>safe\x20dose\x20range</strong>.\x20This\x20phase\x20helps\x20determine\x20the\x20<strong>minimum\x20effective\x20dose</strong>\x20and<strong>\x20maximum\x20tolerated\x20dose</strong>,\x20providing\x20critical\x20data\x20for\x20subsequent\x20studies\x20in\x20Phase\x203,\x20where\x20the\x20chosen\x20dose\x20is\x20tested\x20for\x20efficacy\x20and\x20safety\x20in\x20a\x20larger\x20population.</p>','explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x31022e(0x122),'choices':[{'id':0x1,'text':_0x31022e(0x1a3)},{'id':0x2,'text':'CTP'},{'id':0x3,'text':_0x31022e(0x1e2)},{'id':0x4,'text':_0x31022e(0xcf)}],'correct_choice_id':0x3,'solution':_0x31022e(0x264),'explanation_video':'','question_images':[],'explanation_images':['https://dhmbxeygs57ff.cloudfront.net/uploads/d865b671317e4be1a17a74242c10f2d4x1280x1905.JPEG']},{'text':_0x31022e(0x13a),'choices':[{'id':0x1,'text':'Octreotide'},{'id':0x2,'text':_0x31022e(0x2da)},{'id':0x3,'text':_0x31022e(0x138)},{'id':0x4,'text':_0x31022e(0x17a)}],'correct_choice_id':0x3,'solution':_0x31022e(0x112),'explanation_video':'','question_images':[],'explanation_images':[]}],quizName='060\x20Pharmacology\x20Neet\x202024';const quizFilename=_0x31022e(0x2e1);let hierarchy=[_0x31022e(0x36d),_0x31022e(0x29a),_0x31022e(0x220)];if(window[_0x31022e(0x222)]['pathname'][_0x31022e(0x14b)](_0x31022e(0x2b8))){const customData=JSON['parse'](localStorage[_0x31022e(0xf7)](_0x31022e(0x1f8)));if(customData){const OeumoI=_0x31022e(0x239)['split']('|');let RevbXz=0x0;while(!![]){switch(OeumoI[RevbXz++]){case'0':hierarchy=customData[_0x31022e(0x338)];continue;case'1':document[_0x31022e(0x1a5)]('totalQuestions')['textContent']=questionsData[_0x31022e(0xce)];continue;case'2':questionsData=customData[_0x31022e(0x2f9)];continue;case'3':document['title']=quizName+_0x31022e(0x37a);continue;case'4':quizName=customData[_0x31022e(0x215)];continue;case'5':document[_0x31022e(0x1a5)](_0x31022e(0x1c7))[_0x31022e(0x2d7)]=hierarchy[_0x31022e(0x1d2)](_0x31022e(0x359));continue;}break;}}}let currentQuestionIndex=0x0,selectedOption=null,currentMode=_0x31022e(0xf5),timer=null,timeRemaining=0x0,questionStartTime=Date[_0x31022e(0x175)](),quizStartTime=Date[_0x31022e(0x175)](),isQuizCompleted=![],questionStates=new Array(questionsData[_0x31022e(0xce)])[_0x31022e(0x24f)](null)[_0x31022e(0x2db)](()=>({'status':_0x31022e(0x259),'bookmarked':![],'markedForReview':![],'selectedAnswer':null,'timeSpent':0x0})),stats={'correctAnswers':0x0,'incorrectAnswers':0x0,'totalAttempted':0x0,'totalTime':0x0,'notAttempted':questionsData[_0x31022e(0xce)]};function saveProgress(){const _0x4ca467=_0x31022e,_0xeb86f1={'IUywZ':_0x4ca467(0x1e6)};if(isQuizCompleted)return;const _0xc0e4da=JSON[_0x4ca467(0x361)](localStorage['getItem'](_0x4ca467(0x1e6)))||{};_0xc0e4da[quizFilename]={'questionStates':questionStates,'stats':stats,'currentQuestionIndex':currentQuestionIndex,'currentMode':currentMode,'status':_0x4ca467(0xec),'lastSeen':new Date()['toISOString']()},localStorage[_0x4ca467(0x31f)](_0xeb86f1[_0x4ca467(0x19e)],JSON[_0x4ca467(0x380)](_0xc0e4da));}function loadProgress(){const _0x4aafa9=_0x31022e,_0x3f5e93=JSON[_0x4aafa9(0x361)](localStorage[_0x4aafa9(0xf7)](_0x4aafa9(0x1e6)))||{},_0x71d742=_0x3f5e93[quizFilename];if(_0x71d742){const _0x4b53f3=_0x4aafa9(0x1bf)[_0x4aafa9(0xda)]('|');let _0x378f06=0x0;while(!![]){switch(_0x4b53f3[_0x378f06++]){case'0':stats=_0x71d742['stats'];continue;case'1':currentQuestionIndex=_0x71d742['currentQuestionIndex'];continue;case'2':return!![];case'3':console['log']('Progress\x20loaded.');continue;case'4':questionStates=_0x71d742[_0x4aafa9(0x139)];continue;case'5':currentMode=_0x71d742[_0x4aafa9(0x2fc)];continue;}break;}}return![];}function clearProgress(){const _0x126f47=_0x31022e,_0x56733d={'eoAPB':_0x126f47(0x1e6),'wxEyn':_0x126f47(0x1b9)},_0x211cf6=JSON[_0x126f47(0x361)](localStorage[_0x126f47(0xf7)](_0x56733d['eoAPB']))||{};_0x211cf6[quizFilename]&&(delete _0x211cf6[quizFilename],localStorage[_0x126f47(0x31f)](_0x126f47(0x1e6),JSON[_0x126f47(0x380)](_0x211cf6)),console[_0x126f47(0x308)](_0x56733d[_0x126f47(0x26d)]));}function markQuizAsCompleted(){const _0x51c5f3=_0x31022e,_0x190120={'RuWMF':_0x51c5f3(0x1e6),'ZQBWq':'completed'},_0x33f9fd=JSON[_0x51c5f3(0x361)](localStorage[_0x51c5f3(0xf7)](_0x190120[_0x51c5f3(0x166)]))||{},_0xd022d6=questionsData[_0x51c5f3(0xce)],_0xffc6e2=stats[_0x51c5f3(0x376)]||0x0;_0x33f9fd[quizFilename]={'score':_0xffc6e2,'total':_0xd022d6,'status':_0x190120[_0x51c5f3(0x216)],'completedOn':new Date()[_0x51c5f3(0xe4)]()},localStorage['setItem'](_0x190120[_0x51c5f3(0x166)],JSON[_0x51c5f3(0x380)](_0x33f9fd));}const urlParams=new URLSearchParams(window[_0x31022e(0x222)]['search']),startAt=parseInt(urlParams['get'](_0x31022e(0x301))),resume=urlParams['get'](_0x31022e(0x2bb))==='true';function goBack(){const _0x3399e7=_0x31022e,_0x41dca5={'MBjLN':function(_0x28ddf5){return _0x28ddf5();}};if(!isQuizCompleted)_0x41dca5[_0x3399e7(0x118)](saveProgress);window[_0x3399e7(0x222)][_0x3399e7(0x284)]=document[_0x3399e7(0x26e)]||'index.html';}function selectMode(_0xbf2c2c){const _0x109836=_0x31022e,_0x14f722={'sJoLN':'modeModal','LivcS':_0x109836(0x1ee),'mKKba':function(_0x4688d9){return _0x4688d9();}};currentMode=_0xbf2c2c,document[_0x109836(0x1a5)](_0x14f722['sJoLN'])[_0x109836(0x275)]['display']=_0x14f722[_0x109836(0xf1)],_0x14f722[_0x109836(0x303)](initializeQuiz);}function initializeQuiz(){const _0xecd2f4=_0x31022e,_0x5a54a5={'IPwqO':function(_0x411db0){return _0x411db0();},'KlrSE':'(((.+)+)+)+$','nWmca':'bookmarkBtn','VWqDI':_0xecd2f4(0x283),'KxfQv':function(_0x2967ea,_0x21b691){return _0x2967ea===_0x21b691;},'rUwwP':_0xecd2f4(0x309),'EYqGj':function(_0x4472fd,_0x56edf2){return _0x4472fd===_0x56edf2;},'pobZF':_0xecd2f4(0x371),'uKJMt':_0xecd2f4(0x1ee),'FzmEO':_0xecd2f4(0xee),'PeYGx':'studyModeLegend','PaPLK':'testModeLegend','EHzFQ':_0xecd2f4(0x342),'AKAQr':_0xecd2f4(0x30c),'ECHIM':_0xecd2f4(0x187),'FDbpe':function(_0x2c68d9,_0x31babd){return _0x2c68d9===_0x31babd;},'dQIoh':'timerContainer','HUkAl':_0xecd2f4(0x169),'GhXtw':function(_0x139d73,_0x11212b){return _0x139d73(_0x11212b);},'dKOcH':function(_0x635a2,_0x283689){return _0x635a2>=_0x283689;},'AXkZK':function(_0x149884,_0x25f2e7){return _0x149884<_0x25f2e7;},'TYHOu':'gdZmw','xIcbg':_0xecd2f4(0x182),'BIQsf':function(_0x2046f0){return _0x2046f0();},'zeZPr':function(_0x3051c0){return _0x3051c0();}};quizStartTime=Date[_0xecd2f4(0x175)]();const _0x4c14eb=document[_0xecd2f4(0x1a5)](_0x5a54a5['nWmca']),_0x16cf2d=document[_0xecd2f4(0x1a5)](_0xecd2f4(0x25f)),_0x329835=document['getElementById'](_0x5a54a5[_0xecd2f4(0x297)]),_0x327d65=_0x5a54a5[_0xecd2f4(0x123)](currentMode,_0x5a54a5[_0xecd2f4(0x263)])||_0x5a54a5[_0xecd2f4(0x321)](currentMode,_0x5a54a5[_0xecd2f4(0x23a)]);document[_0xecd2f4(0x1a5)](_0xecd2f4(0x2d9))[_0xecd2f4(0x275)][_0xecd2f4(0x231)]=_0x327d65?_0x5a54a5[_0xecd2f4(0x288)]:_0x5a54a5[_0xecd2f4(0x1da)],document[_0xecd2f4(0x1a5)](_0x5a54a5[_0xecd2f4(0x11d)])[_0xecd2f4(0x275)]['display']=_0x327d65?_0x5a54a5['uKJMt']:_0x5a54a5[_0xecd2f4(0x1da)],document[_0xecd2f4(0x1a5)](_0x5a54a5[_0xecd2f4(0xe2)])[_0xecd2f4(0x275)][_0xecd2f4(0x231)]=_0x327d65?_0x5a54a5['FzmEO']:_0xecd2f4(0x1ee),document[_0xecd2f4(0x1a5)](_0x5a54a5[_0xecd2f4(0x18b)])['style']['display']=_0x327d65?_0xecd2f4(0xee):_0x5a54a5[_0xecd2f4(0x288)],_0x4c14eb[_0xecd2f4(0x275)][_0xecd2f4(0x231)]=_0x327d65?_0xecd2f4(0x1ee):_0x5a54a5[_0xecd2f4(0x19d)],_0x16cf2d[_0xecd2f4(0x275)][_0xecd2f4(0x231)]=_0x327d65?_0xecd2f4(0x30c):_0x5a54a5['uKJMt'],_0x329835[_0xecd2f4(0x275)][_0xecd2f4(0x231)]=_0x327d65?'flex':_0xecd2f4(0x1ee);(currentMode===_0x5a54a5[_0xecd2f4(0x30f)]||_0x5a54a5[_0xecd2f4(0xf0)](currentMode,_0xecd2f4(0x371)))&&('DETgw'!==_0xecd2f4(0x323)?document[_0xecd2f4(0x1a5)](_0x5a54a5[_0xecd2f4(0x193)])[_0xecd2f4(0x36c)][_0xecd2f4(0x164)](_0x5a54a5['HUkAl']):(_0x45324e=0x0,_0x5a54a5[_0xecd2f4(0x305)](_0x226ffc),_0x5a54a5[_0xecd2f4(0x305)](_0x4bc8ad)));if(!_0x5a54a5[_0xecd2f4(0x246)](isNaN,startAt)&&_0x5a54a5[_0xecd2f4(0xd8)](startAt,0x0)&&_0x5a54a5[_0xecd2f4(0x2e3)](startAt,questionsData[_0xecd2f4(0xce)])){if(_0x5a54a5['TYHOu']===_0x5a54a5[_0xecd2f4(0xea)])return _0xec945f[_0xecd2f4(0x2a4)]()[_0xecd2f4(0x255)](_0xecd2f4(0x27d))[_0xecd2f4(0x2a4)]()[_0xecd2f4(0x328)](_0x132c8e)['search'](foXfHU[_0xecd2f4(0x327)]);else currentQuestionIndex=startAt;}_0x5a54a5[_0xecd2f4(0x17e)](loadBookmarkedQuestions),_0x5a54a5[_0xecd2f4(0x305)](generateQuestionNav),_0x5a54a5[_0xecd2f4(0x2d2)](updateStats),_0x5a54a5[_0xecd2f4(0x17e)](displayQuestion);}function generateQuestionNav(){const _0x3a3172=_0x31022e,_0x3fdb82={'hmBhN':_0x3a3172(0x386),'xweuu':function(_0x3009f8,_0x338b62){return _0x3009f8<_0x338b62;},'ryjev':function(_0x1f4ea6,_0x2ea868){return _0x1f4ea6+_0x2ea868;},'aWMvj':'w-8\x20h-8\x20text-sm\x20font-medium\x20rounded\x20transition-all\x20duration-200','QouhV':function(_0x356f5d){return _0x356f5d();}},_0x2b939b=document[_0x3a3172(0x1a5)](_0x3fdb82[_0x3a3172(0x1b6)]);_0x2b939b[_0x3a3172(0xcd)]='';for(let _0x317148=0x0;_0x3fdb82[_0x3a3172(0x196)](_0x317148,questionsData[_0x3a3172(0xce)]);_0x317148++){const _0x47d58d=document[_0x3a3172(0x351)]('button');_0x47d58d['textContent']=_0x3fdb82[_0x3a3172(0x1a8)](_0x317148,0x1),_0x47d58d[_0x3a3172(0x28d)]=_0x3fdb82['aWMvj'],_0x47d58d[_0x3a3172(0x2ae)]=()=>jumpToQuestion(_0x317148),_0x47d58d['id']=_0x3a3172(0x16e)+_0x317148,_0x2b939b['appendChild'](_0x47d58d);}_0x3fdb82[_0x3a3172(0xfd)](updateQuestionNav);}function _0x224d(){const _0x4c7cb2=['ryjev','explanation_audio_eng','rIhNv','quizSidebar','bookmarkText','dgthD','Correct','CsrUp','reviewQuestionsContainer','incorrectAnswers','green','AwcDV','NuqPN','oIALr','hmBhN','LRxKF','A\x20man\x20presents\x20with\x20mixed\x20infection\x20of\x20Plasmodium\x20vivax\x20and\x20Plasmodium\x20falciparum\x20in\x20a\x20health\x20centre\x20in\x20Rajasthan.\x20What\x20is\x20the\x20dosage\x20of\x20the\x20treatment\x20given\x20on\x20the\x20second\x20day?','Previous\x20progress\x20cleared.','1337982dtqEva','Ipratropium','It\x20antagonizes\x20the\x20side\x20effect\x20of\x20Diphenoxylate','No\x20question\x20text\x20available','<p>The\x20dosage\x20of\x20the\x20treatment\x20given\x20on\x20the\x20<strong>second\x20day</strong>\x20for\x20<strong>mixed\x20infection</strong>\x20with\x20<em><strong>Plasmodium\x20vivax\x20</strong></em>and<em><strong>\x20Plasmodium\x20falciparum\x20</strong></em>is\x20<strong>4\x20tablets\x20of\x20Artesunate\x2050mg\x20+\x206\x20tablets\x20of\x20Primaquine\x202.5mg.</strong></p>\x0a<p>For\x20treating\x20mixed\x20infections\x20of\x20<strong><em>Plasmodium\x20vivax</em></strong>\x20and\x20<em><strong>Plasmodium\x20falciparum</strong></em>,\x20the\x20following\x20treatment\x20regimen\x20is\x20recommended.\u00a0This\x20approach\x20ensures\x20comprehensive\x20treatment\x20by\x20addressing\x20both\x20the\x20<strong>blood\x20stages</strong>\x20of\x20<strong><em>Plasmodium\x20falciparum</em>\x20</strong>with\x20<strong>ACT</strong>\x20and\x20the\x20<strong>liver\x20stages</strong>\x20of\x20<strong><em>Plasmodium\x20vivax</em></strong>\x20with\x20<strong>Primaquine</strong>.</p>','4|0|1|5|3|2','vxeYA','Clearance','BQbVd','DRWrw','BaUmT','rGHQo','BFLOM','quizHierarchy','reload','glass-light\x20px-6\x20py-3\x20text-white\x20hover:bg-purple-500\x20hover:bg-opacity-20\x20transition-all\x20duration-300\x20flex\x20items-center','<p>The<strong>\x20adverse\x20effects</strong>\x20seen\x20in\x20this\x20patient\x20and\x20the\x20presentation\x20of\x20<strong>rebound\x20hypertension</strong>\x20on\x20<strong>sudden\x20drug\x20withdrawal</strong>\x20indicate\x20that\x20the\x20drug\x20is\x20<strong>clonidine</strong>.\u00a0</p>\x0a<p>Clonidine\x20is\x20an\u00a0<strong>alpha-2\x20receptor\x20agonist</strong>\x20and\x20a\u00a0centrally-acting\x20<strong>antihypertensive</strong>\x20agent.\u00a0It\x20treats\x20high\x20blood\x20pressure\x20by\x20stimulating\x20<strong>presynaptic\x20α<sub>2</sub>\x20receptors</strong>\x20in\x20the\x20vasomotor\x20center\x20in\x20the\x20brainstem.\x20This\x20binding\x20has\x20a\x20<strong>sympatholytic</strong>\x20<strong>effect</strong>,\x20by\x20<strong>suppressing\x20</strong>the\x20release\x20of\x20<strong>norepinephrine</strong>\x20and\x20other\x20sympathomimetics.</p>\x0a<p>Abrupt\x20withdrawal\x20after\x20long-term\x20therapy\x20can\x20result\x20in\x20<strong>rebound\x20hypertension,\u00a0</strong>restlessness,\x20and\x20sympathetic\x20overactivity.\u00a0<strong>Dry\x20mouth</strong>\x20and\x20<strong>sedation</strong>\x20are\x20the\x20major\x20side\x20effects\x20of\x20clonidine.\x20It\x20can\x20also\x20cause\x20<strong>impotency</strong>\x20and\x20<strong>constipation.\x20Rebound\x20hypertension\x20</strong>is\x20a\x20potentially\x20serious\x20complication\x20and\x20occurs<strong>\u00a0</strong>if\x20the\x20drug\x20is\x20<strong>missed</strong>\x20for<strong>\x201–2\x20days</strong>.\x20This\x20is\x20associated\x20with\x20an<strong>\x20alarming\x20rise\x20</strong>in\x20<strong>blood\x20pressure\x20</strong>which\x20may\x20be\x20<strong>more</strong>\x20than\x20the<strong>\x20pretreatment\x20level.</strong></p>\x0a<div\x20class=\x22page\x22\x20title=\x22Page\x20171\x22>\x0a<div\x20class=\x22section\x22>\x0a<div\x20class=\x22layoutArea\x22>\x0a<div\x20class=\x22column\x22>\x0a<p><strong>Phentolamine</strong>\x20is\x20used\x20for\x20the\x20control\x20of\x20hypertension\x20due\x20to\x20clonidine\x20withdrawal.</p>\x0a</div>\x0a</div>\x0a</div>\x0a</div>','Elotuzumab','JkoKv','heSzR','UlGoQ','kxSWo','mqxGY','Nicotinamide','join','JJeZe','uLcHG','wTTtH','ralRQ','kZWPa','bwMya','zuGrT','FzmEO','oiBLd','BxGAe','HDlZf','OBTEf','padStart','XkLJU','yZzvF','TMP','YKOFg','<p>The\x20<strong>volume\x20of\x20distribution</strong>\x20of\x20the\x20drug\x20<strong>determines</strong>\x20the<strong>\x20loading\x20dose</strong>\x20of\x20the\x20drug.</p>\x0a<p><strong>Loading\x20Dose</strong>\x20=\x20<strong>Volume\x20of\x20distribution</strong>\x20x\x20<strong>Desired\x20steady-state\x20plasma\x20concentration</strong>.</p>\x0a<p>When\x20the\x20time\x20to\x20reach\x20a\x20steady-state\x20is\x20long,\x20as\x20it\x20is\x20for\x20<strong>drugs</strong>\x20with\x20<strong>long\x20half-lives,</strong>\x20it\x20may\x20be\x20desirable\x20to\x20<strong>administer</strong>\x20a\x20<strong>loading\x20dose</strong>\x20that\x20promptly\x20raises\x20the\x20concentration\x20of\x20the\x20drug\x20in\x20plasma\x20to\x20the\x20target\x20concentration.</p>\x0a<p>Other\x20options:</p>\x0a<p>Option\x20A:<strong>\u00a0Clearance</strong>\x20is\x20used\x20to\x20determine\x20the\x20<strong>maintenance\x20dose</strong>.\u00a0</p>\x0a<p>Maintenance\x20dose\x20=\x20clearance\x20x\x20desired\x20steady-state\x20plasma\x20concentration.</p>\x0a<p>Options\x20C\x20and\x20D:\x20Plasma\x20<strong>half-life</strong>\x20primarily\x20<strong>determines</strong>\x20the\x20<strong>frequency</strong>\x20of\x20dosing,\x20while\x20<strong>bioavailability</strong>\x20<strong>determines</strong>\x20the\x20<strong>route</strong>\x20of\x20administration.\u00a0Though\x20bioavailability\x20may\x20affect\x20the\x20dose\x20necessary,\x20it\x20will\x20not\x20be\x20the\x20primary\x20factor\x20considered\x20during\x20the\x20calculation\x20of\x20the\x20loading\x20dose.</p>','hqtaO','userHistory','hbLKa','BrVFa','4\x20tablets\x20of\x20Artesunate\x2050mg\x20+\x206\x20tablets\x20of\x20Primaquine\x207.5mg','MYHSf','ofXCA','toLowerCase','yZVqo','none','src','nRxop','JGHNP','console','You\x20have\x20reached\x20the\x20end\x20of\x20the\x20quiz.\x20Would\x20you\x20like\x20to\x20submit\x20your\x20answers\x20now?','zSXoe','EVZcu','zBwAZ','A\x20hypertensive\x20patient\x20is\x20started\x20on\x20a\x20drug\x20to\x20control\x20his\x20BP.\x20He\x20had\x20complaints\x20of\x20dry\x20mouth,\x20drowsiness,\x20and\x20confusion\x20after\x20taking\x20this\x20drug,\x20but\x20he\x20still\x20continued\x20to\x20take\x20the\x20drug\x20for\x201\x20year.\x20He\x20had\x20to\x20travel\x20abroad\x20for\x20work,\x20and\x20he\x20forgot\x20to\x20take\x20his\x20medications.\x20He\x20now\x20presents\x20with\x20a\x20blood\x20pressure\x20of\x20200/120mmHg.\x20Identify\x20the\x20drug\x20he\x20was\x20on?','customQuizData','explanationVideoPlayer','includes','mJEVb','contains','Marked','LexmI','target','MhqRf','quizPerformanceData','EeMCK','zlkla','bookmarked','\x22\x20class=\x22w-full\x20rounded-lg\x22\x20controls></video></div>','RbLui','qhMXz','Option\x20','unzbI','https://dhmbxeygs57ff.cloudfront.net/uploads/d3d48754732b440fb17b875d2b52a8dax510x812.PNG','</span>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20</div>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<div\x20class=\x22text-white\x20mb-4\x22>','error','gray','ArrowLeft','NwYrv','vWOiO','Scopolamine','Plasma\x20half\x20life','Spironolactone','qHCui','name','ZQBWq','hfwFB','RIxre','Phase\x20II','Ethambutol','4\x20tablets\x20of\x20Artesunate\x2050mg\x20+\x206\x20tablets\x20of\x20Primaquine\x202.5mg','<div\x20class=\x22p-3\x20rounded-lg\x20border\x20','<p>The\x203HP\x20regimen,\x20which\x20involves\x20<strong>once-weekly</strong>\x20doses\x20of\x20<strong>Isoniazid</strong>\x20and\x20<strong>Rifapentine</strong>\x20for\x20<strong>12</strong>\x20<strong>weeks</strong>,\x20has\x20been\x20found\x20to\x20have\x20<strong>higher\x20patient\x20compliance</strong>\x20than\x20the\x20<strong>9-month</strong>\x20regimen\x20of\x20<strong>Isoniazid\x20(9H)</strong>\x20and\x20the\x20<strong>6-month\x20regimen\x20(6H).</strong></p>\x0a<p>The\x20<strong>shorter\x20duration</strong>\x20and\x20<strong>reduced\x20number</strong>\x20of\x20<strong>doses</strong>\x20in\x20the\x203HP\x20regimen\x20make\x20it\x20more\x20<strong>convenient</strong>\x20and\x20thus\x20lead\x20to\x20better\x20<strong>adherence.</strong>\x20Studies\x20have\x20shown\x20that\x20patients\x20are\x20more\x20likely\x20to\x20complete\x20the\x203HP\x20regimen\x20due\x20to\x20the\x20shorter\x20treatment\x20duration\x20and\x20lower\x20pill\x20burden.</p>\x0a<p>TPT\x20stands\x20for\x20<strong>Tuberculosis\x20Preventive\x20Therapy.</strong>\x20It\x20is\x20a\x20treatment\x20given\x20to\x20individuals\x20who\x20are\x20at\x20<strong>high\x20risk</strong>\x20of\x20<strong>developing\x20active\x20tuberculosis</strong>\x20(TB)\x20to\x20prevent\x20the\x20progression\x20from\x20latent\x20TB\x20infection\x20(where\x20the\x20person\x20is\x20infected\x20with\x20the\x20TB\x20bacteria\x20but\x20does\x20not\x20have\x20symptoms)\x20to\x20active\x20TB\x20disease.</p>\x0a<p>There\x20are\x20different\x20regimens\x20for\x20TPT,\x20including:</p>\x0a<ul>\x0a<li>3HP:\x20A\x20regimen\x20consisting\x20of\x20<strong>once-weekly</strong>\x20doses\x20of\x20<strong>Isoniazid</strong>\x20(H)\x20and\x20<strong>Rifapentine</strong>\x20(P)\x20for\x20<strong>12\x20weeks.</strong></li>\x0a<li>6H:\x20A\x20regimen\x20consisting\x20of\x20daily\x20Isoniazid\x20for\x206\x20months.</li>\x0a<li>9H:\x20A\x20regimen\x20consisting\x20of\x20daily\x20Isoniazid\x20for\x209\x20months.</li>\x0a</ul>\x0a<p>TPT\x20is\x20particularly\x20important\x20for\x20individuals\x20with\x20latent\x20TB\x20who\x20have\x20a\x20higher\x20risk\x20of\x20developing\x20active\x20TB,\x20such\x20as\x20those\x20with\x20HIV,\x20close\x20contacts\x20of\x20TB\x20patients,\x20or\x20those\x20with\x20certain\x20medical\x20conditions\x20that\x20weaken\x20the\x20immune\x20system.</p>\x0a<p>Other\x20options:\u00a0</p>\x0a<p>Option\x20B:\x20Research\x20has\x20demonstrated\x20that\x20the\x203HP\x20regimen\x20offers\x20better\x20compliance\x20and\x20similar\x20<strong>effectiveness</strong>\x20compared\x20to\x20the\x20traditional\x206H\x20and\x209H\x20regimens.\x20The\x20shorter\x20duration\x20of\x203HP\x20(once\x20weekly\x20for\x2012\x20weeks)\x20makes\x20it\x20more\x20convenient\x20and\x20tolerable\x20for\x20patients,\x20which\x20leads\x20to\x20higher\x20adherence\x20rates.\x20Thus,\x20there\x20is\x20a\x20significant\x20difference\x20in\x20patient\x20compliance\x20between\x20these\x20regimens,\x20with\x203HP\x20showing\x20clear\x20advantages.</p>\x0a<p>Option\x20C:\x20Although\x20<strong>3HP</strong>\x20is\x20generally\x20considered\x20<strong>safe,</strong>\x20data\x20suggests\x20that\x20the\x20risk\x20profile\x20for\x20adverse\x20effects,\x20including\x20<strong>potential\x20reproductive</strong>\x20impacts\x20like\x20abortion,\x20differs\x20between\x20regimens.\x20Specifically,\x206H\x20may\x20have\x20a\x20different\x20side\x20effect\x20profile\x20due\x20to\x20the\x20<strong>prolonged\x20exposure</strong>\x20to\x20the\x20drug\x20over\x20six\x20months,\x20compared\x20to\x20the\x20shorter\x20and\x20intermittent\x20dosing\x20of\x203HP.\u00a0</p>\x0a<p>Option\x20D:\x20Studies\x20have\x20confirmed\x20that\x20the\x203HP\x20regimen\x20is\x20<strong>as\x20effective</strong>\x20as\x206H\x20and\x209H\x20in\x20preventing\x20active\x20tuberculosis\x20(TB).\x20Both\x20regimens\x20aim\x20to\x20prevent\x20<strong>latent\x20TB</strong>\x20from\x20<strong>progressing</strong>\x20to\x20<strong>active\x20disease,</strong>\x20and\x20<strong>3HP</strong>\x20has\x20been\x20shown\x20to\x20achieve\x20similar\x20outcomes\x20with\x20fewer\x20doses,\x20enhancing\x20patient\x20compliance.</p>','NK-3\x20antagonist','pAvcc','Pharmacology','96468RENHeb','location','totalTimeResult','<p>The\x20given\x20clinical\x20scenario\x20suggests\x20a\x20diagnosis\x20of\x20<strong>Acute\x20Lymphoblastic\x20Leukemia\x20</strong>(ALL),\x20and\x20standard\x20initial\x20treatment\x20in\x20children\x20includes\x20a\x20chemotherapy\x20regimen\x20with\x20drugs\x20like\x20<strong>prednisolone</strong>\x20and\x20<strong>vincristine</strong>\x20during\x20the<strong>\x20induction\x20phase</strong>.\u00a0</p>\x0a<p>Patients\x20diagnosed\x20with\x20ALL\x20present\x20with\x20symptoms\x20of<strong>\x20impaired\x20marrow\x20function</strong>\x20like\x20<strong>anaemia,\x20infections</strong>\x20secondary\x20to\x20neutropenia,\x20and\x20<strong>bleeding</strong>\x20due\x20to\x20thrombocytopenia.\x20Other\x20symptoms\x20include\x20<strong>bone\x20pain</strong>,\x20generalized\x20lymphadenopathy,\x20splenomegaly,\x20hepatomegaly,\x20testicular\x20enlargement,\x20headache,\x20vomiting,\x20and\x20nerve\x20palsies.</p>\x0a<p>Treatment\x20of\x20ALL</p>\x0a<p><strong>Induction:</strong>\x20L-Asparaginase,\x20vincristine,\x20prednisolone,\x20and\x20anthracycline<br\x20/><strong>CNS\x20prophylaxis\x20</strong>with\x20intrathecal\x20methotrexate<br\x20/><strong>Consolidation:</strong>\x20Methotrexate,\x20cytarabine\u00a0<br\x20/><strong>Maintenance:</strong>\x206-Mercaptopurine,\x20methotrexate\x20plus\x20intrathecal\x20therapy</p>\x0a<p>Other\x20Options:</p>\x0a<p>Option\x20A:\x20IVIG:\x20Intravenous\x20immunoglobulin\x20(IVIG)\x20is\x20<strong>not</strong>\x20used\x20for\x20treating\x20ALL.</p>\x0a<p>option\x20B:\x20Both\x20<strong>doxorubicin</strong>\x20and\x20<strong>idarubicin</strong>\x20<strong>are</strong>\x20<strong>anthracyclines</strong>\x20used\x20in\x20chemotherapy.\x20While\x20doxorubicin\x20can\x20be\x20part\x20of\x20certain\x20ALL\x20treatment\x20protocols,\x20idarubicin\x20is\x20more\x20commonly\x20used\x20in\x20Acute\x20Myeloid\x20Leukemia\x20(AML)\x20rather\x20than\x20ALL.\x20This\x20combination\x20is\x20not\x20typically\x20used\x20in\x20the\x20induction\x20phase\x20for\x20ALL\x20children.</p>\x0a<p>Option\x20D:\x20Radiotherapy\x20is\x20<strong>not</strong>\x20a\x20standard\x20initial\x20treatment\x20for\x20ALL.\x20It\x20may\x20be\x20considered\x20in\x20specific\x20cases,\x20such\x20as\x20central\x20nervous\x20system\x20involvement\x20or\x20certain\x20high-risk\x20cases,\x20but\x20the\x20primary\x20treatment\x20for\x20ALL\x20is\x20systemic\x20chemotherapy,\x20not\x20localized\x20radiotherapy.</p>','Pindolol','hPrIy','PtKrB','incorrect','Identify\x20the\x20drug\x20marked\x20as\x20\x27X\x27\x20in\x20the\x20image.','Occur\x20on\x20exposure\x20to\x20only\x20aspirin','attachMedia','correct_choice_id','PGpOK','Rifampicin','currentQuestion','Mark\x20for\x20Review','display','kJsMX','egEAF','qrarl','bjVEp','choices','application/vnd.apple.mpegurl','https://cdn1.dailyrounds.org/uploads/f29f9fa43ba346a29a54c1f5a649c32c.JPEG','2|4|0|3|1|5','pobZF','XmaIO','\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20</div>','UwWpz','MpQnE','w-8\x20h-8\x20text-sm\x20font-medium\x20rounded\x20','\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20','JYeKB','\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<button\x20type=\x22button\x22\x20class=\x22option-button\x20','XiFlS','strokeDasharray','<p>The\x20<strong>beta-adrenergic\x20blocker</strong>\x20that\x20is\x20useful\x20in\x20patients\x20with\x20<strong>reduced\x20ejection\x20fraction\x20a</strong>nd\x20can<strong>\x20reduce\x20mortality\x20</strong>in\x20<strong>chronic\x20heart\x20failure\x20</strong>without\x20causing\x20exacerbations\x20over\x20a\x20few\x20years\x20is\x20<strong>bisoprolol.</strong></p>\x0a<p><strong>Bisoprolol</strong>\x20is\x20preferred\x20for\x20use\x20in\x20patients\x20having\x20<strong>heart\x20failure\x20with\x20reduced\x20ejection\x20fraction\x20(HFrEF)</strong>.</p>\x0a<p>The\x20<strong>exacerbation</strong>\x20mentioned\x20in\x20the\x20context\x20of\x20<strong>beta-blockers</strong>\x20for\x20heart\x20failure\x20refers\x20to\x20the\x20potential\x20<strong>worsening</strong>\x20of\x20<strong>heart\x20failure\x20symptoms</strong>\x20in\x20some\x20patients,\x20despite\x20the\x20overall\x20benefits\x20of\x20these\x20medications.\x20They\x20can\x20sometimes\x20lead\x20to\x20a<strong>\x20decline</strong>\x20in\x20<strong>left\x20ventricular\x20function</strong>,\x20particularly\x20in\x20individuals\x20with\x20<strong>limited\x20cardiac\x20reserve</strong>\x20who\x20rely\x20heavily\x20on\x20<strong>adrenergic\x20stimulation</strong>.\x20This\x20deterioration\x20can\x20manifest\x20as\x20<strong>increased\x20heart\x20failure\x20symptoms</strong>\x20or\x20a\x20<strong>decrease</strong>\x20in\x20<strong>cardiac\x20function</strong>.\x20The\x20<strong>only\x20beta-blockers</strong>\x20that\x20have\x20been\x20proven\x20to<strong>\x20improve</strong>\x20the\x20<strong>survival</strong>\x20of\x20patients\x20with\x20<strong>HFrEF</strong>\x20or\x20<strong>chronic\x20HF</strong>\x20are\x20-</p>\x0a<ul>\x0a<li><strong>B</strong>isoprolol</li>\x0a<li><strong>M</strong>etoprolol</li>\x0a<li><strong>C</strong>arvedilol</li>\x0a</ul>\x0a<p><strong>HFrEF</strong>\x20is\x20a\x20complex\x20clinical\x20syndrome\x20where\x20the\x20ventricle\x20fails\x20to\x20adequately\x20fill\x20with\x20or\x20eject\x20blood,\x20typically\x20defined\x20by\x20an\x20<strong>ejection\x20fraction\x20(EF)\x20less\x20than\x20or\x20equal\x20to\x2040%</strong>.\x20Key\x20etiologies\x20include\x20<strong>coronary\x20artery\x20disease,\x20valvular\x20heart\x20disease,\x20congenital\x20heart\x20diseases,\x20and\x20autoimmune\x20diseases\x20like\x20giant\x20cell\x20myocarditis</strong>.\x20Patients\x20with\x20HFrEF\x20commonly\x20experience\x20symptoms\x20like\x20<strong>dyspnea\x20on\x20exertion</strong>,\x20orthopnea,\x20and\x20paroxysmal\x20nocturnal\x20dyspnea,\x20and\x20may\x20present\x20with\x20<strong>pedal\x20edema</strong>,\x20elevated\x20jugular\x20venous\x20pressure\x20(JVP),\x20ascites,\x20and\x20hepatomegaly\x20on\x20examination.</p>\x0a<p>The\x20pharmacological\x20<strong>management</strong>\x20of\x20HFrEF\x20involves\x20drugs\x20with\x20both\x20<strong>symptomatic</strong>\x20and\x20<strong>mortality\x20benefits</strong>,\x20including\x20<strong>Angiotensin\x20receptor–neprilysin\x20inhibitors\x20(ARNIs)</strong>\x20such\x20as\x20sacubitril/valsartan,\x20angiotensin-converting\x20enzyme\x20<strong>(ACE)\x20inhibitors</strong>\x20like\x20ramipril\x20and\x20enalapril,\x20β-blockers\x20such\x20as\x20metoprolol\x20and\x20carvedilol,\x20mineralocorticoid\x20receptor\x20antagonists\x20like\x20spironolactone\x20and\x20eplerenone,<strong>\x20sodium-glucose\x20cotransporter\x202\x20(SGLT2)\x20inhibitors\x20</strong>like\x20dapagliflozin,\x20and\x20hydralazine\x20plus\x20isosorbide\x20dinitrate\x20(noting\x20a\x20mortality\x20benefit\x20specifically\x20in\x20African-American\x20patients).\x20Drugs\x20used\x20primarily\x20for<strong>\x20symptomatic\x20relief</strong>,\x20such\x20as\x20<strong>loop\x20diuretics</strong>\x20(e.g.,\x20furosemide),\x20and\x20digoxin,\x20are\x20reserved\x20for\x20specific\x20indications\x20or\x20during\x20decompensation.\x20<strong>Non-pharmacological\x20</strong>therapies\x20for\x20HFrEF\x20include\x20<strong>implantable\x20cardioverter-defibrillators\x20(ICD)\x20</strong>and\x20<strong>cardiac\x20resynchronization\x20therapy.</strong></p>','GhXtw','ZYzoQ','snogz','sHzRQ','\x22\x20data-src=\x22','oysXY','QMpNi','juaQW','<div\x20class=\x22glass-light\x20p-4\x20mb-4\x22><audio\x20src=\x22','fill','IxNpw','lAzAn','JIUlZ','cUqqX','Nrbff','search','GOops','sqpqQ','DOMContentLoaded','not_attempted','mogqB','Bisoprolol','Not\x20Attempted','nav-btn-correct','solution','markReviewBtn','A\x2032-year-old\x20woman\x20diagnosed\x20with\x20diarrhoea-predominant\x20irritable\x20bowel\x20syndrome\x20presented\x20to\x20the\x20casualty\x20with\x20severe\x20abdominal\x20pain.\x20She\x20was\x20prescribed\x20a\x20drug\x20that\x20exerts\x20a\x20direct\x20spasmolytic\x20effect\x20on\x20the\x20smooth\x20muscles\x20of\x20the\x20gastrointestinal\x20tract.\x20Which\x20drug\x20could\x20it\x20be?','JqkmR','lYNIw','rUwwP','<p><strong>TMP\x20synthesis\x20</strong>is\u00a0<strong>affected\x20</strong>due\x20to<strong>\x20methotrexate.\u00a0</strong></p>\x0a<p><strong>Methotrexate</strong>\x20inhibits\x20<strong>dihydrofolate\x20reductase</strong>\x20(DHFR),\x20which\x20is\x20required\x20to\x20<strong>synthesize\x20tetrahydrofolate.\x20Tetrahydrofolate</strong>\x20is\x20essential\x20for\x20converting\x20<strong>dUMP</strong>\x20to\x20<strong>dTMP</strong>\x20(thymidine\x20monophosphate)\x20in\x20the\x20<strong>nucleotide\x20synthesis</strong>\x20pathway.\x20Therefore,\x20the\x20<strong>nucleotide\x20synthesis</strong>\x20affected\x20in\x20this\x20patient\x20is\x20<strong>TMP\x20(thymidine\x20monophosphate).</strong></p>\x0a<p>By\x20inhibiting\x20DHFR,\x20methotrexate\x20<strong>reduces</strong>\x20the\x20<strong>availability</strong>\x20of\x20<strong>THF,</strong>\x20thereby\x20disrupting\x20the\x20production\x20of\x20<strong>thymidylate</strong>\x20(TMP),\x20which\x20is\x20necessary\x20for\x20<strong>DNA\x20replication</strong>\x20and\x20<strong>repair.</strong>\x20This\x20disruption\x20leads\x20to\x20<strong>impaired\x20DNA\x20synthesis</strong>\x20in\x20rapidly\x20dividing\x20cells,\x20such\x20as\x20cancer\x20cells.\x20However,\x20it\x20also\x20affects\x20other\x20rapidly\x20dividing\x20cells,\x20including\x20those\x20in\x20the\x20<strong>gastrointestinal</strong>\x20tract\x20and\x20<strong>oral\x20mucosa,</strong>\x20leading\x20to\x20<strong>side\x20effects</strong>\x20like\x20<strong>oral</strong>\x20and\x20<strong>gastric\x20ulcers.</strong></p>','Doxorubicin\x20+\x20Idarubicin','uIVpP','nav-btn-incorrect','NK-1\x20agonist','iwwfo','Incorrect','There\x20is\x20no\x20allergic\x20sensitization\x20to\x20aspirin\x20and\x20its\x20metabolites','reduce','wxEyn','referrer','WPrMC','SRCGq','aMKKK','lZslE','AgrWQ','</h4>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<span\x20class=\x22text-sm\x20px-3\x20py-1\x20rounded-full\x20bg-','style','ufcIx','PwUDP','tXXEV','SlbIH','IbgKJ','div','uuDuc','(((.+)+)+)+$','ffpza','JWgGO','zhNXs','NMEfu','Heparin','testModeReviewLegend','href','ZlxYx','<p>For\x20a\x20<strong>hypertensive</strong>\x20patient\x20with\x20<strong>chronic\x20kidney\x20disease</strong>\x20experiencing\x20frequent\x20attacks\x20of\x20<strong>renal\x20colic</strong>,\x20<strong>hydrochlorothiazide</strong>,\x20a\x20<strong>thiazide\x20diuretic</strong>,\x20is\x20often\x20used.</p>\x0a<p><strong>Thiazide\x20diuretics</strong>\x20are\x20particularly\x20effective\x20in\x20cases\x20of\x20<strong>calcium\x20oxalate\x20kidney\x20stones</strong>\x20because\x20they\x20<strong>reduce\x20urinary\x20calcium\x20excretion</strong>.\x20They\x20work\x20by\x20acting\x20on\x20the\x20<strong>distal\x20convoluted\x20tubule\x20(DCT)</strong>\x20of\x20the\x20nephron,\x20where\x20they<strong>\x20inhibit</strong>\x20the\x20<strong>Na+/Cl-\x20co-transporter</strong>.\x20This\x20<strong>inhibition\x20decreases</strong>\x20the\x20<strong>intracellular\x20sodium\x20concentration</strong>,\x20which,\x20through\x20compensatory\x20mechanisms,\x20leads\x20to<strong>\x20increased\x20calcium\x20reabsorption</strong>\x20into\x20the\x20bloodstream.</p>\x0a<p>While\x20this\x20mechanism\x20helps\x20in\x20<strong>decreasing\x20urinary\x20calcium</strong>\x20and\x20<strong>managing\x20calcium\x20oxalate\x20stones</strong>,\x20thiazide\x20diuretics\x20can\x20also\x20cause\x20<strong>adverse\x20effects</strong>\x20such\x20as\x20<strong>hypokalemia</strong>,\x20<strong>hyperuricemia</strong>,\x20and\x20<strong>hypercalcemia</strong>.\x20The\x20<strong>increased\x20reabsorption</strong>\x20of\x20<strong>uric\x20acid</strong>\x20due\x20to\x20the\x20diuretic\x20effect\x20can\x20exacerbate\x20conditions\x20like\x20<strong>gout</strong>\x20and\x20should\x20be\x20monitored\x20carefully.</p>\x0a<p>In\x20addition\x20to\x20their\x20use\x20in\x20treating\x20calcium\x20oxalate\x20kidney\x20stones,\x20thiazide\x20diuretics\x20are\x20commonly\x20prescribed\x20for\x20managing\x20<strong>uncomplicated\x20hypertension</strong>\x20and\x20treating\x20<strong>edema</strong>\x20associated\x20with\x20<strong>heart,\x20liver</strong>,\x20and\x20<strong>kidney</strong>\x20diseases.\x20They\x20are\x20also\x20used\x20for\x20conditions\x20like\x20<strong>osteoporosis</strong>\x20and\x20<strong>nephrogenic\x20diabetes\x20insipidus</strong>.\u00a0</p>\x0a<p>Other\x20options:</p>\x0a<p>Option\x20A:\x20<strong>Furosemide</strong>\x20is\x20a\x20<strong>diuretic</strong>\x20that\x20can\x20<strong>increase\x20calcium\x20excretion</strong>,\x20potentially\x20<strong>raising\x20PTH\x20</strong>as\x20the\x20body\x20tries\x20to\x20conserve\x20calcium.</p>\x0a<p>Option\x20B:\x20<strong>Osmotic\x20diuretics</strong>,\x20like\x20<strong>mannitol</strong>,<strong>\x20retain\x20water</strong>\x20isoosmotically\x20in\x20the\x20<strong>proximal\x20convoluted\x20tubule\x20(PCT)</strong>\x20and\x20<strong>descending\x20loop\x20of\x20Henle</strong>\x20which\x20are\x20freely\x20permeable\x20to\x20water.\x20Luminal\x20fluid\x20is\x20diluted\x20and\x20opposes\x20NaCl\x20reabsorption\x20and\x20promotes\x20calcium\x20excretion.\x20They\x20are\x20indicated\x20in\x20<strong>raised\x20intracranial\x20tension</strong>\x20and\x20in\x20<strong>dialysis\x20disequilibrium</strong>.</p>\x0a<p>Option\x20D:\x20<strong>Spironolactone</strong>\x20is\x20a\x20<strong>potassium-sparing\x20diuretic</strong>\x20and\x20<strong>aldosterone\x20antagonist</strong>.\x20It\x20works\x20by\x20<strong>competitively\x20inhibiting\x20aldosterone\x20receptors</strong>\x20in\x20the\x20distal\x20tubules\x20of\x20the\x20kidney.</p>','addEventListener','uKJMt','querySelectorAll','JRPuH','Which\x20of\x20the\x20following\x20reasons\x20best\x20explains\x20the\x20combination\x20of\x20Atropine\x20(0.025\x20mg)\x20and\x20Diphenoxylate\x20(2.5\x20mg)\x20for\x20treating\x20secretory\x20diarrhoea?','-600\x20text-white\x22>','className','Butarphanol','xnGwe','sKENj','NK-1\x20antagonist','QdUYj','closest','Adenosine\x200.2\x20mg/kg','<p><strong>Atropine</strong>\x20is\x20included\x20in\x20combination\x20with\x20<strong>diphenoxylate</strong>\x20to\x20prevent\x20<strong>abuse</strong>\x20and\x20<strong>overdose</strong>\x20of\x20diphenoxylate.\u00a0</p>\x0a<p><strong>Diphenoxylate</strong>\x20is\x20structurally\x20similar\x20to\x20<strong>opioids</strong>\x20and\x20has\x20the\x20<strong>potential</strong>\x20for\x20<strong>misuse</strong>\x20at\x20<strong>higher\x20doses.</strong>\x20Additionally,\x20it\x20crosses\x20the\x20<strong>blood-brain</strong>\x20barrier,\x20making\x20it\x20more\x20likely\x20to\x20cause\x20dependence.\x20The\x20anticholinergic\x20effects\x20of\x20atropine\x20(e.g.,\x20dry\x20mouth,\x20tachycardia,\x20blurred\x20vision)\x20become\x20prominent\x20at\x20<strong>higher\x20doses,</strong>\x20discouraging\x20overdose.</p>\x0a<p><strong>Diphenoxylate</strong>\x20is\x20an\x20opioid\x20agonist\x20primarily\x20used\x20as\x20an\x20<strong>antidiarrheal</strong>\x20agent.\x20It\x20works\x20by\x20slowing\x20down\x20<strong>intestinal\x20motility,</strong>\x20allowing\x20more\x20time\x20for\x20water\x20and\x20<strong>electrolytes</strong>\x20to\x20be\x20absorbed\x20from\x20the\x20intestines,\x20which\x20helps\x20<strong>reduce\x20diarrhea.</strong>\x20However,\x20because\x20of\x20its\x20structural\x20similarity\x20to\x20opioids,\x20diphenoxylate\x20has\x20the\x20potential\x20for\x20abuse\x20and\x20dependence\x20if\x20taken\x20in\x20large\x20doses.</p>','__proto__','VWqDI','THWTO','oyiHT','PYQ','nav-btn-bookmarked','table','lwqSv','CccGw','muYwF','bookmarkedQuestions','review-question\x20','<div\x20class=\x22mt-2\x22><p\x20class=\x22text-sm\x20text-white\x20text-opacity-70\x20mb-1\x22>Hinglish\x20Explanation:</p><audio\x20src=\x22','678296uroYTn','toString','scoreCircle','width','uEyml','prototype','DUpae','XujYw','dataset','MhrAG','TKkFS','onclick','lZnBa','knuJZ','NnVjp','accuracyScore','eJHfn','nav-btn-answered','</div>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20</div>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<div\x20class=\x22space-y-2\x20mb-4\x22>','An\x20HIV\x20patient\x20developed\x20a\x20fever\x20and\x20dry\x20cough.\x20He\x20was\x20diagnosed\x20with\x20TB.\x20He\x20is\x20currently\x20on\x20Lamivudine,\x20Zidovudine\x20and\x20Nevirapine.\x20Which\x20Anti\x20-TB\x20drug\x20should\x20be\x20changed\x20in\x20this\x20patient?','<p><strong>Rifampicin\x20</strong>should\x20be\x20avoided\x20as\x20it\x20is\x20a\x20potent<strong>\x20inducer\x20</strong>of<strong>\x20CYP\x20enzymes\x20</strong>including\x20CYPs\x201A2,\x203A4,\x202C9,\x20and\x202C19,\x20which\x20in\x20turn\u00a0can\x20<strong>induce\x20</strong>the<strong>\x20metabolism\x20</strong>of<strong>\x20nevirapine</strong>\x20and\x20results\x20in\x20<strong>therapeutic\x20failure\x20</strong>of\x20<strong>ART.</strong></p>\x0a<p><strong>Rifabutin\u00a0</strong>causes\x20the\x20<strong>least\x20induction</strong>\x20of\x20cytochrome\x20enzymes\x20and\x20is\x20therefore\u00a0<strong>preferred\x20in\x20HIV\x20patients</strong>\x20who\x20are\x20on<strong>\x20protease\x20inhibitors/NNRTIs.</strong></p>\x0a<p>Cytochrome\x20enzyme-inducing\x20potency\x20of\x20rifamycins\x20is\x20<strong>rifampicin\x20&gt;\x20rifapentine\x20&gt;\x20rifabutin.</strong></p>\x0a<p>Note:\u00a0</p>\x0a<table\x20style=\x22border-collapse:\x20collapse;\x20width:\x2044.9183%;\x20height:\x20255.984px;\x22\x20border=\x221\x22>\x0a<tbody>\x0a<tr\x20style=\x22height:\x2022.3984px;\x22>\x0a<td\x20style=\x22width:\x2020.2543%;\x20height:\x2022.3984px;\x20text-align:\x20center;\x22>Cytochrome\x20p-450\x20inducers</td>\x0a<td\x20style=\x22width:\x2079.7457%;\x20height:\x2022.3984px;\x20text-align:\x20center;\x22>Cytochrome\x20p-450\x20inhibitors</td>\x0a</tr>\x0a<tr\x20style=\x22height:\x20233.586px;\x22>\x0a<td\x20style=\x22width:\x2020.2543%;\x20height:\x20233.586px;\x22>\x0a<ul>\x0a<li>Barbiturates</li>\x0a<li>Carbamazepine</li>\x0a<li>Rifampin</li>\x0a<li>Phenytoin</li>\x0a<li>Aminoglutethimide</li>\x0a<li>Cigarette\x20smoking</li>\x0a<li>Chronic\x20alcoholism</li>\x0a</ul>\x0a</td>\x0a<td\x20style=\x22width:\x2079.7457%;\x20height:\x20233.586px;\x22>\x0a<ul>\x0a<li>Macrolide\x20antibiotics</li>\x0a<li>Azole\x20antifungals</li>\x0a<li>Chloramphenicol</li>\x0a<li>Omeprazole</li>\x0a<li>Selective\x20serotonin\x20reuptake\x20inhibitors\x20(SSRIs)</li>\x0a<li>HIV\x20protease\x20inhibitors</li>\x0a<li>Cimetidine</li>\x0a<li>Ciprofloxacin</li>\x0a<li>Metronidazole</li>\x0a</ul>\x0a</td>\x0a</tr>\x0a</tbody>\x0a</table>','custom_quiz.html','oLUwQ','<p>In\x20this\x20patient\x20with\x20<strong>raised\x20intracranial\x20pressure</strong>\x20after\x20a\x20<strong>road\x20traffic\x20accident,\x20mannitol</strong>\x20is\x20the\x20<strong>diuretic</strong>\x20of\x20<strong>choice</strong>\x20in\x20her\x20management\x20to\x20reduce\x20intracranial\x20pressure.\u00a0</p>\x0a<p>Mannitol\x20is\x20an\x20osmotic\x20diuretic\x20that\x20draws\x20<strong>fluid</strong>\x20out\x20of\x20the\x20<strong>brain\x20tissue</strong>\x20and\x20into\x20the\x20<strong>bloodstream</strong>\x20as\x20it\x20forms\x20a\x20<strong>hypertonic</strong>\x20solution\x20when\x20it\x20reaches\x20the\x20bloodstream,\x20thereby\x20reducing\x20intracranial\x20pressure\x20(ICP).\x20It\x20is\x20commonly\x20used\x20in\x20cases\x20of\x20<strong>traumatic\x20brain\x20injury</strong>\x20or\x20other\x20conditions\x20that\x20cause\x20<strong>elevated\x20ICP.</strong>\x20This\x20effect\x20helps\x20to\x20<strong>relieve\x20pressure</strong>\x20on\x20the\x20<strong>brain,</strong>\x20preventing\x20<strong>further\x20damage.</strong></p>\x0a<p>Other\x20options:\u00a0</p>\x0a<p>The\x20other\x20diuretics\x20listed\x20Hydrochlorothiazide,\x20Spironolactone,\x20and\x20Acetazolamide\x20are\x20not\x20typically\x20used\x20for\x20managing\x20elevated\x20ICP.\x20They\x20are\x20not\x20hypertonic\x20solutes\x20and\x20thus\x20do\x20not\x20lead\x20to\x20a\x20rapid\x20reduction\x20of\x20the\x20ICP\x20as\x20mannitol\x20does.\u00a0</p>','resume','Which\x20of\x20the\x20following\x20beta-adrenergic\x20blockers\x20are\x20beneficial\x20for\x20patients\x20with\x20reduced\x20ejection\x20fraction\x20and\x20can\x20reduce\x20mortality\x20in\x20chronic\x20heart\x20failure\x20without\x20causing\x20exacerbations\x20over\x20a\x20few\x20years?','dVICx','CwNye','rjazV','floor','lcQIP','appendChild','MAyWa','hjrYJ','zuMRL','SlxBu','WJXnh','add','progressBar','ECZMr','4\x20tablets\x20of\x20Artesunate\x2045mg\x20+\x20Sulphadoxine\x201500mg\x20\x20+\x206\x20tablets\x20of\x20Primaquine\x207.5mg','yXXcM','EhLvq','mAcBC','GgFsi','bWzqw','BUZyB','zeZPr','fIosU','</div>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<div\x20class=\x22bg-green-900\x20bg-opacity-20\x20p-4\x20rounded-lg\x20border\x20border-green-700\x22>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<h5\x20class=\x22text-green-400\x20font-bold\x20mb-2\x22>Explanation:</h5>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<div\x20class=\x22text-white\x20text-opacity-90\x22>','KYbpI','WOoTL','textContent','push','statsBar','Somatropin','map','lzAvY','kSTTv','<p>The\x20drug\x20most\x20likely\x20responsible\x20for\x20causing\x20<strong>flushing,\x20hyperglycemia,</strong>\x20and\x20elevated\x20liver\x20enzymes\x20in\x20a\x20patient\x20being\x20treated\x20for\x20<strong>hypertriglyceridemia</strong>\x20is\x20<strong>Nicotinamide</strong>\x20(Niacin).\u00a0</p>\x0a<p>Niacin\x20(nicotinic\x20acid),\x20is\x20commonly\x20used\x20to\x20treat\x20hypertriglyceridemia\x20and\x20hypercholesterolemia.\x20However,\x20it\x20is\x20associated\x20with\x20side\x20effects\x20such\x20as\x20<strong>flushing,</strong>\x20which\x20is\x20due\x20to\x20<strong>prostaglandin-mediated\x20vasodilation.</strong>\x20Niacin\x20can\x20also\x20lead\x20to\x20<strong>hyperglycemia</strong>\x20by\x20<strong>impairing\x20insulin\x20sensitivity</strong>\x20and\x20may\x20cause\x20<strong>elevated\x20liver\x20enzymes,</strong>\x20indicating\x20<strong>potential\x20hepatotoxicity.</strong>\u00a0</p>\x0a<p>Other\x20options:\u00a0</p>\x0a<p>Option\x20B:\x20<strong>Rosuvastatin</strong>\x20is\x20a\x20statin,\x20primarily\x20used\x20to\x20lower\x20<strong>LDL</strong>\x20cholesterol,\x20and\x20while\x20it\x20may\x20elevate\x20liver\x20enzymes,\x20it\x20is\x20less\x20commonly\x20associated\x20with\x20flushing\x20and\x20hyperglycemia.\x20It\x20can\x20cause\x20<strong>myopathy</strong>\x20in\x20patients.\u00a0</p>\x0a<p>Option\x20C:\x20<strong>Ezetimibe</strong>\x20inhibits\x20<strong>cholesterol\x20absorption</strong>\x20in\x20the\x20intestines\x20and\x20is\x20not\x20typically\x20associated\x20with\x20these\x20side\x20effects.</p>\x0a<p>Option\x20D:\x20<strong>Fenofibrate</strong>\x20is\x20used\x20to\x20lower\x20<strong>triglycerides</strong>\x20can\x20elevate\x20<strong>liver\x20enzymes</strong>\x20and\x20can\x20increase\x20the\x20risk\x20of\x20developing\x20myopathy\x20if\x20used\x20concomitantly\x20with\x20statins,\x20but\x20it\x20does\x20not\x20commonly\x20cause\x20flushing\x20or\x20hyperglycemia.</p>','border-gray-600','OtGDl','060-pharmacology-neet-2024-267cd3c2.html','Daratumumab','AXkZK','683983baLDrY','uJNTw','qEBuo','WaPVH','NuyCB','yYvGk','nVcyD','Bortezomib','Clopidogrel','TuBYB','apply','rHvMa','timeDisplay','Lignocaine\x20is\x20used\x20in\x20a\x20loading\x20dose\x20for\x20the\x20treatment\x20of\x20arrhythmias.\x20The\x20loading\x20dose\x20of\x20this\x20drug\x20depends\x20upon\x20which\x20of\x20the\x20following\x20factors?','\x22\x20alt=\x22Question\x20Image\x22\x20class=\x22w-full\x20rounded-lg\x22></div>','questionText','IAMSz','RBZPB','<p>For\x20managing\x20<strong>urinary\x20incontinence</strong>\x20in\x20a\x2075-year-old\x20female\x20with\x20<strong>cognitive\x20decline</strong>\x20and\x20<strong>dementia</strong>,\x20<strong>tolterodine</strong>\x20is\x20useful.</p>\x0a<p>Tolterodine\x20is\x20a\x20<strong>muscarinic\x20receptor\x20antagonist</strong>\x20specifically\x20effective\x20for\x20treating\x20urinary\x20incontinence.\x20It\x20exhibits\x20selectivity\x20for\x20the\x20urinary\x20bladder,\x20which\x20helps\x20to\x20minimize\x20side\x20effects\x20compared\x20to\x20other\x20antimuscarinic\x20agents.\x20This\x20selectivity\x20is\x20<strong>beneficial</strong>\x20for\x20patients\x20with\x20<strong>cognitive\x20decline\x20</strong>or\x20dementia,\x20as\x20it\x20<strong>reduces\x20</strong>the\x20risk\x20of\x20<strong>adverse\x20effects.</strong>\x20Tolterodine\x20is\x20<strong>metabolized</strong>\x20by\x20<strong>CYP2D6</strong>,\x20so\x20its\x20dosage\x20may\x20need\x20adjustment\x20based\x20on\x20individual\x20CYP2D6\x20activity,\x20making\x20it\x20a\x20suitable\x20option\x20for\x20managing\x20urinary\x20incontinence\x20while\x20minimizing\x20potential\x20side\x20effects.</p>\x0a<p>Other\x20muscarinic\x20antagonists\x20for\x20urinary\x20incontinence\x20include\x20<strong>oxybutynin,\x20trospium\x20chloride,\x20darifenacin,\x20solifenacin</strong>,\x20and\x20<strong>fesoterodine</strong>.\x20<strong>Oxybutynin</strong>,\x20though\x20effective,\x20often\x20causes\x20antimuscarinic\x20side\x20effects\x20such\x20as\x20<strong>xerostomia</strong>.\x20<strong>Trospium</strong>\x20chloride,\x20being\x20a\x20quaternary\x20amine,\x20is\x20better\x20tolerated\x20and\x20<strong>excreted\x20primarily</strong>\x20via\x20the<strong>\x20kidneys</strong>,\x20requiring\x20dosage\x20adjustments\x20in\x20renal\x20impairment.\x20<strong>Darifenacin</strong>\x20and\x20<strong>solifenacin</strong>\x20have\x20selectivity\x20for<strong>\x20M3\x20receptors</strong>,\x20which\x20helps\x20balance\x20efficacy\x20and\x20side\x20effects,\x20while\x20<strong>fesoterodine</strong>,\x20a\x20<strong>prodrug</strong>,\x20provides\x20a\x20stable\x20pharmacokinetic\x20profile\x20due\x20to\x20its\x20<strong>conversion</strong>\x20to\x20<strong>tolterodine’s\x20active\x20metabolite</strong>.</p>\x0a<p>Other\x20Options:</p>\x0a<p>Option\x20A:\x20<strong>Tiotropium</strong>\x20and\x20Option\x20C:\x20<strong>Ipratropium</strong>\x20are\x20<strong>muscarinic\x20antagonists</strong>\x20used\x20primarily\x20for\x20respiratory\x20conditions\x20such\x20as\x20<strong>chronic\x20obstructive\x20pulmonary\x20disease\x20(COPD)</strong>\x20and\x20<strong>asthma</strong>,\x20rather\x20than\x20urinary\x20incontinence.\x20<strong>Tiotropium</strong>\x20is\x20a\x20<strong>long</strong>-acting\x20agent\x20with\x20selectivity\x20for\x20<strong>M1\x20</strong>and\x20<strong>M3</strong>\x20receptors,\x20while\x20<strong>Ipratropium</strong>\x20is\x20used\x20more\x20frequently\x20for\x20its<strong>\x20short</strong>-acting\x20effects.</p>\x0a<p>Option\x20D:\x20<strong>Telenzepine</strong>,\x20an\x20<strong>analogue</strong>\x20of\x20<strong>Pirenzepine</strong>,\x20displays\x20higher\x20potency\x20and\x20selectivity\x20for\x20<strong>M1</strong>\x20receptors\x20compared\x20to\x20pirenzepine\x20and\x20is\x20used\x20in\x20treating\x20<strong>acid-peptic\x20diseas</strong>e,\x20not\x20urinary\x20incontinence.\u00a0</p>','dhvHT','https://dhmbxeygs57ff.cloudfront.net/uploads/61107bbff6054604a20f8b083695fb2dx1279x685.JPEG','questions','YNRAr','findIndex','currentMode','TAnxI','Tolterodine','WORZu','</span><span>','startAt','FwbNb','mKKba','wIHvk','IPwqO','OsCdG','pop','log','test','217bpZTxq','cGpkh','flex','gLqEJ','wTACu','ECHIM','yQxTV','correctResult','strokeDashoffset','EROft','ekfiL','figZC','OhESS','NnAco','performanceModal','hVEKg','rzRuJ','DfLYG','oBPbU','EGtCl','kkRZI','setItem','IwAEP','EYqGj','markReviewText','vQxKj','Mannitol','It\x20has\x20fewer\x20side\x20effects\x20compared\x20to\x20other\x20inhalational\x20steroids','UajFy','KlrSE','constructor','PForp','xYJni','canPlayType','zVCYT','replace','3jYxDRw','cDdvI','amoIo','selectedAnswer','GNdAS','.option-button','hYWWH','notAttemptedResult','pathname','solutionAudio','hierarchy','Esmolol','answered','<div\x20class=\x22mt-4\x22><img\x20src=\x22','keydown','MXsfW','You\x20have\x20completed\x20all\x20questions.\x20Would\x20you\x20like\x20to\x20review\x20from\x20the\x20beginning?','ZipQW','QUzYW','correctCount','submitSection','Oral\x20bioavailability\x20is\x20negligible','Epibw','Atenolol','bookmarkBtn','Which\x20drug\x20is\x20used\x20to\x20treat\x20multiple\x20myeloma\x20that\x20is\x20known\x20to\x20cause\x20reactivation\x20of\x20Herpes\x20Zoster?','rSHST','nav-btn-not-attempted\x20hover:bg-white\x20hover:bg-opacity-20','Isoniazid','HhhhI','A\x20patient\x20is\x20started\x20on\x20a\x203\x20HP\x20TPT\x20regimen.\x20Which\x20of\x20the\x20following\x20is\x20true\x20regarding\x20the\x20regimen?','wDtRK','QZolK','The\x20occurence\x20of\x20oral\x20candidiasis\x20is\x20more\x20compared\x20to\x20other\x20inhaled\x20steroids','explanation_images','createElement','A\x20patient\x20presented\x20with\x20breathing\x20difficulty\x20and\x20nasal\x20polyposis\x20when\x20he\x20took\x20aspirin\x20for\x20fever.\x20He\x20faced\x20this\x20issue\x20previously\x20too\x20when\x20he\x20took\x20aspirin.\x20Which\x20among\x20the\x20following\x20is\x20not\x20true\x20about\x20this?','xhciW','SuFXF','fromCharCode','Xyiau','modeModal','No\x20solution\x20provided','\x20>\x20','RbSmd','GGxIp','KNkZC','GRdHz','DPJHB','FknGp','11uPqwmc','parse','<p>The\x20incorrect\x20statement\x20is\x20option\x20C\x20as\x20<strong>ciclesonide</strong>\x20has\x20a\x20<strong>lower\x20risk</strong>\x20of\x20<strong>oral\x20candidiasis</strong>\x20as\x20compared\x20to\x20<strong>other\x20inhaled\x20steroids</strong>.</p>\x0a<p><strong>Ciclesonide</strong>\x20is\x20an\x20<strong>inhaled\x20corticosteroid</strong>\x20that\x20is\x20unique\x20because\x20it\x20is\x20a\x20<strong>prodrug.</strong>\x20It\x20is\x20metabolised\x20by\x20<strong>bronchial\x20esterases</strong>\x20in\x20the\x20<strong>lungs</strong>\x20to\x20its\x20active\x20form,\x20which\x20allows\x20for\x20<strong>targeted\x20action</strong>\x20within\x20the\x20<strong>airways.</strong>\x20This\x20feature\x20<strong>reduces</strong>\x20<strong>systemic\x20side\x20effects</strong>\x20and\x20the\x20risk\x20of\x20<strong>local\x20side\x20effects,</strong>\x20such\x20as\x20<strong>oral\x20candidiasis</strong>\x20(thrush),\x20compared\x20to\x20other\x20inhaled\x20steroids.</p>\x0a<p>Other\x20options:</p>\x0a<p>Option\x20A:\x20Ciclesonide\x27s\x20activation\x20in\x20the\x20lungs\x20minimises\x20systemic\x20absorption,\x20leading\x20to\x20fewer\x20side\x20effects.</p>\x0a<p>Option\x20B:\x20Ciclesonide\x20is\x20inactive\x20until\x20it\x20is\x20converted\x20to\x20its\x20active\x20form\x20in\x20the\x20lungs.</p>\x0a<p>Option\x20D:\x20Due\x20to\x20its\x20prodrug\x20nature\x20and\x20metabolism\x20in\x20the\x20lungs,\x20ciclesonide\x20has\x20low\x20oral\x20bioavailability,\x20reducing\x20systemic\x20exposure.</p>','SKzAW','FhqaZ','data-option-index','\x22\x20alt=\x22Explanation\x20Image\x22\x20class=\x22w-full\x20rounded-lg\x22></div>','nfChC','UaaUu','ArrowRight','iwljM','XyNlJ','classList','Marrow','CvNXs','explanation_audio_hin','npygY','timed_exam','qsDta','video[data-src]','dsNlb','XGwVu','correctAnswers','gradient-yellow\x20px-6\x20py-3\x20text-white\x20transition-all\x20duration-300\x20flex\x20items-center','totalAttempted','nav-btn-current','\x20-\x20Brain\x20And\x20Scalpel','solutionText','WWfZk','CKAPx','filter','Are\x20you\x20sure\x20you\x20want\x20to\x20submit\x20the\x20quiz?','stringify','notAttempted','cgsil','solutionImages','XtBUc','ihBuk','questionNav','CbDRj','ebHMl','PJRSE','4858420zDriLm','bgCpt','pYMTK','Vvcqk','key','totalTime','RkYjl','quizFile','Tiotropium','gradient-purple\x20px-6\x20py-3\x20text-white\x20transition-all\x20duration-300\x20flex\x20items-center','HhCsO','innerHTML','length','GMP','gOnef','USXgx','YwxEP','selected','Adenosine\x200.1\x20mg/kg','wOTKD','VmxvI','Enalapril','dKOcH','AtBvV','split','SKxRf','kaYrN','</div>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20</button>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20','gFQPP','https://cdn1.dailyrounds.org/uploads/027728f8da6746d1b3504b71d1062798.JPEG','<p>PONV\x20Physiology:\x20<span\x20style=\x22font-family:\x20arial,\x20helvetica,\x20sans-serif;\x20font-size:\x2012pt;\x22><strong>Afferents</strong>\x20from\x20the\x20<strong>chemoreceptor\x20trigger\x20zone\x20</strong>(CTZ),\x20<strong>vagal\x20neurons</strong>\x20in\x20the\x20gastrointestinal\x20system,\x20neurons\x20from\x20the\x20vestibular\x20system\x20and\x20midbrain\x20afferents\x20<strong>relay</strong>\x20within\x20the\x20<strong>vomiting\x20centre</strong>\x20in\x20the\x20reticular\x20formation\x20of\x20the\x20brainstem\x20which\x20then\x20project\x20into\x20the\x20<strong>nucleus\x20tractus\x20solitarius</strong>.</span></p>\x0a<p><strong>Risk\x20factors</strong>\x20for\x20PONV\x20are\x20divided\x20into:</p>\x0a<ul>\x0a<li>Patient\x20factors\x0a<ul>\x0a<li><strong>Female</strong>&gt;male</li>\x0a<li>Age<strong>&lt;50\x20years</strong></li>\x0a<li>Prior\x20history\x20of\x20<strong>motion\x20sickness</strong></li>\x0a<li><strong>Non-smokers</strong>\x20&gt;\x20smokers\x20(<strong>CTZ</strong>\x20is\x20<strong>desensitized</strong>)</li>\x0a</ul>\x0a</li>\x0a<li>Preoperative\x20factors\x0a<ul>\x0a<li>(<strong>Fasting\x20</strong>and\x20<strong>anxiety</strong>,\x20while\x20possibly\x20contributing\x20to\x20PONV,\x20have\x20yet\x20to\x20be\x20demonstrated)</li>\x0a</ul>\x0a</li>\x0a<li>Intraoperative\x20factors\x0a<ul>\x0a<li>Surgical\x20-\x20<strong>Cholecystectomy,\x20gynaecological</strong>\x20and\x20<strong>laparoscopic</strong>\x20procedures\x20have\x20higher\x20incidences</li>\x0a<li>Drugs\x20-\x20<strong>Nitrous\x20oxide</strong>,\x20<strong>Opioids</strong>,\x20Cyclopropane,</li>\x0a<li><strong>General\x20anaesthesia</strong>\x20has\x20a\x20times\x20<strong>more\x20risk</strong>\x20of\x20developing\x20PONV\x20than\x20regional\x20anaesthesia.</li>\x0a</ul>\x0a</li>\x0a<li>Postoperative\x20factors\x0a<ul>\x0a<li><strong>Pain</strong>\x20and\x20<strong>early\x20ambulatio</strong>n\x20contribute\x20to\x20a\x20higher\x20risk\x20of\x20PONV.</li>\x0a</ul>\x0a</li>\x0a</ul>\x0a<p><strong>Scoring\x20systems\x20</strong>used\x20to\x20grade\x20PONV\x20are<strong>\x20</strong>the<strong>\x20Apfel\x20score\x20</strong>and\x20the<strong>\x20Koivuranta\x20score.</strong></p>\x0a<p>Drugs\x20used\x20in\x20the\x20<strong>prophylaxis</strong>\x20and\x20treatment\x20of\x20PONV:</p>\x0a<ul>\x0a<li>5-HT\x203\x20antagonists\x20-\x20<strong>ondansetron</strong>,\x20palonosetron</li>\x0a<li>Butyrophenones-\x20<strong>droperidol</strong></li>\x0a<li><strong>Dexamethasone</strong></li>\x0a<li>Transdermal\x20scopolamine</li>\x0a<li><strong>Aprepitant</strong></li>\x0a</ul>\x0a<p>Note:<strong>\x20Double-blind\x20studies</strong>\x20have\x20found\x20<strong>no\x20difference</strong>\x20in\x20the\x20efficacy\x20between\x20<strong>aprepitant(NK1\x20antagonists)</strong>\x20and\x20<strong>ondansetron\x20(5HT3\x20antagonist)</strong>\x20in\x20the\x20<strong>first\x2024\x20hours</strong>\x20following\x20surgery.\x20But\x20<strong>after\x2024\x20hours</strong>\x20<strong>aprepitant</strong>\x20has\x20proven\x20to\x20be\x20<strong>more\x20productive</strong>\x20than\x20ondansetron\x20in\x20the\x20management\x20of\x20<strong>PONV</strong>.</p>','TtIxr','PaPLK','button','toISOString','HhBkJ','{}.constructor(\x22return\x20this\x22)(\x20)','lVTXY','Which\x20drug\x20is\x20used\x20for\x20maintenance\x20therapy\x20in\x20opium\x20addiction?','isSupported','xIcbg','oLnAH','incomplete','kHhLJ','block','lQyVp','FDbpe','LivcS','\x22\x20controls\x20class=\x22w-full\x22></audio></div>','https://dhmbxeygs57ff.cloudfront.net/uploads/eaf426b95b65411ab20b432201766924x1280x1403.JPEG','trace','study','jmimW','getItem','Phase\x20I','<div\x20class=\x22mt-2\x22><p\x20class=\x22text-sm\x20text-white\x20text-opacity-70\x20mb-1\x22>Hinglish:</p><audio\x20src=\x22','There\x20is\x20more\x20compliance\x20in\x203HP\x20than\x209H\x20and\x206H','Bioavailability','XxVcM','QouhV','VEByd','AHcPr','border-red-500','jTCxO','Bookmarked','tscNP','hgNZQ','Phase\x20IV','kvtPl','\x22\x20data-option-index=\x22','</div>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20','Hydrochlorothiazide','cOYsN','wjvGz','eHGsZ','Acetazolamide','GXsMd','fRLAH','HgoPz','Wsonu','<p><strong>Tesamorelin</strong>\x20is\x20approved\x20for\x20use\x20in\x20<strong>HIV-associated\x20lipodystrophy</strong>\x20but\x20<strong>not</strong>\x20for\x20<strong>GH\x20deficiency</strong>.\x20It\x20is\x20a<strong>\x20synthetic\x20N-terminal\x20modified\x20</strong>form\x20of\x20human\x20GHRH<strong>.</strong>\x20It\x20does\x20not\x20get\x20degraded\x20by\x20dipeptidyl\x20peptidase\x204\x20and\x20therefore\x20has\x20a\x20longer\x20duration\x20of\x20action.</p>\x0a<p>It\x20increases\x20the\x20levels\x20of\x20growth\x20hormone\x20(GH)\x20and\x20insulin-like\x20growth\x20factor\x20(IGF-1)\x20but\x20reduces\x20visceral\x20fat\x20accumulation.</p>\x0a<p>Tesamorelin\x20is\x20approved\x20for\x20use\x20in\x20HIV-associated\x20lipodystrophy\x20but\x20<strong>not</strong>\x20for\x20<strong>GH</strong>\u00a0<strong>deficiency.</strong>\u00a0</p>\x0a<p>Other\x20options:</p>\x0a<p>Option\x20A:\x20<strong>Octreotide\u00a0</strong>is\x20a\x20<strong>somatostatin\x20analogue</strong>\x20that\x20decreases\x20growth\x20hormone\x20levels.\x20It\x20is\x20used\x20in\x20the\x20treatment\x20of\x20<strong>acromegaly</strong>,\x20<strong>variceal\x20bleeding,</strong>\x20diarrhoea\x20due\x20to\x20adenomas\x20secreting\x20VIP\x20(vasoactive\x20intestinal\x20peptide),\x20and\x20<strong>sulfonylurea\x20toxicity.</strong>\x20One\x20of\x20its\x20adverse\x20effects\x20is\x20<strong>gallstone</strong>\x20formation.</p>\x0a<p>Option\x20B:\x20<strong>Somatropin\u00a0</strong>is\x20a\x20<strong>growth\x20hormone\x20analogue</strong>.\x20It\x20is\x20used\x20in\x20growth\x20hormone\x20deficiency\x20and\x20other\x20short-stature\x20conditions\x20like\x20Turner\x27s\x20syndrome,\x20Noonan\x20syndrome,\x20and\x20Prader-Willi\x20syndrome.\x20Their\x20use\x20is\x20contraindicated\x20in\x20acute\x20critical\x20illness,\x20active\x20malignancy,\x20and\x20proliferative\x20retinopathy.</p>\x0a<p>Option\x20D:\x20<strong>Mecasermin\u00a0</strong>is\x20a\x20<strong>recombinant\x20human\x20IGF-1</strong>.\x20It\x20is\x20used\x20in\x20IGF-1\x20deficiency,\x20growth\x20hormone\x20receptor\x20defects,\x20and\x20antibodies\x20against\x20growth\x20hormone\x20receptors.\x20Adverse\x20effects\x20include\x20<strong>hypoglycemia</strong>\x20and\x20<strong>lipohypertrophy</strong>.\x20Another\x20recombinant\x20human\x20IGF-1\x20with\x20its\x20IGFBP-3,\x20<strong>mecasermin\x20rinfabate</strong>\x20has\x20been\x20FDA-approved\x20for\x20<strong>HIV-associated\x20adipose\x20redistribution\x20syndrome</strong>.</p>','text','FcfdH','<p>The\x20given\x20ECG\x20shows\x20<strong>pseudo\x20R\x27\x20waves</strong>:</p>','A\x20patient\x20diagnosed\x20with\x20hypertriglyceridemia\x20was\x20started\x20on\x20a\x20medication,\x20following\x20which,\x20he\x20developed\x20flushing,\x20hyperglycemia,\x20and\x20elevated\x20liver\x20enzymes.\x20Identify\x20the\x20drug\x20consumed\x20by\x20the\x20patient.','irEhC','MBjLN','markedForReview','toggle','tmvFt','jnjau','PeYGx','explanation_video','removeItem','A\x20patient\x20who\x20recently\x20underwent\x20surgery\x20has\x20complaints\x20of\x20nausea\x20and\x20vomiting.\x20He\x20was\x20prescribed\x20a\x20drug\x20called\x20aprepitant.\x20What\x20is\x20its\x20mechanism\x20of\x20action?','vKLFj','A\x20patient\x20with\x20a\x20gynecological\x20malignancy\x20is\x20started\x20on\x20Methotrexate.\x20Later\x20she\x20develops\x20oral\x20and\x20gastric\x20ulcers.\x20Which\x20nucleotide\x20synthesis\x20is\x20affected\x20in\x20her?','KxfQv','Furosemide','Hvafq','question_audio','pNXvR','Phase\x20III','hvmKM','exception','accuracy','nav-btn-marked-review','bind','eAkFA','EzEuC','open','Lenalidomide','timerContainer','fmsNG','w-8\x20h-8\x20text-sm\x20font-medium\x20rounded\x20transition-all\x20duration-200','LPeFN','Propanolol','WzOVw','Tesamorelin','questionStates','The\x20drug\x20\x27X\x27\x20is\x20a\x20GHRH\x20analogue\x20that\x20is\x20FDA-approved\x20for\x20the\x20treatment\x20of\x20HIV-associated\x20lipodystrophy\x20and\x20not\x20used\x20for\x20Growth\x20hormone\x20deficiency.\x20Identify\x20the\x20drug\x20\x27X\x27.','WFySO','OlcBL','YeOen','wEDzm','JzVyT','correct','rkjbe','RaupO','.m3u8','optionsContainer','kqPqa','HWxTy','txKVE','questionIndex','mTCEw','NieSC','endsWith','Galantamine','CLUqL','Atropine\x20potentiates\x20the\x20action\x20of\x20smooth\x20muscle\x20relaxation','Telenzipine','Ezetemibe','asMey','<p>Among\x20the\x20given\x20drugs,\x20<strong>astemizole</strong>\x20increases\x20the\x20risk\x20of\x20Torsades\x20de\x20pointes\x20when\x20used\x20concomitantly\x20with\x20erythromycin.\u00a0</p>\x0a<p>Drugs\x20that\x20<strong>block\x20potassium\x20channels</strong>\x20and\x20prolong\x20<strong>QT\x20increase\x20arrhythmogenic</strong>\x20potential.\x20Astemizole\x20is\x20a\x20<strong>second-generation\x20antihistamine</strong>\x20that\x20<strong>blocks</strong>\x20delayed\x20potassium\x20channels\x20and\x20prolongs\x20the\x20QT\x20interval.</p>\x0a<p>Other\x20options:</p>\x0a<p>Option\x20A:\x20<strong>Doxylamine</strong>\x20is\x20an\x20<strong>antihistamine</strong>\x20commonly\x20used\x20as\x20a\x20<strong>short-term\x20treatment</strong>\x20for\x20<strong>insomnia.</strong>\x20It\x20is\x20combined\x20with\x20pyridoxine\x20(vitamin\x20B6)\x20to\x20treat\x20nausea\x20and\x20vomiting\x20during\x20pregnancy\x20(morning\x20sickness).\x20It\x20does\x20<strong>not</strong>\x20prolong\x20the\x20QT\x20interval.</p>\x0a<p><span\x20style=\x22font-family:\x20-apple-system,\x20BlinkMacSystemFont,\x20\x27Segoe\x20UI\x27,\x20Roboto,\x20Oxygen,\x20Ubuntu,\x20Cantarell,\x20\x27Open\x20Sans\x27,\x20\x27Helvetica\x20Neue\x27,\x20sans-serif;\x22>Option\x20B:\x20<strong>Loratadine</strong>\x20is\x20a\x20<strong>second-generation</strong>\x20antihistamine\x20used\x20to\x20treat\x20allergic\x20rhinitis\x20(hay\x20fever)\x20and\x20urticaria\x20(hives).\x20It\x20is\x20known\x20for\x20being\x20non-sedating\x20due\x20to\x20its\x20minimal\x20penetration\x20into\x20the\x20central\x20nervous\x20system.\x20It\x20does\x20<strong>not</strong>\x20prolong\x20the\x20QT\x20interval.</span></p>\x0a<p>Option\x20C:\x20<strong>Promethazine</strong>\x20is\x20a\x20<strong>first-generation</strong>\x20antihistamine\x20with\x20multiple\x20uses,\x20including\x20the\x20treatment\x20of\x20allergies,\x20motion\x20sickness,\x20nausea\x20and\x20vomiting,\x20and\x20as\x20a\x20sedative\x20or\x20sleep\x20aid.\x20It\x20also\x20has\x20antiemetic\x20properties\x20and\x20is\x20sometimes\x20used\x20in\x20the\x20management\x20of\x20<strong>postoperative\x20nausea</strong>\x20and\x20<strong>vomiting.</strong></p>','WhORF','qQaNc','incorrectCount','Promethazine','THgxP','qMAQg','rURjx','disabled','glass-light\x20px-6\x20py-3\x20text-white\x20hover:bg-yellow-500\x20hover:bg-opacity-20\x20transition-all\x20duration-300\x20flex\x20items-center','XNoCw','ryFes','LuAGn','4\x20tablets\x20of\x20Artesunate\x2050mg\x20+\x20Sulphadoxine\x201500mg\x20+\x206\x20tablets\x20of\x20Primaquine\x202.5mg','Occurs\x20with\x20exposure\x20to\x20other\x20NSAIDs\x20too\x20that\x20block\x20COX\x201','hSlwQ','question_images','loadSource','remove','status','RuWMF','ugfte','VxUUw','hidden','fWMkf','jByfj','10292BkowbZ','solutionContainer','navBtn_','ppNqy','avgTimeResult','forEach','round','TdIND','bKrXZ','now','nwWHH','SIjlV','DmRWD','OhmUq','Mecasermin','<div\x20class=\x22glass-light\x20p-4\x20mb-4\x22><video\x20src=\x22','https://dhmbxeygs57ff.cloudfront.net/uploads/412d569ccab6464c923b959231b29e98x512x371.PNG','timeSpent','BIQsf','getAttribute','bQzaB','cVvCb','srbwU','questionMedia','SiqIh','BHwaD','A\x2075-year-old\x20female\x20presented\x20with\x20urinary\x20incontinence.\x20She\x20also\x20has\x20cognition\x20decline\x20and\x20dementia.\x20Which\x20of\x20the\x20following\x20drugs\x20is\x20useful\x20for\x20treating\x20urinary\x20incontinence?','timed_study','click','DNbug','nWDmQ','EHzFQ','vrTaA','Which\x20of\x20the\x20following\x20drugs\x20when\x20added\x20with\x20erythromycin\x20can\x20lead\x20to\x20torsades\x20de\x20pointes?','125zXigPa','question_video','GfRPR','Synchronized\x20cardioversion\x20with\x202J\x20of\x20current','rairm','dQIoh','HHdaN','AkaMY','xweuu','bfINs','VMrDh','qboYo','toIJz','incorrectResult','VyndE','AKAQr','IUywZ','frZvk','lGLnH','imKgR','7180983rJjtpT','UDP','bQsqd','getElementById','Clonidine','Astemizole'];_0x224d=function(){return _0x4c7cb2;};return _0x224d();}function updateQuestionNav(){const _0x3e1b2e=_0x31022e,_0x33224f={'EirGq':function(_0x47ab1b,_0x125458){return _0x47ab1b===_0x125458;},'XujYw':_0x3e1b2e(0xf5),'SlbIH':function(_0xf54150,_0x52e00c){return _0xf54150===_0x52e00c;},'yYvGk':'timed_study','PtKrB':'incorrectCount','zPbKl':'totalAttempted','hSlwQ':function(_0x13d7fc,_0x35b62e){return _0x13d7fc>_0x35b62e;},'SiqIh':function(_0x478b40,_0x2077a6){return _0x478b40*_0x2077a6;},'BxGAe':function(_0x42431e,_0x468bd8){return _0x42431e/_0x468bd8;},'lGLnH':_0x3e1b2e(0x12b),'fIosU':function(_0x51ee88,_0x3b7597){return _0x51ee88/_0x3b7597;},'fmsNG':function(_0x27c837,_0x59a1c4){return _0x27c837+_0x59a1c4;},'EVZcu':'nav-btn-current','mnIFB':function(_0x275abe){return _0x275abe();},'RbLui':_0x3e1b2e(0x228),'hHacZ':function(_0x3dfe07,_0x2ef437){return _0x3dfe07<_0x2ef437;},'UlGoQ':function(_0x493c8a,_0x4860d4){return _0x493c8a===_0x4860d4;},'Hvafq':_0x3e1b2e(0x101),'DRWrw':'kUkou','NieSC':_0x3e1b2e(0x29b),'hlLNJ':function(_0x4be462,_0x29d914){return _0x4be462===_0x29d914;},'psIUO':_0x3e1b2e(0x21f),'VmxvI':_0x3e1b2e(0x12c),'WJXnh':function(_0x3817f3,_0x15cd26){return _0x3817f3===_0x15cd26;},'qQaNc':'DPJHB','MXsfW':function(_0x4a0ba4,_0x51d118){return _0x4a0ba4===_0x51d118;},'ZlxYx':_0x3e1b2e(0x140),'OpeXU':function(_0x3c41d2,_0x1e27a9){return _0x3c41d2===_0x1e27a9;},'Xyiau':_0x3e1b2e(0x349),'nwWHH':function(_0x10e176,_0x1f30aa){return _0x10e176!==_0x1f30aa;},'XGwVu':'sAJdh','jmimW':function(_0x43d720,_0x3ed25c){return _0x43d720!==_0x3ed25c;},'HDlZf':_0x3e1b2e(0x2b4)};for(let _0x5226b4=0x0;_0x33224f['hHacZ'](_0x5226b4,questionsData[_0x3e1b2e(0xce)]);_0x5226b4++){const _0x35b085=document[_0x3e1b2e(0x1a5)](_0x3e1b2e(0x16e)+_0x5226b4),_0x1b9a8c=questionStates[_0x5226b4];let _0x39ce02='';if(_0x33224f[_0x3e1b2e(0x279)](_0x5226b4,currentQuestionIndex))_0x39ce02=_0x3e1b2e(0x379);else{if(_0x1b9a8c[_0x3e1b2e(0x204)]){if(_0x33224f[_0x3e1b2e(0x1ce)](_0x33224f[_0x3e1b2e(0x125)],_0x33224f[_0x3e1b2e(0x1c3)])){if(_0x33224f['EirGq'](_0x167f4d,_0x33224f[_0x3e1b2e(0x2aa)])||_0x33224f[_0x3e1b2e(0x279)](_0x3a63fc,_0x33224f[_0x3e1b2e(0x2e9)])){_0x1bb583[_0x3e1b2e(0x1a5)](_0x3e1b2e(0x341))[_0x3e1b2e(0x2d7)]=_0x4c527b['correctAnswers'],_0x29b60c[_0x3e1b2e(0x1a5)](_0x33224f[_0x3e1b2e(0x227)])[_0x3e1b2e(0x2d7)]=_0x4591ee['incorrectAnswers'],_0x169456[_0x3e1b2e(0x1a5)](_0x33224f['zPbKl'])[_0x3e1b2e(0x2d7)]=_0x5a38d5[_0x3e1b2e(0x378)];const _0x1508a3=_0x33224f[_0x3e1b2e(0x161)](_0x3d5a08[_0x3e1b2e(0x378)],0x0)?_0x372d69[_0x3e1b2e(0x172)](_0x33224f[_0x3e1b2e(0x184)](_0x33224f[_0x3e1b2e(0x1dc)](_0x1fd4b1[_0x3e1b2e(0x376)],_0x204790[_0x3e1b2e(0x378)]),0x64)):0x0;_0x41295a[_0x3e1b2e(0x1a5)](_0x33224f[_0x3e1b2e(0x1a0)])[_0x3e1b2e(0x2d7)]=_0x1508a3+'%',_0xd4528f[_0x3e1b2e(0xc7)]=_0x4762ca[_0x3e1b2e(0x26c)]((_0x56908e,_0x3eca91)=>_0x56908e+_0x3eca91[_0x3e1b2e(0x17d)],0x0);const _0x16ad70=_0x5bd65e[_0x3e1b2e(0x2c0)](_0x33224f[_0x3e1b2e(0x2d3)](_0x11e157['totalTime'],0x3e8)),_0x58647a=_0x37e0d8[_0x3e1b2e(0x2c0)](_0x33224f['BxGAe'](_0x16ad70,0x3c)),_0xa1d0f=_0x16ad70%0x3c;_0x575cbc[_0x3e1b2e(0x1a5)](_0x3e1b2e(0x17d))[_0x3e1b2e(0x2d7)]=_0x33224f[_0x3e1b2e(0x133)](_0x58647a,':')+_0xa1d0f['toString']()[_0x3e1b2e(0x1df)](0x2,'0');}}else _0x39ce02=_0x33224f[_0x3e1b2e(0x14a)];}else{if(_0x1b9a8c[_0x3e1b2e(0x119)])_0x33224f['hlLNJ'](_0x3e1b2e(0x21f),_0x33224f['psIUO'])?_0x39ce02=_0x33224f[_0x3e1b2e(0xd6)]:_0x5bdfcf=_0x33224f[_0x3e1b2e(0x1f5)];else{if(currentMode===_0x3e1b2e(0xf5)||currentMode===_0x33224f['yYvGk']){if(_0x33224f[_0x3e1b2e(0x2c7)](_0x3e1b2e(0x35e),_0x33224f[_0x3e1b2e(0x154)])){if(_0x33224f[_0x3e1b2e(0x33d)](_0x1b9a8c[_0x3e1b2e(0x165)],_0x33224f[_0x3e1b2e(0x285)]))_0x39ce02='nav-btn-correct';else{if(_0x33224f['OpeXU'](_0x1b9a8c[_0x3e1b2e(0x165)],_0x33224f[_0x3e1b2e(0x206)]))_0x39ce02=_0x3e1b2e(0x267);else _0x39ce02=_0x33224f['Xyiau'];}}else _0x33224f['mnIFB'](_0x16892b);}else{if(_0x33224f[_0x3e1b2e(0x176)](_0x33224f[_0x3e1b2e(0x375)],'sAJdh'))_0x301957++,_0x351df0[_0x3e1b2e(0x165)]=_0x33224f[_0x3e1b2e(0x206)];else{if(_0x33224f[_0x3e1b2e(0xf6)](_0x1b9a8c[_0x3e1b2e(0x331)],null))_0x39ce02=_0x33224f[_0x3e1b2e(0x1dd)];else _0x39ce02=_0x33224f[_0x3e1b2e(0x356)];}}}}}_0x35b085[_0x3e1b2e(0x28d)]=_0x3e1b2e(0x23f)+_0x39ce02;}}function jumpToQuestion(_0x35176d){const _0x1d2948=_0x31022e,_0x154536={'nWDmQ':function(_0x47166a,_0x3656a6){return _0x47166a>=_0x3656a6;},'cDdvI':function(_0x5049c6,_0x1c8138){return _0x5049c6!==_0x1c8138;},'wTACu':_0x1d2948(0x1eb),'FknGp':function(_0x44dbfd){return _0x44dbfd();}};_0x154536[_0x1d2948(0x18a)](_0x35176d,0x0)&&_0x35176d<questionsData['length']&&(questionStartTime&&(_0x154536[_0x1d2948(0x32f)](_0x154536[_0x1d2948(0x30e)],_0x154536[_0x1d2948(0x30e)])?_0x5dd67b=_0x1f001c:questionStates[currentQuestionIndex][_0x1d2948(0x17d)]+=Date[_0x1d2948(0x175)]()-questionStartTime),currentQuestionIndex=_0x35176d,_0x154536[_0x1d2948(0x35f)](displayQuestion),saveProgress());}function updateStats(){const _0x3eaf0e=_0x31022e,_0x2c9520={'fRLAH':function(_0x419406,_0x3a1c87){return _0x419406>_0x3a1c87;},'vxeYA':function(_0x268996,_0x55afd5){return _0x268996-_0x55afd5;},'tscNP':function(_0x41a58e){return _0x41a58e();},'rkjbe':function(_0x595124){return _0x595124();},'JzVyT':_0x3eaf0e(0xf5),'ERUmz':function(_0x15384d,_0x2abdc7){return _0x15384d===_0x2abdc7;},'CwNye':_0x3eaf0e(0x187),'WFySO':_0x3eaf0e(0x142),'GXsMd':_0x3eaf0e(0x341),'mogqB':_0x3eaf0e(0x155),'xbsju':_0x3eaf0e(0x378),'shUzW':function(_0x488bbe,_0x173f2a){return _0x488bbe*_0x173f2a;},'tmvFt':function(_0x3dca23,_0x34cc79){return _0x3dca23/_0x34cc79;},'kSTTv':'accuracy','ZYzoQ':function(_0x582096,_0x186b56){return _0x582096+_0x186b56;},'HdFlq':function(_0xfb58bd,_0x552c43){return _0xfb58bd/_0x552c43;},'bCcHM':function(_0xe45cb9,_0x80dc26){return _0xe45cb9/_0x80dc26;},'dCCrl':_0x3eaf0e(0x17d)};if(currentMode===_0x2c9520[_0x3eaf0e(0x13f)]||_0x2c9520['ERUmz'](currentMode,_0x2c9520[_0x3eaf0e(0x2be)])){if(_0x2c9520['WFySO']!==_0x2c9520[_0x3eaf0e(0x13b)])_0x2c9520[_0x3eaf0e(0x10f)](_0x4fbef5,0x0)&&(_0x10459e&&(_0xea3f3a[_0x56636d][_0x3eaf0e(0x17d)]+=_0x2c9520[_0x3eaf0e(0x1c0)](_0x14a23a[_0x3eaf0e(0x175)](),_0x58fbb7)),_0x22aba7--,_0x2c9520[_0x3eaf0e(0x103)](_0x245cfc),_0x2c9520[_0x3eaf0e(0x141)](_0x456db3));else{document[_0x3eaf0e(0x1a5)](_0x2c9520[_0x3eaf0e(0x10e)])[_0x3eaf0e(0x2d7)]=stats[_0x3eaf0e(0x376)],document[_0x3eaf0e(0x1a5)](_0x2c9520[_0x3eaf0e(0x25a)])[_0x3eaf0e(0x2d7)]=stats[_0x3eaf0e(0x1b1)],document[_0x3eaf0e(0x1a5)](_0x2c9520['xbsju'])['textContent']=stats['totalAttempted'];const _0x2bd2d1=stats[_0x3eaf0e(0x378)]>0x0?Math[_0x3eaf0e(0x172)](_0x2c9520['shUzW'](_0x2c9520[_0x3eaf0e(0x11b)](stats[_0x3eaf0e(0x376)],stats[_0x3eaf0e(0x378)]),0x64)):0x0;document[_0x3eaf0e(0x1a5)](_0x2c9520[_0x3eaf0e(0x2dd)])['textContent']=_0x2c9520[_0x3eaf0e(0x247)](_0x2bd2d1,'%'),stats[_0x3eaf0e(0xc7)]=questionStates[_0x3eaf0e(0x26c)]((_0x20f809,_0x28db4b)=>_0x20f809+_0x28db4b['timeSpent'],0x0);const _0x56a426=Math[_0x3eaf0e(0x2c0)](_0x2c9520['HdFlq'](stats[_0x3eaf0e(0xc7)],0x3e8)),_0xded325=Math['floor'](_0x2c9520['bCcHM'](_0x56a426,0x3c)),_0x1a7209=_0x56a426%0x3c;document[_0x3eaf0e(0x1a5)](_0x2c9520['dCCrl'])['textContent']=_0x2c9520[_0x3eaf0e(0x247)](_0xded325+':',_0x1a7209[_0x3eaf0e(0x2a4)]()[_0x3eaf0e(0x1df)](0x2,'0'));}}}function setupVideo(_0x119286,_0xc2476c){const _0x20dd11=_0x31022e,_0x144319={'UaaUu':'application/vnd.apple.mpegurl'};if(Hls[_0x20dd11(0xe9)]()){const _0x594902=new Hls();_0x594902[_0x20dd11(0x163)](_0xc2476c),_0x594902[_0x20dd11(0x22b)](_0x119286);}else _0x119286[_0x20dd11(0x32b)](_0x144319[_0x20dd11(0x368)])&&(_0x119286['src']=_0xc2476c);}function displayQuestion(){const _0x2d2004=_0x31022e,_0x5bb795={'JqkmR':function(_0x52c962,_0x327a8f){return _0x52c962===_0x327a8f;},'GNdAS':function(_0x2add1a){return _0x2add1a();},'pYMTK':_0x2d2004(0x357),'cgsil':'none','oLnAH':_0x2d2004(0x1e6),'JIUlZ':_0x2d2004(0x1b9),'SIjlV':_0x2d2004(0x237),'fWMkf':function(_0x519944,_0x2c8957){return _0x519944===_0x2c8957;},'dVICx':_0x2d2004(0x257),'DNbug':'mFwfV','oiBLd':function(_0x455b10,_0x46a4fa){return _0x455b10+_0x46a4fa;},'hqtaO':_0x2d2004(0xd3),'oIALr':_0x2d2004(0x208),'lZnBa':function(_0x62c9bb,_0x242b9d){return _0x62c9bb+_0x242b9d;},'NuqPN':function(_0x2e5207,_0x399d44){return _0x2e5207===_0x399d44;},'BFKfx':_0x2d2004(0x259),'UmoIX':_0x2d2004(0x33a),'rzRuJ':function(_0x1e679d,_0x3bdd08){return _0x1e679d===_0x3bdd08;},'qsDta':'ICsCt','bjVEp':_0x2d2004(0x333),'TAnxI':_0x2d2004(0x365),'XmaIO':function(_0x345e90,_0x40de56){return _0x345e90(_0x40de56);},'kJsMX':_0x2d2004(0x169),'zlkla':function(_0x386a53,_0xd2bcbb){return _0x386a53===_0xd2bcbb;},'OsCdG':function(_0x4ffc24,_0x210344){return _0x4ffc24!==_0x210344;},'yZzvF':'qByGL','toIJz':_0x2d2004(0x2f3),'fQDri':'No\x20questions\x20available\x20for\x20this\x20quiz.','OBTEf':function(_0x491c9f,_0x287e67){return _0x491c9f*_0x287e67;},'GGxIp':_0x2d2004(0x2c9),'ngjWz':function(_0xcbc35c,_0xca576e){return _0xcbc35c+_0xca576e;},'PwUDP':_0x2d2004(0x22f),'YeOen':function(_0x41c6a5,_0x833a62){return _0x41c6a5+_0x833a62;},'XxVcM':function(_0x4e6353){return _0x4e6353();},'CLUqL':_0x2d2004(0x2cc),'VyndE':_0x2d2004(0x183),'NuyCB':_0x2d2004(0x144),'cGpkh':'OtGDl','hbLKa':function(_0x118338,_0x4eb303){return _0x118338===_0x4eb303;},'Nrbff':'timed_exam','BUZyB':'rGHQo'};if(!questionsData||_0x5bb795[_0x2d2004(0x203)](questionsData[_0x2d2004(0xce)],0x0)){if(_0x5bb795[_0x2d2004(0x306)](_0x5bb795[_0x2d2004(0x1e1)],_0x2d2004(0x2ac))){document['getElementById'](_0x5bb795[_0x2d2004(0x19a)])[_0x2d2004(0xcd)]=_0x5bb795['fQDri'];return;}else{const _0xdfd0b0=_0x134c1e[_0x2a08af],_0x453c9f=_0xdfd0b0[_0x2d2004(0x22c)];if(_0x4730e2===null)return;const _0x3693d3=_0xdfd0b0[_0x2d2004(0x236)][_0x395cd5],_0x3aeb2a=_0x5bb795[_0x2d2004(0x261)](_0x3693d3['id'],_0x453c9f);if(_0x5bb795[_0x2d2004(0x261)](_0x2a331c[_0x223569][_0x2d2004(0x165)],_0x2d2004(0x259))){_0x42e698[_0x2d2004(0x378)]++,_0x22fee8[_0x2d2004(0x381)]--;if(_0x3aeb2a)_0x1be1a6['correctAnswers']++;else _0x2b12f9['incorrectAnswers']++;}_0x427a98[_0x229674][_0x2d2004(0x165)]=_0x3aeb2a?_0x2d2004(0x140):_0x2d2004(0x228),_0x314b74(),_0x1e16b7(_0x3aeb2a),_0x5bb795[_0x2d2004(0x332)](_0x18503f);}};const _0x1959f1=questionsData[currentQuestionIndex];questionStartTime=Date['now'](),selectedOption=questionStates[currentQuestionIndex][_0x2d2004(0x331)];const _0x273461=_0x5bb795[_0x2d2004(0x1de)]((currentQuestionIndex+0x1)/questionsData[_0x2d2004(0xce)],0x64);document['getElementById'](_0x5bb795[_0x2d2004(0x35b)])[_0x2d2004(0x275)][_0x2d2004(0x2a6)]=_0x5bb795['ngjWz'](_0x273461,'%'),document[_0x2d2004(0x1a5)](_0x5bb795[_0x2d2004(0x277)])['textContent']=_0x5bb795[_0x2d2004(0x13d)](currentQuestionIndex,0x1),_0x5bb795[_0x2d2004(0xfc)](updateQuestionNav),document['getElementById']('prevBtn')[_0x2d2004(0x15a)]=currentQuestionIndex===0x0,document[_0x2d2004(0x1a5)](_0x2d2004(0x16d))[_0x2d2004(0x36c)][_0x2d2004(0x2c8)](_0x5bb795[_0x2d2004(0x232)]),document[_0x2d2004(0x1a5)](_0x5bb795[_0x2d2004(0x19a)])[_0x2d2004(0xcd)]=_0x1959f1[_0x2d2004(0x113)]||_0x2d2004(0x1bd);let _0x388c50='';if(_0x1959f1[_0x2d2004(0x126)])_0x388c50+=_0x2d2004(0x24e)+_0x1959f1[_0x2d2004(0x126)]+_0x2d2004(0xf2);if(_0x1959f1[_0x2d2004(0x18f)])_0x388c50+=_0x2d2004(0x17b)+_0x1959f1[_0x2d2004(0x18f)]+'\x22\x20controls\x20class=\x22w-full\x20rounded-lg\x22></video></div>';_0x1959f1[_0x2d2004(0x162)]&&(_0x5bb795[_0x2d2004(0x14d)]!==_0x5bb795['CLUqL']?(_0x14aaa3=_0x2d1e46,_0x456dfc['getElementById'](_0x5bb795[_0x2d2004(0xc4)])[_0x2d2004(0x275)]['display']=_0x5bb795[_0x2d2004(0x382)],_0x5bb795[_0x2d2004(0x332)](_0x1d4eb1)):_0x1959f1['question_images']['forEach'](_0x5152d7=>{const _0x22a738=_0x2d2004;if(_0x5152d7)_0x388c50+='<div\x20class=\x22glass-light\x20p-4\x20mb-4\x22><img\x20src=\x22'+_0x5152d7+_0x22a738(0x2f2);}));document['getElementById'](_0x5bb795[_0x2d2004(0x19c)])[_0x2d2004(0xcd)]=_0x388c50;const _0x3fe4a1=document[_0x2d2004(0x1a5)](_0x5bb795[_0x2d2004(0x2e8)]);_0x3fe4a1[_0x2d2004(0xcd)]='',_0x3fe4a1['classList']['remove'](_0x5bb795['UmoIX']),_0x1959f1[_0x2d2004(0x236)]&&Array['isArray'](_0x1959f1[_0x2d2004(0x236)])&&(_0x5bb795['OsCdG'](_0x2d2004(0x2e0),_0x5bb795[_0x2d2004(0x30b)])?(delete _0x155810[_0x4c63b6],_0x41e65b[_0x2d2004(0x31f)](_0x5bb795[_0x2d2004(0xeb)],_0x4a50da[_0x2d2004(0x380)](_0x2721df)),_0x2fd3c5[_0x2d2004(0x308)](_0x5bb795[_0x2d2004(0x252)])):(_0x1959f1[_0x2d2004(0x236)][_0x2d2004(0x171)]((_0x4dff0b,_0x4b23e3)=>{const _0x4316f8=_0x2d2004;if(_0x5bb795[_0x4316f8(0x16a)](_0x5bb795[_0x4316f8(0x2bd)],_0x5bb795[_0x4316f8(0x189)])){if(_0x6c21e0['isSupported']()){const _0x5db275=new _0x37c8c2();_0x5db275['loadSource'](_0x92092c),_0x5db275[_0x4316f8(0x22b)](_0x56b46a);}else _0xce50ff[_0x4316f8(0x32b)](_0x5bb795[_0x4316f8(0x177)])&&(_0x373244['src']=_0xfd1731);}else{const _0x3704e6=String[_0x4316f8(0x355)](_0x5bb795[_0x4316f8(0x1db)](0x41,_0x4b23e3)),_0x2c6214=_0x5bb795[_0x4316f8(0x261)](selectedOption,_0x4b23e3),_0x56360f=document[_0x4316f8(0x351)](_0x4316f8(0x27b));_0x56360f[_0x4316f8(0xcd)]=_0x4316f8(0x242)+(_0x2c6214?_0x5bb795[_0x4316f8(0x1e5)]:'')+_0x4316f8(0x107)+_0x4b23e3+'\x22>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<div\x20class=\x22option-letter\x22>'+_0x3704e6+'</div>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<div\x20class=\x22option-text\x22>'+(_0x4dff0b[_0x4316f8(0x113)]||_0x5bb795[_0x4316f8(0x1db)](_0x5bb795[_0x4316f8(0x1b5)],_0x5bb795[_0x4316f8(0x2af)](_0x4b23e3,0x1)))+_0x4316f8(0xdd),_0x3fe4a1['appendChild'](_0x56360f);}}),_0x3fe4a1[_0x2d2004(0x287)](_0x2d2004(0x188),function(_0x113c36){const _0x52a007=_0x2d2004;if(_0x5bb795[_0x52a007(0x31a)](_0x5bb795[_0x52a007(0x372)],_0x52a007(0x2ef)))_0x5bb795[_0x52a007(0x1b4)](_0x57d68e[_0x3c5833][_0x52a007(0x165)],_0x5bb795['BFKfx'])&&(_0x56adf0[_0x3733dc][_0x52a007(0x165)]=_0x5bb795['UmoIX'],_0x30cc69[_0x52a007(0x378)]++,_0x150a98[_0x52a007(0x381)]--),_0x238ace();else{const _0x418914=_0x113c36[_0x52a007(0x1ff)][_0x52a007(0x293)](_0x5bb795[_0x52a007(0x235)]);if(_0x418914){const _0x1bca0f=parseInt(_0x418914[_0x52a007(0x17f)](_0x5bb795[_0x52a007(0x2fd)]));_0x5bb795[_0x52a007(0x23b)](selectOption,_0x1bca0f);}}}))),updateBookmarkButton(),_0x5bb795[_0x2d2004(0xfc)](updateMarkReviewButton),(_0x5bb795[_0x2d2004(0x1e7)](currentMode,'timed_study')||currentMode===_0x5bb795[_0x2d2004(0x254)])&&!isQuizCompleted&&(_0x5bb795[_0x2d2004(0x261)](_0x2d2004(0x1c5),_0x5bb795[_0x2d2004(0x2d1)])?startTimer():_0x5eea35[_0x2d2004(0x36c)][_0x2d2004(0x2c8)](_0x5bb795['kJsMX']));}function selectOption(_0x41383f){const _0x1c81a8=_0x31022e,_0x7e4e31={'NnAco':_0x1c81a8(0xd3),'OvJRP':function(_0x1bab22,_0x40e4f9){return _0x1bab22===_0x40e4f9;},'CccGw':_0x1c81a8(0x140),'eAkFA':_0x1c81a8(0x228),'hUIqN':_0x1c81a8(0x144),'kaYrN':function(_0xd3e053,_0x4b0220){return _0xd3e053-_0x4b0220;},'fDLfW':_0x1c81a8(0x333),'DUpae':function(_0x4b42ad,_0x3e3fa6){return _0x4b42ad===_0x3e3fa6;},'hfwFB':function(_0x4a3ec8,_0x501a89){return _0x4a3ec8!==_0x501a89;},'jDpRm':_0x1c81a8(0x180),'sgplg':_0x1c81a8(0x35a),'OhESS':function(_0x4a42e9){return _0x4a42e9();},'WWfZk':function(_0x565629,_0x4e0e21){return _0x565629===_0x4e0e21;},'ntLVs':_0x1c81a8(0x259),'jByfj':_0x1c81a8(0x33a)},_0x401156=document[_0x1c81a8(0x1a5)](_0x7e4e31['hUIqN']);if(_0x401156[_0x1c81a8(0x36c)][_0x1c81a8(0x1fc)]('answered'))return;questionStartTime&&(questionStates[currentQuestionIndex][_0x1c81a8(0x17d)]+=_0x7e4e31[_0x1c81a8(0xdc)](Date[_0x1c81a8(0x175)](),questionStartTime),questionStartTime=Date[_0x1c81a8(0x175)]()),selectedOption=_0x41383f,questionStates[currentQuestionIndex]['selectedAnswer']=_0x41383f,document[_0x1c81a8(0x289)](_0x7e4e31['fDLfW'])[_0x1c81a8(0x171)]((_0x2dd237,_0x585110)=>{const _0x4046f4=_0x1c81a8;_0x2dd237[_0x4046f4(0x36c)][_0x4046f4(0x11a)](_0x7e4e31[_0x4046f4(0x317)],_0x585110===_0x41383f);}),_0x7e4e31[_0x1c81a8(0x2a9)](currentMode,_0x1c81a8(0xf5))||currentMode===_0x1c81a8(0x187)?_0x7e4e31[_0x1c81a8(0x217)](_0x7e4e31['jDpRm'],_0x7e4e31['sgplg'])?_0x7e4e31[_0x1c81a8(0x316)](processAnswer):_0x7e4e31['OvJRP'](_0x149d2e[_0x1c81a8(0x236)][_0x4fb7f6['selectedAnswer']]['id'],_0x3ad085['correct_choice_id'])?(_0x11ed68++,_0x1d441[_0x1c81a8(0x165)]=_0x7e4e31[_0x1c81a8(0x29e)]):(_0x4ff1b0++,_0x52368b[_0x1c81a8(0x165)]=_0x7e4e31[_0x1c81a8(0x12e)]):(_0x7e4e31[_0x1c81a8(0x37c)](questionStates[currentQuestionIndex][_0x1c81a8(0x165)],_0x7e4e31['ntLVs'])&&(questionStates[currentQuestionIndex]['status']=_0x7e4e31[_0x1c81a8(0x16b)],stats[_0x1c81a8(0x378)]++,stats['notAttempted']--),updateQuestionNav()),_0x7e4e31[_0x1c81a8(0x316)](saveProgress);}function processAnswer(){const _0x3074ff=_0x31022e,_0x12717d={'jnjau':function(_0x56e9bb){return _0x56e9bb();},'rjazV':_0x3074ff(0x357),'vWOiO':'none','CsrUp':function(_0x3b507d){return _0x3b507d();},'txKVE':function(_0x263e5e,_0x145d45){return _0x263e5e===_0x145d45;},'PJRSE':'not_attempted','erLHK':function(_0x2ce8c6,_0x53ae20){return _0x2ce8c6!==_0x53ae20;},'CbDRj':_0x3074ff(0x2ed),'hYWWH':'correct','MGqkP':_0x3074ff(0x228),'LRxKF':function(_0x3cabbc,_0x411c86){return _0x3cabbc(_0x411c86);}},_0xb7994f=questionsData[currentQuestionIndex],_0x3a15b4=_0xb7994f[_0x3074ff(0x22c)];if(_0x12717d[_0x3074ff(0x147)](selectedOption,null))return;const _0x5981ed=_0xb7994f[_0x3074ff(0x236)][selectedOption],_0x2848ee=_0x5981ed['id']===_0x3a15b4;if(_0x12717d['txKVE'](questionStates[currentQuestionIndex][_0x3074ff(0x165)],_0x12717d[_0x3074ff(0xc1)])){if(_0x12717d['erLHK'](_0x12717d[_0x3074ff(0xbf)],_0x3074ff(0x2ed)))_0x12717d[_0x3074ff(0x11c)](_0x5cf58f)?(_0x1f0892[_0x3074ff(0x1a5)](_0x12717d[_0x3074ff(0x2bf)])[_0x3074ff(0x275)][_0x3074ff(0x231)]=_0x12717d[_0x3074ff(0x210)],_0x2bf0dc()):(_0x12717d[_0x3074ff(0x1af)](_0x40877a),_0x44d1bc[_0x3074ff(0x1a5)](_0x12717d[_0x3074ff(0x2bf)])['style']['display']=_0x3074ff(0x30c));else{stats[_0x3074ff(0x378)]++,stats[_0x3074ff(0x381)]--;if(_0x2848ee)stats[_0x3074ff(0x376)]++;else stats[_0x3074ff(0x1b1)]++;}}questionStates[currentQuestionIndex][_0x3074ff(0x165)]=_0x2848ee?_0x12717d[_0x3074ff(0x334)]:_0x12717d['MGqkP'],updateStats(),_0x12717d[_0x3074ff(0x1b7)](showInlineFeedback,_0x2848ee),_0x12717d['CsrUp'](updateQuestionNav);}function showInlineFeedback(_0x1d7e99){const _0x88783b=_0x31022e,_0x1da9b2={'hgNZQ':_0x88783b(0xd3),'zuGrT':function(_0x362f88,_0x2836ed){return _0x362f88===_0x2836ed;},'vKLFj':_0x88783b(0x140),'lAzAn':function(_0x81ef50,_0x2a320a){return _0x81ef50===_0x2a320a;},'AwcDV':_0x88783b(0x228),'qboYo':_0x88783b(0xf5),'WORZu':function(_0x5ea301,_0x2a585f){return _0x5ea301!==_0x2a585f;},'yQxTV':_0x88783b(0x333),'wqDnn':_0x88783b(0x33a),'NMEfu':function(_0x54d3f3){return _0x54d3f3();}};if(currentMode!==_0x1da9b2[_0x88783b(0x199)]&&_0x1da9b2[_0x88783b(0x2ff)](currentMode,_0x88783b(0x187)))return;const _0x28f3f2=document[_0x88783b(0x1a5)](_0x88783b(0x144)),_0x4c55fb=_0x28f3f2[_0x88783b(0x289)](_0x1da9b2[_0x88783b(0x310)]),_0x38203f=questionsData[currentQuestionIndex],_0x55e11d=_0x38203f[_0x88783b(0x22c)];let _0x32a50d=_0x38203f[_0x88783b(0x236)][_0x88783b(0x2fb)](_0x38f0d4=>_0x38f0d4['id']===_0x55e11d);_0x28f3f2['classList'][_0x88783b(0x2c8)](_0x1da9b2['wqDnn']),_0x4c55fb[_0x88783b(0x171)]((_0xba9dc2,_0x5c40f0)=>{const _0x241dc1=_0x88783b;_0xba9dc2['classList'][_0x241dc1(0x164)](_0x1da9b2[_0x241dc1(0x104)]);if(_0x1da9b2[_0x241dc1(0x1d9)](_0x5c40f0,_0x32a50d))_0xba9dc2[_0x241dc1(0x36c)][_0x241dc1(0x2c8)](_0x1da9b2[_0x241dc1(0x121)]);else{if(_0x1da9b2[_0x241dc1(0x251)](_0x5c40f0,selectedOption)&&!_0x1d7e99)_0xba9dc2[_0x241dc1(0x36c)][_0x241dc1(0x2c8)](_0x1da9b2[_0x241dc1(0x1b3)]);}}),_0x1da9b2[_0x88783b(0x281)](showSolution);}function showSolution(){const _0x118054=_0x31022e,_0x5121e2={'iwljM':function(_0x424d97){return _0x424d97();},'lzAvY':_0x118054(0x143),'cUqqX':function(_0x2f589f,_0xb3d832,_0x131a07){return _0x2f589f(_0xb3d832,_0x131a07);},'hjrYJ':_0x118054(0x333),'VxUUw':function(_0x5d611d,_0x5b758d){return _0x5d611d(_0x5b758d);},'wTTtH':_0x118054(0x365),'VEByd':function(_0x1a0389,_0xcec299){return _0x1a0389!==_0xcec299;},'SKxRf':'study','qhMXz':_0x118054(0x37b),'BQbVd':_0x118054(0x358),'uLcHG':'solutionVideo','ffpza':function(_0x59d406,_0x587557,_0x5e7b37){return _0x59d406(_0x587557,_0x5e7b37);},'yPVrm':function(_0x4eaae0,_0x522ec0){return _0x4eaae0===_0x522ec0;},'oBPbU':_0x118054(0x276),'PForp':_0x118054(0x337),'kqPqa':function(_0xb6fe71,_0x238f8f){return _0xb6fe71!==_0x238f8f;},'IxNpw':_0x118054(0x249),'TtIxr':_0x118054(0x383),'cVvCb':_0x118054(0x34d),'THgxP':'hidden'};if(_0x5121e2[_0x118054(0xfe)](currentMode,_0x5121e2[_0x118054(0xdb)])&&currentMode!==_0x118054(0x187))return;const _0x512644=questionsData[currentQuestionIndex];document[_0x118054(0x1a5)](_0x5121e2[_0x118054(0x207)])['innerHTML']=_0x512644[_0x118054(0x25e)]||_0x5121e2[_0x118054(0x1c2)];const _0x44f8d8=document['getElementById'](_0x5121e2[_0x118054(0x1d4)]),_0x593e8e=document[_0x118054(0x1a5)](_0x118054(0x1f9)),_0x19c2c6=_0x512644['explanation_video'];if(_0x19c2c6){_0x44f8d8['classList'][_0x118054(0x164)](_0x118054(0x169));if(_0x19c2c6[_0x118054(0x1fa)](_0x5121e2[_0x118054(0x2dc)]))_0x5121e2[_0x118054(0x27e)](setupVideo,_0x593e8e,_0x19c2c6);else _0x593e8e[_0x118054(0x1ef)]=_0x19c2c6;}else _0x5121e2['yPVrm'](_0x5121e2[_0x118054(0x31c)],_0x5121e2[_0x118054(0x31c)])?_0x44f8d8[_0x118054(0x36c)]['add'](_0x118054(0x169)):_0x5121e2[_0x118054(0x36a)](_0x187300);const _0x86e963=document[_0x118054(0x1a5)](_0x5121e2[_0x118054(0x329)]);_0x86e963[_0x118054(0xcd)]='';_0x512644[_0x118054(0x1a9)]&&(_0x86e963['innerHTML']+='<div\x20class=\x22mt-2\x22><p\x20class=\x22text-sm\x20text-white\x20text-opacity-70\x20mb-1\x22>English\x20Explanation:</p><audio\x20src=\x22'+_0x512644[_0x118054(0x1a9)]+_0x118054(0xf2));if(_0x512644[_0x118054(0x36f)]){if(_0x5121e2[_0x118054(0x145)](_0x5121e2[_0x118054(0x250)],'awQpT'))_0x86e963[_0x118054(0xcd)]+=_0x118054(0x2a2)+_0x512644[_0x118054(0x36f)]+_0x118054(0xf2);else{_0xc73f1[_0x118054(0x36c)][_0x118054(0x164)]('hidden');if(_0x8ab928[_0x118054(0x1fa)](_0x5121e2[_0x118054(0x2dc)]))_0x5121e2[_0x118054(0x253)](_0x3fd826,_0xa1a459,_0x5e67e2);else _0x1e305d[_0x118054(0x1ef)]=_0x2e69ea;}}const _0x1fa321=document[_0x118054(0x1a5)](_0x5121e2[_0x118054(0xe1)]);_0x1fa321[_0x118054(0xcd)]='';if(_0x512644['explanation_images']){if(_0x5121e2[_0x118054(0x181)]!==_0x5121e2[_0x118054(0x181)]){const _0xbe1599=_0x20d2e7[_0x118054(0x1ff)][_0x118054(0x293)](_0x5121e2[_0x118054(0x2c4)]);if(_0xbe1599){const _0x255662=_0x5121e2[_0x118054(0x168)](_0x3cca15,_0xbe1599['getAttribute'](_0x5121e2[_0x118054(0x1d5)]));_0x5121e2[_0x118054(0x168)](_0x55ce48,_0x255662);}}else _0x512644[_0x118054(0x350)][_0x118054(0x171)](_0x2f9b42=>{const _0x35eef8=_0x118054;if(_0x2f9b42)_0x1fa321['innerHTML']+='<div\x20class=\x22mt-4\x22><img\x20src=\x22'+_0x2f9b42+_0x35eef8(0x366);});}document[_0x118054(0x1a5)](_0x118054(0x16d))[_0x118054(0x36c)]['remove'](_0x5121e2[_0x118054(0x157)]);}function submitQuiz(){const _0xd11805=_0x31022e,_0x459a4f={'pAugh':_0xd11805(0x1b9),'WhORF':function(_0x41a258,_0x134fc1){return _0x41a258!==_0x134fc1;},'uJNTw':function(_0x4ef003,_0x8ee52d){return _0x4ef003===_0x8ee52d;},'QdUYj':_0xd11805(0xc3),'VhonY':'correct','uIVpP':'incorrect','WOoTL':function(_0x1d0810,_0x2d874b){return _0x1d0810(_0x2d874b);},'yvTUh':_0xd11805(0x37f),'figZC':function(_0x3c0c00,_0x21b6bc){return _0x3c0c00-_0x21b6bc;},'YKOFg':function(_0x1d6997,_0x184a9f){return _0x1d6997+_0x184a9f;},'RkYjl':_0xd11805(0x201),'zuMRL':function(_0x38ee57,_0x4072d6,_0x454ac7,_0x57a561,_0x5cae59){return _0x38ee57(_0x4072d6,_0x454ac7,_0x57a561,_0x5cae59);},'myusM':function(_0x3b925e,_0x32c831){return _0x3b925e-_0x32c831;}};if(timer)clearInterval(timer);if(!_0x459a4f[_0xd11805(0x2d6)](confirm,_0x459a4f['yvTUh']))return;isQuizCompleted=!![];let _0x25da03=0x0,_0x15bec6=0x0;const _0x1280f4=_0x459a4f[_0xd11805(0x315)](Date['now'](),quizStartTime);questionsData[_0xd11805(0x171)]((_0x35f4bb,_0x1127bb)=>{const _0x5213a6=_0xd11805,_0x5ba3a5={'MpQnE':_0x5213a6(0x1e6),'EzEuC':_0x459a4f['pAugh']},_0xb054a=questionStates[_0x1127bb];if(_0x459a4f['WhORF'](_0xb054a[_0x5213a6(0x331)],null)){if(_0x459a4f[_0x5213a6(0x2e5)](_0x35f4bb[_0x5213a6(0x236)][_0xb054a[_0x5213a6(0x331)]]['id'],_0x35f4bb[_0x5213a6(0x22c)])){if(_0x459a4f[_0x5213a6(0x153)](_0x459a4f['QdUYj'],_0x459a4f[_0x5213a6(0x292)])){const _0x5e8ac4=_0x548fb4[_0x5213a6(0x361)](_0x12e138['getItem'](_0x5213a6(0x1e6)))||{};_0x5e8ac4[_0x3349cf]&&(delete _0x5e8ac4[_0x555d24],_0x4d0210[_0x5213a6(0x31f)](_0x5ba3a5[_0x5213a6(0x23e)],_0x3af564[_0x5213a6(0x380)](_0x5e8ac4)),_0x157df4['log'](_0x5ba3a5[_0x5213a6(0x12f)]));}else _0x25da03++,_0xb054a[_0x5213a6(0x165)]=_0x459a4f['VhonY'];}else _0x15bec6++,_0xb054a['status']=_0x459a4f[_0x5213a6(0x266)];}});const _0x36d90c=JSON[_0xd11805(0x361)](localStorage[_0xd11805(0xf7)](_0xd11805(0x201)))||[];_0x36d90c[_0xd11805(0x2d8)]({'quizName':quizName,'hierarchy':hierarchy,'timestamp':Date[_0xd11805(0x175)](),'totalTime':_0x1280f4,'stats':{'correct':_0x25da03,'incorrect':_0x15bec6,'notAttempted':_0x459a4f[_0xd11805(0x315)](questionsData[_0xd11805(0xce)],_0x459a4f[_0xd11805(0x1e3)](_0x25da03,_0x15bec6))}}),localStorage[_0xd11805(0x31f)](_0x459a4f[_0xd11805(0xc8)],JSON[_0xd11805(0x380)](_0x36d90c)),stats[_0xd11805(0x376)]=_0x25da03,stats['incorrectAnswers']=_0x15bec6,markQuizAsCompleted(),_0x459a4f[_0xd11805(0x2c5)](showPerformanceAnalysis,_0x25da03,_0x15bec6,_0x459a4f['myusM'](questionsData[_0xd11805(0xce)],_0x25da03+_0x15bec6),_0x1280f4);}function showPerformanceAnalysis(_0x5e00e3,_0x1a28f0,_0x352395,_0x5a1e46){const _0x874c6a=_0x31022e,_0x1fd7fd={'XNoCw':'performanceModal','IAMSz':function(_0x4b5f6e,_0x3b6194){return _0x4b5f6e>_0x3b6194;},'zSXoe':function(_0x3bd2b7,_0x36b4fd){return _0x3bd2b7+_0x36b4fd;},'heSzR':function(_0x452292,_0x402b0a){return _0x452292*_0x402b0a;},'LuAGn':function(_0x4c6fb6,_0x3370e0){return _0x4c6fb6-_0x3370e0;},'unzbI':function(_0x1373fc,_0x36ebca){return _0x1373fc/_0x36ebca;},'LexmI':_0x874c6a(0x2b2),'JICzS':'totalQuestionsResult','VKIIb':_0x874c6a(0x311),'HhhhI':_0x874c6a(0x335),'pOdoW':function(_0x1c8bfb,_0x636723){return _0x1c8bfb%_0x636723;},'frZvk':_0x874c6a(0x223),'ihBuk':function(_0x199428,_0x479ef1){return _0x199428/_0x479ef1;},'QZolK':function(_0x22cd02,_0x42e30a){return _0x22cd02/_0x42e30a;},'rairm':function(_0x3f95e9,_0x15fb80){return _0x3f95e9/_0x15fb80;},'slLbS':_0x874c6a(0x170),'CvNXs':_0x874c6a(0x169)},_0x1e8f62=document[_0x874c6a(0x1a5)](_0x1fd7fd[_0x874c6a(0x15c)]),_0x4e2828=_0x1fd7fd[_0x874c6a(0x2f4)](_0x1fd7fd[_0x874c6a(0x1f4)](_0x5e00e3,_0x1a28f0),0x0)?Math['round'](_0x5e00e3/(_0x5e00e3+_0x1a28f0)*0x64):0x0,_0x205c21=_0x1fd7fd[_0x874c6a(0x1cd)](_0x1fd7fd[_0x874c6a(0x1cd)](0x2,Math['PI']),0x41),_0x388ec2=document['getElementById'](_0x874c6a(0x2a5));_0x388ec2['style'][_0x874c6a(0x244)]=_0x205c21+'\x20'+_0x205c21,_0x388ec2[_0x874c6a(0x275)][_0x874c6a(0x312)]=_0x1fd7fd[_0x874c6a(0x15e)](_0x205c21,_0x1fd7fd[_0x874c6a(0x1cd)](_0x1fd7fd[_0x874c6a(0x209)](_0x4e2828,0x64),_0x205c21)),document['getElementById'](_0x1fd7fd[_0x874c6a(0x1fe)])['textContent']=_0x4e2828+'%',document[_0x874c6a(0x1a5)](_0x1fd7fd['JICzS'])[_0x874c6a(0x2d7)]=questionsData[_0x874c6a(0xce)],document[_0x874c6a(0x1a5)](_0x1fd7fd['VKIIb'])[_0x874c6a(0x2d7)]=_0x5e00e3,document[_0x874c6a(0x1a5)](_0x874c6a(0x19b))[_0x874c6a(0x2d7)]=_0x1a28f0,document[_0x874c6a(0x1a5)](_0x1fd7fd[_0x874c6a(0x34b)])['textContent']=_0x352395;const _0x3a36e0=Math[_0x874c6a(0x2c0)](_0x5a1e46/0xea60),_0x564832=Math[_0x874c6a(0x2c0)](_0x1fd7fd['unzbI'](_0x1fd7fd['pOdoW'](_0x5a1e46,0xea60),0x3e8));document['getElementById'](_0x1fd7fd[_0x874c6a(0x19f)])['textContent']=_0x3a36e0+':'+_0x564832[_0x874c6a(0x2a4)]()[_0x874c6a(0x1df)](0x2,'0');const _0xf59241=_0x1fd7fd[_0x874c6a(0x385)](_0x5a1e46,questionsData[_0x874c6a(0xce)]),_0x1d6251=Math['floor'](_0x1fd7fd[_0x874c6a(0x34e)](_0xf59241,0xea60)),_0x2f7210=Math[_0x874c6a(0x2c0)](_0x1fd7fd[_0x874c6a(0x192)](_0xf59241%0xea60,0x3e8));document[_0x874c6a(0x1a5)](_0x1fd7fd['slLbS'])[_0x874c6a(0x2d7)]=_0x1d6251+':'+_0x2f7210[_0x874c6a(0x2a4)]()[_0x874c6a(0x1df)](0x2,'0'),_0x1e8f62[_0x874c6a(0x36c)][_0x874c6a(0x164)](_0x1fd7fd[_0x874c6a(0x36e)]);}function closePerformanceModal(){const _0x2d66fd=_0x31022e,_0x33c865={'jTZbq':_0x2d66fd(0x318),'VAshv':_0x2d66fd(0x169)};document[_0x2d66fd(0x1a5)](_0x33c865['jTZbq'])['classList']['add'](_0x33c865['VAshv']);}function reviewQuestions(){const _0x3c3c26=_0x31022e,_0x421977={'RBZPB':function(_0x2dfb57,_0x5e2a11){return _0x2dfb57===_0x5e2a11;},'ralRQ':'border-green-500','XtBUc':function(_0x3f33c7,_0x2faac3){return _0x3f33c7+_0x2faac3;},'WzOVw':'not-attempted','UpJod':_0x3c3c26(0x25c),'UXYst':function(_0x40aabc,_0xb655fa){return _0x40aabc!==_0xb655fa;},'asMey':_0x3c3c26(0x140),'MAyWa':_0x3c3c26(0x1ae),'MnUtE':_0x3c3c26(0x26a),'zhNXs':_0x3c3c26(0x27b),'NwYrv':_0x3c3c26(0x1b2),'SKzAW':'red','VMrDh':_0x3c3c26(0x20d),'oysXY':'No\x20solution\x20available.','ZhFeb':'hidden','NnVjp':_0x3c3c26(0x1b0),'GRdHz':function(_0x1c25e4){return _0x1c25e4();}};document['getElementById']('questionReviewSection')[_0x3c3c26(0x36c)]['remove'](_0x421977['ZhFeb']);const _0xa80c74=document['getElementById'](_0x421977[_0x3c3c26(0x2b1)]);_0xa80c74['innerHTML']='',questionsData['forEach']((_0x2df199,_0x5b186f)=>{const _0x1bf6e4=_0x3c3c26,_0x2f5966={'Epibw':function(_0x5af3d7,_0x5bb52d){const _0x1ea10b=_0x13fe;return _0x421977[_0x1ea10b(0x2f5)](_0x5af3d7,_0x5bb52d);},'HWxTy':function(_0x20c38c,_0x58f645){return _0x20c38c===_0x58f645;},'rSHST':_0x1bf6e4(0x2df),'ztwVq':_0x421977[_0x1bf6e4(0x1d6)],'lcQIP':function(_0x134cca,_0x541fc1){const _0x4e8360=_0x1bf6e4;return _0x421977[_0x4e8360(0x384)](_0x134cca,_0x541fc1);}},_0x369cc9=questionStates[_0x5b186f],_0x452a8f=_0x2df199[_0x1bf6e4(0x22c)];let _0x27d409=_0x421977[_0x1bf6e4(0x137)],_0x2192e6=_0x421977['UpJod'];if(_0x369cc9[_0x1bf6e4(0x331)]!==null){if(_0x421977['UXYst']('QQCkX',_0x1bf6e4(0x30d))){const _0x5af1b3=_0x2df199[_0x1bf6e4(0x236)][_0x369cc9[_0x1bf6e4(0x331)]];_0x421977[_0x1bf6e4(0x2f5)](_0x5af1b3['id'],_0x452a8f)?(_0x27d409=_0x421977[_0x1bf6e4(0x151)],_0x2192e6=_0x421977[_0x1bf6e4(0x2c3)]):(_0x27d409=_0x1bf6e4(0x228),_0x2192e6=_0x421977['MnUtE']);}else{const _0x119ae8=_0x511ffd?function(){if(_0x201bca){const _0xfc765f=_0x51f794['apply'](_0x464431,arguments);return _0x6ae9af=null,_0xfc765f;}}:function(){};return _0x2f4bd4=![],_0x119ae8;}}const _0x35ec43=document['createElement'](_0x421977[_0x1bf6e4(0x280)]);_0x35ec43['className']=_0x1bf6e4(0x2a1)+_0x27d409;let _0x3f9765=(_0x2df199['choices']||[])[_0x1bf6e4(0x2db)]((_0x3ff08a,_0x54265d)=>{const _0x243cd5=_0x1bf6e4,_0xd750f9=_0x2f5966[_0x243cd5(0x344)](_0x369cc9[_0x243cd5(0x331)],_0x54265d),_0x103bab=_0x2f5966[_0x243cd5(0x146)](_0x3ff08a['id'],_0x452a8f);let _0xa2d4f0=_0x2f5966[_0x243cd5(0x348)];if(_0x103bab)_0xa2d4f0=_0x2f5966['ztwVq'];else{if(_0xd750f9)_0xa2d4f0=_0x243cd5(0x100);}return _0x243cd5(0x21c)+_0xa2d4f0+'\x22><span\x20class=\x22font-bold\x20mr-3\x22>'+String[_0x243cd5(0x355)](_0x2f5966[_0x243cd5(0x2c1)](0x41,_0x54265d))+_0x243cd5(0x300)+_0x3ff08a['text']+'</span></div>';})[_0x1bf6e4(0x1d2)]('');const _0x24340b=_0x2df199[_0x1bf6e4(0x11e)]?'<div\x20class=\x22mt-4\x22><video\x20id=\x22review-video-'+_0x5b186f+_0x1bf6e4(0x24a)+_0x2df199['explanation_video']+_0x1bf6e4(0x205):'';let _0xddf454='';if(_0x2df199[_0x1bf6e4(0x1a9)])_0xddf454+='<div\x20class=\x22mt-2\x22><p\x20class=\x22text-sm\x20text-white\x20text-opacity-70\x20mb-1\x22>English:</p><audio\x20src=\x22'+_0x2df199[_0x1bf6e4(0x1a9)]+_0x1bf6e4(0xf2);if(_0x2df199[_0x1bf6e4(0x36f)])_0xddf454+=_0x1bf6e4(0xf9)+_0x2df199['explanation_audio_hin']+_0x1bf6e4(0xf2);let _0x50194f=(_0x2df199[_0x1bf6e4(0x350)]||[])[_0x1bf6e4(0x2db)](_0x3329d1=>_0x3329d1?'<div\x20class=\x22mt-4\x22><img\x20src=\x22'+_0x3329d1+_0x1bf6e4(0x366):'')[_0x1bf6e4(0x1d2)]('');_0x35ec43['innerHTML']='\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<div\x20class=\x22mb-4\x22>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<div\x20class=\x22flex\x20justify-between\x20items-center\x20mb-3\x22>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<h4\x20class=\x22text-lg\x20font-bold\x20text-white\x22>Question\x20'+_0x421977[_0x1bf6e4(0x384)](_0x5b186f,0x1)+_0x1bf6e4(0x274)+(_0x27d409===_0x1bf6e4(0x140)?_0x421977[_0x1bf6e4(0x20f)]:_0x421977['RBZPB'](_0x27d409,_0x1bf6e4(0x228))?_0x421977[_0x1bf6e4(0x363)]:_0x421977[_0x1bf6e4(0x198)])+_0x1bf6e4(0x28c)+_0x2192e6+_0x1bf6e4(0x20b)+_0x2df199[_0x1bf6e4(0x113)]+_0x1bf6e4(0x2b5)+_0x3f9765+_0x1bf6e4(0x2d4)+(_0x2df199[_0x1bf6e4(0x25e)]||_0x421977[_0x1bf6e4(0x24b)])+_0x1bf6e4(0x108)+_0x24340b+_0x1bf6e4(0x240)+_0xddf454+_0x1bf6e4(0x240)+_0x50194f+_0x1bf6e4(0x23c),_0xa80c74[_0x1bf6e4(0x2c2)](_0x35ec43);}),_0x421977[_0x3c3c26(0x35d)](initializeReviewVideos);}function initializeReviewVideos(){const _0x332eaa=_0x31022e,_0x399852={'FcfdH':function(_0x1345df){return _0x1345df();},'kxSWo':_0x332eaa(0x143),'vMOic':function(_0x455540,_0x56ddb8){return _0x455540!==_0x56ddb8;},'HhBkJ':_0x332eaa(0x233),'Kpfhu':function(_0x4c8aa3,_0x35e0ba,_0x442b53){return _0x4c8aa3(_0x35e0ba,_0x442b53);},'DFIxu':_0x332eaa(0x373)};document['querySelectorAll'](_0x399852['DFIxu'])[_0x332eaa(0x171)](_0x44d528=>{const _0x2855d4=_0x332eaa,_0x6daca2={'HgoPz':function(_0x4f7d67){const _0x34d8a3=_0x13fe;return _0x399852[_0x34d8a3(0x114)](_0x4f7d67);}},_0x425dbd=_0x44d528[_0x2855d4(0x2ab)][_0x2855d4(0x1ef)];if(_0x425dbd&&_0x425dbd[_0x2855d4(0x1fa)](_0x399852[_0x2855d4(0x1cf)]))_0x399852['vMOic'](_0x399852['HhBkJ'],_0x399852[_0x2855d4(0xe5)])?(_0x194c4a++,_0x6daca2[_0x2855d4(0x110)](_0x55a62f),_0x1ee2f2()):_0x399852['Kpfhu'](setupVideo,_0x44d528,_0x425dbd);else _0x425dbd&&(_0x44d528[_0x2855d4(0x1ef)]=_0x425dbd);});}function retakeQuiz(){const _0x349e2d=_0x31022e,_0x1d7645={'gFQPP':function(_0xa93730,_0x34c60c){return _0xa93730(_0x34c60c);},'kZWPa':'Are\x20you\x20sure\x20you\x20want\x20to\x20retake\x20the\x20quiz?\x20This\x20will\x20reset\x20all\x20your\x20answers.','AZUUY':_0x349e2d(0x1f8)};_0x1d7645[_0x349e2d(0xde)](confirm,_0x1d7645[_0x349e2d(0x1d7)])&&(window[_0x349e2d(0x222)][_0x349e2d(0x336)][_0x349e2d(0x14b)]('custom_quiz.html')&&localStorage[_0x349e2d(0x11f)](_0x1d7645['AZUUY']),clearProgress(),location[_0x349e2d(0x1c8)]());}function loadBookmarkedQuestions(){const _0x429b19=_0x31022e,_0x52d953={'nVcyD':function(_0xfb166b){return _0xfb166b();},'BjqFn':function(_0xe68495,_0x5313a8){return _0xe68495===_0x5313a8;},'tagnL':_0x429b19(0x1ad),'astin':function(_0x24648f,_0x1e7ac9){return _0x24648f<_0x1e7ac9;},'uuDuc':_0x429b19(0x2a0)},_0x12cc75=JSON['parse'](localStorage[_0x429b19(0xf7)](_0x52d953[_0x429b19(0x27c)]))||[];_0x12cc75['forEach'](_0x44989e=>{const _0xfa31e0=_0x429b19,_0x2f78f0={'GVjkH':function(_0x28e601){const _0x4e80ae=_0x13fe;return _0x52d953[_0x4e80ae(0x2ea)](_0x28e601);},'mTCEw':_0xfa31e0(0x357),'FhqaZ':_0xfa31e0(0x30c)};_0x52d953['BjqFn']('dgthD',_0x52d953['tagnL'])?_0x44989e['quizFile']['includes'](quizName[_0xfa31e0(0x1ec)]()[_0xfa31e0(0x32d)](/ /g,'-'))&&(_0x52d953['astin'](_0x44989e[_0xfa31e0(0x148)],questionsData['length'])&&(questionStates[_0x44989e[_0xfa31e0(0x148)]]['bookmarked']=!![])):(_0x2f78f0['GVjkH'](_0x333710),_0xc84c2e[_0xfa31e0(0x1a5)](_0x2f78f0[_0xfa31e0(0x149)])[_0xfa31e0(0x275)][_0xfa31e0(0x231)]=_0x2f78f0[_0xfa31e0(0x364)]);});}function toggleBookmark(){const _0x31e590=_0x31022e,_0x4eb5b6={'wIHvk':_0x31e590(0x132),'LPeFN':_0x31e590(0x169),'MYHSf':function(_0x2dc715,_0xe577b6){return _0x2dc715===_0xe577b6;},'lNfbd':_0x31e590(0x25d),'bQsqd':_0x31e590(0x228),'cOYsN':_0x31e590(0x267),'ekfiL':_0x31e590(0x2a0),'AcuwZ':function(_0x4bdbb9,_0x3a5c24){return _0x4bdbb9!==_0x3a5c24;},'XkLJU':_0x31e590(0xe7),'IbgKJ':_0x31e590(0xd5),'qHCui':function(_0x3e3d04){return _0x3e3d04();}},_0x4860da=!questionStates[currentQuestionIndex][_0x31e590(0x204)];questionStates[currentQuestionIndex]['bookmarked']=_0x4860da;let _0x5d97fd=JSON[_0x31e590(0x361)](localStorage[_0x31e590(0xf7)](_0x4eb5b6[_0x31e590(0x314)]))||[];if(_0x4860da){if(_0x4eb5b6['AcuwZ'](_0x4eb5b6['XkLJU'],_0x4eb5b6[_0x31e590(0x1e0)]))_0x382a6d['getElementById'](_0x4eb5b6[_0x31e590(0x304)])[_0x31e590(0x36c)]['remove'](_0x4eb5b6[_0x31e590(0x135)]);else{const _0x322d57={'quizName':quizName,'quizFile':window[_0x31e590(0x222)]['pathname'][_0x31e590(0xda)]('/')[_0x31e590(0x307)](),'questionIndex':currentQuestionIndex,'question':questionsData[currentQuestionIndex],'hierarchy':hierarchy,'timestamp':Date[_0x31e590(0x175)]()};_0x5d97fd[_0x31e590(0x2d8)](_0x322d57);}}else{if('wOTKD'!==_0x4eb5b6[_0x31e590(0x27a)]){if(_0x4eb5b6[_0x31e590(0x1ea)](_0x517605[_0x31e590(0x165)],_0x31e590(0x140)))_0x3adb04=_0x4eb5b6['lNfbd'];else{if(_0x4eb5b6[_0x31e590(0x1ea)](_0x77a1a2[_0x31e590(0x165)],_0x4eb5b6[_0x31e590(0x1a4)]))_0x10c332=_0x4eb5b6[_0x31e590(0x10a)];else _0x136bc1='nav-btn-not-attempted\x20hover:bg-white\x20hover:bg-opacity-20';}}else _0x5d97fd=_0x5d97fd[_0x31e590(0x37e)](_0x1dd676=>!(_0x1dd676[_0x31e590(0xc9)][_0x31e590(0x1fa)](quizName[_0x31e590(0x1ec)]()[_0x31e590(0x32d)](/ /g,'-'))&&_0x1dd676[_0x31e590(0x148)]===currentQuestionIndex));}localStorage[_0x31e590(0x31f)](_0x4eb5b6[_0x31e590(0x314)],JSON[_0x31e590(0x380)](_0x5d97fd)),_0x4eb5b6[_0x31e590(0x214)](updateBookmarkButton),updateQuestionNav();}function updateBookmarkButton(){const _0x4d632f=_0x31022e,_0x501d94={'lQyVp':_0x4d632f(0x346),'irEhC':_0x4d632f(0x377),'aMKKK':_0x4d632f(0x15b),'TKkFS':'Bookmark'},_0x72794c=document['getElementById'](_0x501d94[_0x4d632f(0xef)]),_0x55bd88=document['getElementById'](_0x4d632f(0x1ac)),_0x15307a=questionStates[currentQuestionIndex]['bookmarked'];_0x72794c[_0x4d632f(0x28d)]=_0x15307a?_0x501d94[_0x4d632f(0x117)]:_0x501d94[_0x4d632f(0x271)],_0x55bd88[_0x4d632f(0x2d7)]=_0x15307a?_0x4d632f(0x102):_0x501d94[_0x4d632f(0x2ad)];}function toggleMarkForReview(){const _0x452ca3=_0x31022e,_0x3cd9c7={'EiLRp':function(_0x289341){return _0x289341();}};questionStates[currentQuestionIndex][_0x452ca3(0x119)]=!questionStates[currentQuestionIndex]['markedForReview'],_0x3cd9c7['EiLRp'](updateMarkReviewButton),updateQuestionNav();}function updateMarkReviewButton(){const _0xe793ff=_0x31022e,_0x212fde={'BFLOM':'markReviewBtn','ugfte':_0xe793ff(0xcb),'DmRWD':_0xe793ff(0x1fd),'JyrTU':_0xe793ff(0x230)},_0x1779bc=document[_0xe793ff(0x1a5)](_0x212fde[_0xe793ff(0x1c6)]),_0x4c53e1=document[_0xe793ff(0x1a5)](_0xe793ff(0x322)),_0x5026d2=questionStates[currentQuestionIndex][_0xe793ff(0x119)];_0x1779bc[_0xe793ff(0x28d)]=_0x5026d2?_0x212fde[_0xe793ff(0x167)]:_0xe793ff(0x1c9),_0x4c53e1['textContent']=_0x5026d2?_0x212fde[_0xe793ff(0x178)]:_0x212fde['JyrTU'];}function previousQuestion(){const _0x20caa8=_0x31022e,_0xfd0e01={'EROft':_0x20caa8(0x2f3),'EGtCl':'No\x20questions\x20available\x20for\x20this\x20quiz.','iwwfo':_0x20caa8(0x340),'nfChC':_0x20caa8(0xd0),'MhqRf':function(_0x2b50a9,_0x40ade7){return _0x2b50a9-_0x40ade7;},'XslvH':function(_0x38c59b){return _0x38c59b();}};if(currentQuestionIndex>0x0){if(_0xfd0e01[_0x20caa8(0x269)]!==_0xfd0e01[_0x20caa8(0x367)])questionStartTime&&(questionStates[currentQuestionIndex][_0x20caa8(0x17d)]+=_0xfd0e01[_0x20caa8(0x200)](Date['now'](),questionStartTime)),currentQuestionIndex--,_0xfd0e01['XslvH'](displayQuestion),saveProgress();else{_0xd97c42[_0x20caa8(0x1a5)](_0xfd0e01[_0x20caa8(0x313)])[_0x20caa8(0xcd)]=_0xfd0e01[_0x20caa8(0x31d)];return;}}}function nextQuestion(){const _0x34f4d2=_0x31022e,_0xe10ee6={'GgFsi':'incomplete','ECZMr':_0x34f4d2(0x1e6),'PGpOK':function(_0x83b132,_0x4db6a4){return _0x83b132<_0x4db6a4;},'jsTjz':function(_0x48e251,_0x43b0d9){return _0x48e251-_0x43b0d9;},'muYwF':function(_0x5b638b){return _0x5b638b();},'bWzqw':function(_0x270d94){return _0x270d94();},'CKAPx':function(_0x84d7ea,_0x430ebe){return _0x84d7ea===_0x430ebe;},'UajFy':'UMWpf','ZaPUF':_0x34f4d2(0x309),'QRLye':function(_0x23a1f1,_0x4f03ef){return _0x23a1f1===_0x4f03ef;},'nKfhl':'timed_exam','ewizP':function(_0x5dfcf0,_0x28ef43){return _0x5dfcf0!==_0x28ef43;},'GfRPR':_0x34f4d2(0x2b9),'FnEJs':function(_0x29552f,_0x2950b6){return _0x29552f(_0x2950b6);},'ebHMl':_0x34f4d2(0x1f3),'hVEKg':_0x34f4d2(0x33e),'IwAEP':function(_0x16f301){return _0x16f301();}};questionStartTime&&(questionStates[currentQuestionIndex][_0x34f4d2(0x17d)]+=Date[_0x34f4d2(0x175)]()-questionStartTime);if(_0xe10ee6[_0x34f4d2(0x22d)](currentQuestionIndex,_0xe10ee6['jsTjz'](questionsData[_0x34f4d2(0xce)],0x1)))currentQuestionIndex++,_0xe10ee6[_0x34f4d2(0x29f)](displayQuestion),_0xe10ee6[_0x34f4d2(0x2d0)](saveProgress);else{if(_0xe10ee6[_0x34f4d2(0x37d)](_0xe10ee6[_0x34f4d2(0x326)],'UMWpf')){if(_0xe10ee6[_0x34f4d2(0x37d)](currentMode,_0xe10ee6['ZaPUF'])||_0xe10ee6['QRLye'](currentMode,_0xe10ee6['nKfhl'])){if(_0xe10ee6['ewizP'](_0xe10ee6[_0x34f4d2(0x190)],_0xe10ee6[_0x34f4d2(0x190)])){const _0x54e056=_0x2ec2eb?function(){if(_0x17e428){const _0x13ade9=_0x50475a['apply'](_0x5aa972,arguments);return _0x422f5e=null,_0x13ade9;}}:function(){};return _0xc9e74c=![],_0x54e056;}else _0xe10ee6['FnEJs'](confirm,_0xe10ee6[_0x34f4d2(0xc0)])&&submitQuiz();}else confirm(_0xe10ee6[_0x34f4d2(0x319)])&&(currentQuestionIndex=0x0,_0xe10ee6['bWzqw'](displayQuestion),_0xe10ee6[_0x34f4d2(0x320)](saveProgress));}else{if(_0xc05e5c)return;const _0x488bff=_0x273fe1[_0x34f4d2(0x361)](_0xdc6d20[_0x34f4d2(0xf7)](_0x34f4d2(0x1e6)))||{};_0x488bff[_0x3620c8]={'questionStates':_0x3b1294,'stats':_0x7aa71f,'currentQuestionIndex':_0x2e1511,'currentMode':_0x293bd3,'status':_0xe10ee6[_0x34f4d2(0x2cf)],'lastSeen':new _0x433ccc()[_0x34f4d2(0xe4)]()},_0x271dec[_0x34f4d2(0x31f)](_0xe10ee6[_0x34f4d2(0x2ca)],_0x3c2758[_0x34f4d2(0x380)](_0x488bff));}}}function startTimer(){const _0x3a8cf0=_0x31022e,_0x47ab5a={'kkRZI':_0x3a8cf0(0xe3),'JkoKv':function(_0x3ddf74,_0x2b4ee6){return _0x3ddf74+_0x2b4ee6;},'HHdaN':_0x3a8cf0(0x134),'JYeKB':function(_0x5d8633){return _0x5d8633();},'HCbsx':function(_0x28fc90,_0x46cd38){return _0x28fc90<=_0x46cd38;},'mqxGY':function(_0x3eb7f7,_0x136dcc){return _0x3eb7f7(_0x136dcc);},'QmPrI':function(_0x19dfa9,_0x1fc83e){return _0x19dfa9===_0x1fc83e;},'kHhLJ':function(_0x261211,_0x56e15e){return _0x261211!==_0x56e15e;},'iUBZb':function(_0x1ca7d7){return _0x1ca7d7();},'xuVqn':function(_0x27d228){return _0x27d228();},'vrTaA':function(_0x41925e,_0x24c404,_0x4c3119){return _0x41925e(_0x24c404,_0x4c3119);}};if(timer)clearInterval(timer);timeRemaining=0x78,_0x47ab5a['xuVqn'](updateTimerDisplay),timer=_0x47ab5a[_0x3a8cf0(0x18c)](setInterval,()=>{const _0x555dac=_0x3a8cf0;timeRemaining--,_0x47ab5a['JYeKB'](updateTimerDisplay);if(_0x47ab5a['HCbsx'](timeRemaining,0x0)){_0x47ab5a[_0x555dac(0x1d0)](clearInterval,timer);if(_0x47ab5a['QmPrI'](currentMode,_0x555dac(0x371))){if(_0x47ab5a[_0x555dac(0xed)](_0x555dac(0x1e8),_0x555dac(0x33f)))_0x47ab5a['iUBZb'](submitQuiz);else{const _0x50c81f=_0x1c1873[_0x555dac(0x351)](_0x47ab5a[_0x555dac(0x31e)]);_0x50c81f[_0x555dac(0x2d7)]=_0x47ab5a[_0x555dac(0x1cc)](_0x5cd10f,0x1),_0x50c81f[_0x555dac(0x28d)]=_0x47ab5a[_0x555dac(0x194)],_0x50c81f['onclick']=()=>_0x3d2bdc(_0x1c060f),_0x50c81f['id']=_0x555dac(0x16e)+_0x5c4ef2,_0x5010b2[_0x555dac(0x2c2)](_0x50c81f);}}else _0x47ab5a[_0x555dac(0x241)](nextQuestion);}},0x3e8);}function updateTimerDisplay(){const _0x233b9e=_0x31022e,_0x93e925={'VaZmk':function(_0x3532aa,_0x5a5810){return _0x3532aa/_0x5a5810;},'YNRAr':function(_0x5bb5e0,_0x4053eb){return _0x5bb5e0%_0x4053eb;},'rIhNv':_0x233b9e(0x2f0),'JRPuH':function(_0x1c12df,_0x2bef06){return _0x1c12df+_0x2bef06;},'AgrWQ':function(_0x54b8b4,_0x12ec72){return _0x54b8b4+_0x12ec72;}},_0x4fac86=Math[_0x233b9e(0x2c0)](_0x93e925['VaZmk'](timeRemaining,0x3c)),_0x223ee8=_0x93e925[_0x233b9e(0x2fa)](timeRemaining,0x3c);document[_0x233b9e(0x1a5)](_0x93e925[_0x233b9e(0x1aa)])['textContent']=_0x93e925[_0x233b9e(0x28a)](_0x93e925[_0x233b9e(0x273)](_0x4fac86,':'),_0x223ee8[_0x233b9e(0x2a4)]()[_0x233b9e(0x1df)](0x2,'0'));}function toggleSidebar(){const _0xfd29ef=_0x31022e,_0x3bce05={'lYNIw':_0xfd29ef(0x1ab),'lZslE':_0xfd29ef(0x130)};document[_0xfd29ef(0x1a5)](_0x3bce05[_0xfd29ef(0x262)])[_0xfd29ef(0x36c)]['toggle'](_0x3bce05[_0xfd29ef(0x272)]);}document[_0x31022e(0x287)](_0x31022e(0x258),()=>{const _0x4906b9=_0x31022e,_0x438bed={'zBwAZ':_0x4906b9(0x2a0),'DfLYG':function(_0x5adab3){return _0x5adab3();},'zVCYT':_0x4906b9(0xd3),'SuFXF':function(_0x587ef2,_0x277f7e){return _0x587ef2===_0x277f7e;},'qrarl':_0x4906b9(0x228),'WaPVH':function(_0x200102,_0x1c4477){return _0x200102!==_0x1c4477;},'yZVqo':_0x4906b9(0xf5),'sKENj':'timed_study','KYbpI':_0x4906b9(0x144),'wjvGz':_0x4906b9(0x333),'xxSMk':_0x4906b9(0x33a),'vXopk':function(_0x55ff44){return _0x55ff44();},'JJeZe':function(_0x4c3f09){return _0x4c3f09();},'SRCGq':_0x4906b9(0x243),'lwqSv':_0x4906b9(0x357),'mAcBC':'none','dhvHT':function(_0x532d2b){return _0x532d2b();},'JGHNP':_0x4906b9(0x111),'BaUmT':_0x4906b9(0x30c)};if(resume){if(_0x438bed[_0x4906b9(0x1d3)](loadProgress)){if(_0x438bed[_0x4906b9(0x2e7)](_0x438bed[_0x4906b9(0x270)],_0x438bed[_0x4906b9(0x270)])){const _0x137df0=!_0x21c278[_0x2f1229][_0x4906b9(0x204)];_0x57f7ad[_0x630e20]['bookmarked']=_0x137df0;let _0x3917de=_0x1a53d8[_0x4906b9(0x361)](_0x5708d4['getItem'](_0x438bed['zBwAZ']))||[];if(_0x137df0){const _0x23a460={'quizName':_0x2127b5,'quizFile':_0x1d3fb3[_0x4906b9(0x222)][_0x4906b9(0x336)]['split']('/')[_0x4906b9(0x307)](),'questionIndex':_0x51c804,'question':_0x44133b[_0x524f4d],'hierarchy':_0x6e4f99,'timestamp':_0xb46ad4[_0x4906b9(0x175)]()};_0x3917de[_0x4906b9(0x2d8)](_0x23a460);}else _0x3917de=_0x3917de[_0x4906b9(0x37e)](_0x36056d=>!(_0x36056d[_0x4906b9(0xc9)]['includes'](_0x2f10ae[_0x4906b9(0x1ec)]()[_0x4906b9(0x32d)](/ /g,'-'))&&_0x36056d['questionIndex']===_0x116f2f));_0x14b95d[_0x4906b9(0x31f)](_0x438bed[_0x4906b9(0x1f6)],_0x4e8dd5['stringify'](_0x3917de)),_0x1715fb(),_0x438bed[_0x4906b9(0x31b)](_0x5ea9b4);}else document[_0x4906b9(0x1a5)](_0x438bed[_0x4906b9(0x29d)])[_0x4906b9(0x275)][_0x4906b9(0x231)]=_0x438bed[_0x4906b9(0x2ce)],_0x438bed[_0x4906b9(0x2f7)](initializeQuiz);}else{if(_0x438bed[_0x4906b9(0x1f1)]!==_0x438bed[_0x4906b9(0x1f1)]){if(_0x438bed[_0x4906b9(0x2e7)](_0x1ea803,_0x438bed[_0x4906b9(0x1ed)])&&_0x438bed[_0x4906b9(0x2e7)](_0x9e6210,_0x438bed[_0x4906b9(0x290)]))return;const _0x381388=_0x11d502[_0x4906b9(0x1a5)](_0x438bed[_0x4906b9(0x2d5)]),_0x889005=_0x381388[_0x4906b9(0x289)](_0x438bed[_0x4906b9(0x10b)]),_0x2e93bc=_0x3d1b58[_0x54314f],_0x11d4f3=_0x2e93bc[_0x4906b9(0x22c)];let _0x386399=_0x2e93bc[_0x4906b9(0x236)]['findIndex'](_0x5477fe=>_0x5477fe['id']===_0x11d4f3);_0x381388['classList'][_0x4906b9(0x2c8)](_0x438bed['xxSMk']),_0x889005['forEach']((_0x3522d1,_0x1509a9)=>{const _0x5339b7=_0x4906b9;_0x3522d1[_0x5339b7(0x36c)][_0x5339b7(0x164)](_0x438bed[_0x5339b7(0x32c)]);if(_0x438bed[_0x5339b7(0x354)](_0x1509a9,_0x386399))_0x3522d1[_0x5339b7(0x36c)][_0x5339b7(0x2c8)](_0x5339b7(0x140));else{if(_0x438bed[_0x5339b7(0x354)](_0x1509a9,_0x27a2a7)&&!_0x4c73f2)_0x3522d1['classList'][_0x5339b7(0x2c8)](_0x438bed[_0x5339b7(0x234)]);}}),_0x438bed['vXopk'](_0x83b469);}else clearProgress(),document[_0x4906b9(0x1a5)](_0x438bed[_0x4906b9(0x29d)])[_0x4906b9(0x275)][_0x4906b9(0x231)]=_0x438bed[_0x4906b9(0x1c4)];}}else!window['location']['pathname'][_0x4906b9(0x14b)](_0x4906b9(0x2b8))?(_0x438bed[_0x4906b9(0x1d3)](clearProgress),document['getElementById'](_0x438bed['lwqSv'])[_0x4906b9(0x275)][_0x4906b9(0x231)]=_0x438bed[_0x4906b9(0x1c4)]):initializeQuiz();}),document[_0x31022e(0x287)](_0x31022e(0x33c),function(_0x3e724a){const _0x121539=_0x31022e,_0x1e5411={'AtBvV':function(_0x23b551,_0x2d0bab){return _0x23b551-_0x2d0bab;},'dsNlb':function(_0x54c55c,_0x128a8b){return _0x54c55c(_0x128a8b);},'kvtPl':_0x121539(0x333),'eHGsZ':function(_0x5caf26,_0x563c7f){return _0x5caf26<_0x563c7f;},'imKgR':function(_0x41d15e,_0x4b5f44){return _0x41d15e(_0x4b5f44);},'uYVwg':function(_0x19ffea,_0x4c7170){return _0x19ffea!==_0x4c7170;},'FSLUO':_0x121539(0x1ee),'UwWpz':function(_0x5b6f8f,_0x58e968){return _0x5b6f8f===_0x58e968;},'eJHfn':_0x121539(0x169),'UAfQX':function(_0x4848fc,_0x5810a8){return _0x4848fc>=_0x5810a8;},'hlMTv':function(_0x3ca461,_0x6478d5){return _0x3ca461<=_0x6478d5;},'JWgGO':_0x121539(0x202),'GOops':function(_0x5a3262,_0x5b2dcd){return _0x5a3262(_0x5b2dcd);},'LvVka':_0x121539(0x20e),'SlxBu':function(_0x2ce394){return _0x2ce394();},'BHwaD':function(_0x1de2c7,_0x3c870f){return _0x1de2c7===_0x3c870f;},'bwMya':function(_0x4db682,_0x53c1cd){return _0x4db682===_0x53c1cd;},'TdIND':_0x121539(0x187),'ryFes':_0x121539(0x26f),'mBSGM':function(_0x893651){return _0x893651();},'AcsUp':_0x121539(0x309),'bfINs':function(_0x416189,_0x55d8b7){return _0x416189===_0x55d8b7;}};if(_0x1e5411['uYVwg'](document[_0x121539(0x1a5)](_0x121539(0x357))['style'][_0x121539(0x231)],_0x1e5411['FSLUO']))return;if(_0x1e5411['UwWpz'](document[_0x121539(0x1a5)](_0x121539(0x318))[_0x121539(0x36c)][_0x121539(0x1fc)](_0x1e5411[_0x121539(0x2b3)]),![]))return;if(_0x1e5411['UAfQX'](_0x3e724a[_0x121539(0xc6)],'1')&&_0x1e5411['hlMTv'](_0x3e724a[_0x121539(0xc6)],'4')){if(_0x1e5411['uYVwg'](_0x1e5411[_0x121539(0x27f)],_0x1e5411[_0x121539(0x27f)]))_0x5aebb4[_0x43fa9f[_0x121539(0x148)]]['bookmarked']=!![];else{const _0xd97cef=_0x1e5411['imKgR'](parseInt,_0x3e724a[_0x121539(0xc6)])-0x1,_0x8df225=document['querySelectorAll'](_0x1e5411['kvtPl']);if(_0xd97cef<_0x8df225['length'])_0x1e5411[_0x121539(0x256)](selectOption,_0xd97cef);}}else{if(_0x1e5411[_0x121539(0x23d)](_0x3e724a[_0x121539(0xc6)],_0x1e5411['LvVka'])){if(_0x1e5411[_0x121539(0x23d)]('snogz',_0x121539(0x248)))_0x1e5411[_0x121539(0x2c6)](previousQuestion);else{const _0x337512=_0x1e5411[_0x121539(0xd9)](_0x1e5411[_0x121539(0x374)](_0x5b072d,_0x2d66f6['key']),0x1),_0x4dd3c5=_0x41ae84['querySelectorAll'](_0x1e5411[_0x121539(0x106)]);if(_0x1e5411[_0x121539(0x10c)](_0x337512,_0x4dd3c5[_0x121539(0xce)]))_0x1e5411[_0x121539(0x1a1)](_0x29bfc7,_0x337512);}}else{if(_0x1e5411[_0x121539(0x23d)](_0x3e724a[_0x121539(0xc6)],_0x121539(0x369))||_0x1e5411[_0x121539(0x23d)](_0x3e724a[_0x121539(0xc6)],'\x20'))_0x3e724a['preventDefault'](),_0x1e5411[_0x121539(0x2c6)](nextQuestion);else{if(_0x1e5411[_0x121539(0x23d)](_0x3e724a[_0x121539(0xc6)][_0x121539(0x1ec)](),'b')&&(_0x1e5411[_0x121539(0x185)](currentMode,_0x121539(0xf5))||_0x1e5411[_0x121539(0x1d8)](currentMode,_0x1e5411[_0x121539(0x173)])))_0x121539(0x2cd)===_0x1e5411[_0x121539(0x15d)]?_0x2a9789[_0x121539(0xcd)]+=_0x121539(0x2a2)+_0x3a4ec4[_0x121539(0x36f)]+_0x121539(0xf2):_0x1e5411['mBSGM'](toggleBookmark);else{if(_0x3e724a[_0x121539(0xc6)][_0x121539(0x1ec)]()==='m'&&(currentMode===_0x1e5411['AcsUp']||_0x1e5411[_0x121539(0x23d)](currentMode,'timed_exam')))_0x1e5411['mBSGM'](toggleMarkForReview);else _0x1e5411[_0x121539(0x185)](_0x3e724a[_0x121539(0xc6)][_0x121539(0x1ec)](),'s')&&(_0x1e5411[_0x121539(0x197)](currentMode,_0x1e5411['AcsUp'])||currentMode===_0x121539(0x371))&&_0x1e5411[_0x121539(0x2c6)](submitQuiz);}}}}});</script>

</body></html>